



Modifiable Risk Factors in the Progression of Multiple Sclerosis: A Systematic Review of the Epidemiology and Treatment

December 2015

Prepared for:

Department of Veterans Affairs
Veterans Health Administration
Quality Enhancement Research Initiative
Health Services Research & Development Service
Washington, DC 20420

Prepared by:

Evidence-based Synthesis Program (ESP) Center
West Los Angeles VA Medical Center
Los Angeles, CA
Paul G. Shekelle, MD, PhD, Director

Investigators:

Principal Investigator:

Susanne Hempel, PhD
Paul Shekelle, MD, PhD

Co-investigators:

Ning Fu, PhD
Elena Estrada, BS, BA, MS
Annie Chen, BS, BA

Research Associates:

Isomi Miake-Lye, PhD
Jessica Beroes, BS
Roberta Shanman, MS
Jeremy Miles, PhD



VA Defining
HEALTH CARE EXCELLENCE
in the 21st Century

PREFACE

The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D.

The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The ESP disseminates these reports throughout VA and in the published literature; some evidence syntheses have informed the clinical guidelines of large professional organizations.

The ESP Coordinating Center (ESP CC), located in Portland, Oregon, was created in 2009 to expand the capacity of QUERI/HSR&D and is charged with oversight of national ESP program operations, program development and evaluation, and dissemination efforts. The ESP CC establishes standard operating procedures for the production of evidence synthesis reports; facilitates a national topic nomination, prioritization, and selection process; manages the research portfolio of each Center; facilitates editorial review processes; ensures methodological consistency and quality of products; produces “rapid response evidence briefs” at the request of VHA senior leadership; collaborates with HSR&D Center for Information Dissemination and Education Resources (CIDER) to develop a national dissemination strategy for all ESP products; and interfaces with stakeholders to effectively engage the program.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP CC Program Manager, at Nicole.Floyd@va.gov.

Recommended citation: Hempel S, Fu, N, Estrada E, Chen A, Miake-Lye I, Beroes J, Miles JNV, Shanman R, Shekelle P. Risk Factors for Multiple Sclerosis Progression: A Systematic Review. VA ESP Project #05-226; 2015.

This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the **West Los Angeles VA Medical Center, Los Angeles, CA**, funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

TABLE OF CONTENTS

Executive Summary	1
Introduction.....	1
Methods	1
Data Sources and Searches	1
Study Selection.....	1
Data Abstraction and Quality Assessment	2
Data Synthesis and Analysis.....	2
Results	3
Results of Literature Search.....	3
Summary of Results for Key Questions	3
Discussion.....	4
Key Findings and Strength of Evidence	4
Applicability	5
Research Gaps/Future Research.....	5
Conclusions.....	6
Abbreviations	7
Introduction	8
Methods	10
Topic Development.....	10
Search Strategy	10
Study Selection	11
Data Abstraction	13
Quality Assessment.....	14
Data Synthesis and Analysis.....	14
Rating the Body of Evidence	15
Technical Expert Panel.....	16
Peer Review	16
Results	17
Literature Flow.....	17
Key Question 1: What modifiable epidemiologic factors are related to multiple sclerosis progression following diagnosis?.....	19

Key Question 2: What environmental exposures prior to or during military service are related to multiple sclerosis progression following onset symptoms?	65
Key Question 3: Among identified risk factors for progression, what treatment/risk factor modification therapies have been shown to delay or hasten the progression of MS once it has initiated?	67
Summary and Discussion	88
Summary of Evidence by Key Question	88
Limitations	91
Applicability of Findings to the VA Population	91
Research Gaps/Future Research	91
Conclusions	93
References	94

TABLES

Table 1. Evidence for KQ1 (MS Progression Risk Factors): Vitamin D or Sunshine Exposure	20
Table 2. Evidence for KQ1 (MS Progression Risk Factors): Smoking	28
Table 3. Evidence for KQ1 (MS Progression Risk Factors): Childbirth-associated Factors	37
Table 4. Evidence for KQ1 (MS Progression Risk Factors): Diet	40
Table 5. Evidence for KQ1 (MS Progression Risk Factors): Exercise	43
Table 6. Evidence for KQ1 (MS Progression Risk Factors): Other	46
Table 7. Evidence for KQ1 (MS Progression Risk Factors): Multiple	49
Table 8. Summary of Findings for KQ1	64
Table 9. Summary of Findings for KQ2	66
Table 10: Evidence for KQ3: Effects of Exercise Interventions on MS Progression	68
Table 11: Evidence for KQ3: Effects of Dietary Interventions on MS Progression	74
Table 12. Evidence for KQ3: Effects of Vitamin D Supplementation Interventions on MS Progression	80
Table 13. Summary of Findings for KQ3	87

FIGURES

Figure 1: Literature Flow Chart	18
Figure 2: Correlation between EDSS Score and Vitamin D Level	58
Figure 3: Time to Progression and Smoking	60
Figure 4: Effect of Exercise Interventions on EDSS Scores	83
Figure 5: Effect of Fatty Acid Supplementation Interventions on the Relative Risk of Progression	84

Figure 6: Effect of Dietary Interventions on EDSS Scores85

Figure 7: Effect of Vitamin D Interventions on EDSS Scores86

Appendix A. Search Strategies104

Appendix B. Study Selection and List of Excluded Studies109

Appendix C. Criteria Used in Quality Assessment.....126

Appendix D. Peer Review Comments/Author Responses132



EXECUTIVE SUMMARY

INTRODUCTION

Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age. Epidemiologic data suggest that rates of MS vary with demographic and environmental factors. The disease presentation is very heterogeneous with diverse clinical manifestations. Progression of MS may vary with modifiable risk factors.

This systematic review focused on modifiable risk factors and exposures that are associated with MS progression, and interventions that are directed at modifiable risk factors to delay progression.

The Key Questions (KQs) were:

KQ1: What modifiable epidemiologic factors are related to multiple sclerosis progression following diagnosis?

KQ2: What environmental exposures prior to or during military service are related to multiple sclerosis progression following onset symptoms?

KQ3: Among identified risk factors for progression, what treatment/risk factor modification therapies have been shown to delay or hasten the progression of multiple sclerosis once it has initiated?

The review will be used by the VA Multiple Sclerosis Centers of Excellence to initiate new research studies, refine clinical guidelines, and plan for targeted disease-modifying and disease-prevention strategies.

METHODS

Data Sources and Searches

We searched the databases PubMed, EMBASE, AMED, Web of Science, SCOPUS, GreenFILE, ProQuest Military Collection, and DTIC to March 2015; reference-mined reviews and included studies; and consulted with experts to identify pertinent studies. Literature searches were not restricted to a narrow set of known risk factors but were exploratory in nature.

Study Selection

The review focused on patient-modifiable risk factors, such as food intake or health behaviors of patients with MS. Studies meeting the following criteria were eligible for inclusion in the review:

Population: Adults with MS (KQ1, KQ3), military personnel/Veterans with MS (KQ2)

Interventions/exposure: Potential MS progression risk factors (KQ1, KQ2; *eg*, smoking, nutrition) and interventions targeting risk factors (KQ3; *eg*, smoking cessation programs, dietary interventions)

Comparators (study design): Observational and experimental studies analyzing factors associated with MS progression (KQ1, KQ2), randomized controlled trials (RCTs) regardless of the comparator (KQ3)

Outcomes: Progression of MS, primary outcome measure Expanded Disability Status Scale (EDSS)

Timing: not restricted

Setting: No restriction but planned subgroup analyses for *Veteran* population.

Data Abstraction and Quality Assessment

For KQ1 we extracted sample characteristics, geographical region, and number of participants; study design, analysis, and assessment timing (*eg*, prospective); the predicted outcome, assessed potential risk factors, and controlled variables; EDSS results and other MS progression results. For studies relevant to KQ2, we extracted study details and MS progression results associated with prior military service exposure and exposure during military service. For intervention studies (KQ3) we extracted methodological characteristics; number and characteristics of participants; intervention and comparator content and duration; EDSS results and other MS progression outcomes together with the follow-up point, and adverse events.

For KQ1 and KQ2 we distinguished concurrent, retrospective, and prospective studies. Prospective studies were assessed with QUIPS, a critical appraisal tool for prognostic studies. The RCTs informing KQ3 were assessed with the Cochrane risk of bias tool.

Data Synthesis and Analysis

All included studies were presented in evidence tables, grouped by key question, to allow a comprehensive overview. We differentiated results based on standardized and common measures of disease status, the EDSS, and other results. Where possible, variables were pooled using a restricted maximum-likelihood estimator and the Hartung-Knapp-Sidik-Jonkman standard error method for random-effects models to identify reliable and valid effects across studies. Continuous outcomes were reported as standardized mean differences (SMD), dichotomous outcomes as relative risks (RR), time to event data as hazard ratios (HR), and correlations were transformed to z statistics (using the Fisher transformation) to pool across studies. Point estimates were reported with the 95 percent confidence interval (CI). Heterogeneity was assessed with the I^2 statistic, publication bias with the Egger and Begg test, and we used the trim-and-fill method in the presence of publication bias.

KQ1 studies were grouped by evaluated risk factors. A summary of findings table documented the number of available studies for all risk factors that had been addressed in more than one study, the strength of association with MS progression, and our confidence in the finding. For studies in military personnel and Veterans relevant to KQ2, we differentiated assessed variables and statistically significant effects across studies documented in a summary of findings table. Intervention studies (KQ3) were stratified by intervention category and summarized across studies in a summary of findings table. The quality of evidence assessment followed the standard GRADE approach for RCTs and an adaptation for prognostic factor research for KQ1 and KQ2. The quality of evidence indicates the confidence in the results that are drawn from the literature, and we distinguished high, moderate, low, and very low quality of evidence.

RESULTS

Results of Literature Search

The search identified 8,594 citations. In total, 94 studies met inclusion criteria.

Summary of Results for Key Questions

Fifty-nine studies contributed to KQ1, 4 studies contributed to KQ2 (all also relevant to KQ1), and 36 RCTs addressed KQ3.

KQ1: Modifiable Risk Factors

Studies assessed a number of risk factors and used a variety of progression measures, including EDSS scores, time to conversion from remitting relapsing to secondary progressive MS, and odds of reaching EDSS 6 (requiring a cane for walking). Thirteen studies were prospective studies, assessing risk factors and subsequent outcome measures at 2 different time points.

Vitamin D has been addressed in a large number of studies. Across studies, there was a negative correlation of -0.22 (CI -0.32, -0.12; 11 studies; I^2 66%) indicating that lower Vitamin D levels are associated with higher EDSS scores. The result is primarily based on concurrent predictor studies (measuring Vitamin D level and disability status at the same time).

Across studies, we identified an increased risk of faster progression in smokers than nonsmokers (HR 1.55; CI 1.10, 2.19; I^2 72%; 7 studies, 8 datasets). The result is primarily based on retrospective studies.

The use of epidural analgesics during childbirth delivery has been assessed in 3 studies and none reported a statistically significant association with EDSS or DSS scores.

Results for sun exposure, sunscreen use, month of birth, diet, fish consumption, alcohol consumption, exercise, trauma, oral contraception, geographic region, and education have been addressed in more than one study, but the differences in risk factor operationalizations and outcome measures did not allow concrete evidence statements to be made.

All other investigated factors have been addressed in only one of the included studies and have not been replicated. These include effects of cesarean delivery; breast feeding; having been breast fed; obstetrical and spinal anesthesia; childhood maltreatment; working outdoors; individual health-promoting lifestyle domains; meditation practice; insurance coverage; medical care satisfaction variables; exposure to different types of animals; coal heating; wood heating; humid living space; no sewage system; no piped water; type of environment (*eg*, farm); specific diet factors such as coffee consumption, liver consumption, vitamin supplementation, fortified foods, vegetarian diet; cod liver oil intake; occupational status; deployment to a war theater; being a Veteran; and earthquake experience.

KQ2: Exposures Prior to or During Military Service

We identified 4 studies that reported on exposures prior to and during military services associated with MS progression (KQ2) in active military personnel or Veterans. Assessed risk factors were geographic location at entry to the military, occupational status at entry to the military, average fall/winter sun exposures before MS onset, cod liver oil intake at ages 6-15,

fish consumption at ages 6-15, deployment, being a Veteran, and dietary treatment. None of the studies assessed the same risk factors and outcome measures varied across studies.

KQ3: Risk Factor Modification Therapies

Despite the inclusive and extensive systematic search, all identified risk factor modification interventions targeted either physical exercise, dietary interventions, or vitamin D supplementation. Across the 36 predominantly small RCTs, we did not detect interventions with statistically significant treatment effects compared to passive control groups on MS progression.

The pooled effect of exercise interventions on EDSS scores was not different from untreated control groups (SMD 0.02; CI -0.40, 0.44; I^2 0%; 7 RCTs). However, using baseline-adjusted data for a sensitivity analysis, the result favored the exercise intervention (SMD -0.19; CI -0.34, -0.03).

The 12 identified dietary intervention evaluations primarily assessed the effects of fatty acid supplements. We did not identify a statistically significant effect on the relative risk of progression (RR 0.86; CI 0.67, 1.05; I^2 0%; 4 RCTs) or EDSS scores (SMD -0.13; -0.83, 0.45; I^2 5%; 3 RCTs) compared to placebo.

Vitamin D supplementation showed a trend for improved EDSS scores but the pooled standardized mean difference was not statistically significant from placebo groups (SMD -0.15; CI -0.33, 0.02; I^2 0; 5 RCTs). However, the weighted mean difference favored vitamin D supplementation and showed that supplements were associated with a 0.22-point difference in EDSS scores (WMD -0.22; CI -0.39, -0.05).

DISCUSSION

Key Findings and Strength of Evidence

Our systematic review and meta-analysis focused on modifiable risk factors. We systematically searched for, documented, and synthesized evidence available in the research literature on MS progression. A large number of relevant studies is available to contribute to the evidence base but the research area is very complex.

We did not identify factors that were shown to be significant risk factors in epidemiological studies and published evidence that shows their amenability to intervention and their effects on MS progression.

KQ1

There was great variation in assessment and prediction details across studies relevant to KQ1 and only 13 prospective studies were identified, limiting the conclusions that can be drawn from the literature. There is moderate-quality evidence of a correlation between vitamin D levels and EDSS scores. Our confidence in the result was downgraded to moderate quality of evidence due to *indirectness*. The correlation does not allow causal inferences and prospective studies are needed linking vitamin D intake to MS progression. There is moderate-quality evidence (downgraded due to unexplained heterogeneity) suggesting an association between the time to progression and smoking. There is low-quality evidence (due to study design limitation and lack of point estimates) suggesting that epidural analgesia during childbirth is not associated with

EDSS scores. A large number of potential risk factors have been reported in the literature; however, the existing evidence is insufficient for providing concrete evidence statements for individual outcomes.

KQ2

The quality of the evidence for research on environmental exposures during military service was determined to be insufficient for evidence statements because all factors were reported in only one included study without replication in another participant sample.

KQ3

Despite substantially more available literature on risk factor modification therapies, we confirmed earlier reviews showing that currently no statistically significant evidence exists to supports specific interventions for MS progression and more research is needed.

The quality of the evidence for the result of no difference between exercise interventions and untreated control groups on EDSS scores was downgraded due to severe *study limitations* and conflicting results in a sensitivity analysis (*imprecision*). Our confidence in the evidence summary is limited because studies were not designed to assess EDSS changes, study sample sizes were very small, there were baseline imbalances, and the interventions may have been too short to achieve and detect changes with standard diagnostic criteria. Nonetheless, any treatment effect is likely to be very small; adjusting for baseline imbalances, the estimate was 0.20 points on the EDSS scale.

The quality of evidence for the dietary intervention results showing the absence of an effect on MS progression measured as deterioration or EDSS scores were both downgraded to moderate due to *study limitations*. The early studies lack reporting detail while the more recently published studies were small and did not report statistical power calculations to determine whether studies could detect an effect of the intervention on MS progression.

The quality of evidence for a non-significant effect of vitamin D supplementation on EDSS scores was downgraded due to *study limitations* and *imprecision*. The included studies were small and the lack of reported power calculations makes it unclear whether the studies were sufficiently powered to be able to detect small treatment effects. The statistical significance was dependent on the effect measure, showing that the effect estimate is not very robust. Nonetheless, any potential treatment effects are likely to be small with an estimated difference of 0.22 points in EDSS scores between intervention and control groups.

Applicability

Very few studies reported specifically on VA samples. However, there is no indication that risk factor results and treatment effects are not applicable to the VA population.

Research Gaps/Future Research

Our systematic review showed that more prospective research studies are needed to allow predictions and meaningful interpretation of risk factor analyses. Furthermore, future studies should report more details and statistical analyses in order to facilitate evidence synthesis in

meta-analyses. Specific areas that need more research are the consumption of alcohol and sun exposure and their potential effects in slowing progression.

The existing intervention studies testing the effect on MS progression should determine the statistical power needed to detect a difference between treatment groups, in particular for vitamin D supplementation trials. Effects of smoking cessation should be investigated given the association between smoking and MS progression. Based on sensitivity analyses we found that more studies evaluating the effects of long-term exercise interventions are warranted.

Finally, although our review addressed a broad research field, there are other, potential risk factors of interest that are outside the scope of this review, including the effect of treatable comorbidities of MS.

Conclusions

A large number of studies is available to contribute to the growing research literature on modifiable risk factors and MS progression, but the research field is very complex.

Risk factor studies used diverse operationalizations of risk factors and different outcome measures, and more prospective studies are needed. Most consistent results were shown for the association between EDSS scores and Vitamin D levels. Smoking was associated with a faster progression of MS in smokers compared to nonsmokers.

Risk factors in Veterans and active military personnel were one of the key questions for this review but very few studies are available to inform on this participant subgroup.

We did not identify interventions that showed a statistically significant effect of exercise, dietary, or vitamin D supplementation on EDSS scores across studies. However, studies were not designed to assess effects on MS progression. More research is, in particular, needed on interventions for smoking cessation, adequately powered vitamin D supplementation RCTs, and RCTs testing the effects of long-term exercise interventions.

ABBREVIATIONS

EDSS Expanded Disability Status Scale

HR Hazard ratio

OR Odds ratio

KQ Key question

MS Multiple sclerosis

r Correlation

RR Relative risk

EVIDENCE REPORT

INTRODUCTION

Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the most common cause of serious physical disability in adults of working age.¹ The estimated incidence is 7 per 100,000 per year and the median age of onset is 30 years.³ For the military it is a significant neurological disease burden in terms of diagnosis, management, and disability retirement.

MS is characterized pathologically by focal areas of inflammation, demyelination, gliosis, and axonal damage throughout the central nervous system.^{4,5} The course of MS is characterized by clinical relapses and disease progression. Relapse, exacerbations, or attacks, are acute, inflammatory events that occur episodically within the central nervous system. They can correspond to either the development of new focal inflammatory lesions or the reactivation of old lesions, and after an exacerbation, symptoms spontaneously remit, either partially or completely. Progression describes a steady deterioration in neurologic function associated with new symptoms and continuously worsening disability which takes place over a period of at least 6 (Poser criteria) or 12 months (McDonald criteria).^{6,7} Once progression has developed, the course is continuous despite occasional plateaus and temporary minor improvements.⁸

MS disease presentation is very heterogeneous with variable clinical manifestations that evolve over time. About 80% of patients present with relapsing-remitting disease which manifests in relapses followed by periods of partial or complete recovery (remissions). Other subtypes of MS include secondary progressive MS (patients develop relapsing-remitting MS but then begin progressing with or without relapses). In about 50% of patients the course of MS changes from relapsing-remitting to secondary progressive disease after 10 years.⁹ Active progressive MS shows a slow progression of disability from onset with periods of stability and occasional relapses, while patients with primary progressive MS show progressive worsening in disability from onset without exacerbations. It is estimated that while 15% of patients with MS will become severely disabled within a short time, for 25% of patients MS will never affect daily life.¹⁰

Epidemiologic data show that rates of MS appear to vary with environmental factors.¹⁰ This suggests a role of potentially modifiable risk factors associated with the onset and phenotypic manifestation of the disease. Similarly, the course of MS varies with demographic variables and possibly other factors. Furthermore, the mechanism that changes the disease pattern from relapsing-remitting to secondary progressive MS is largely unknown.⁹ Factors that may explain the diversity in clinical presentation, help predict the course of the disease, and identify potential triggers of disease progression are of great interest to patients and clinicians, in particular modifiable risk factors.¹¹

Disease-modifying therapies for relapsing forms of MS are only partially effective in slowing short-term morbidity and there are no effective medication options for progressive MS.¹² Additional MS treatment and management options are needed to support patients with a diagnosis of MS. Some risk factors associated with the onset or progression of MS may be translatable into interventions, such as in the case of the potential risk factor vitamin D

deficiency, which can be tested in effectiveness trials by treating MS patients with a vitamin D supplement.¹³

This project focuses on empirical evidence on modifiable exposures and risk factors that are related to MS progression and approaches to reduce progression that are directed at modifiable risk factors. This review will be used by the VA Multiple Sclerosis Centers of Excellence to initiate new research studies, refine clinical guidelines, and plan for targeted disease-modifying and disease-prevention strategies.

METHODS

TOPIC DEVELOPMENT

This topic was developed in response to a nomination by the VA Multiple Sclerosis Center of Excellence-East, for an evidence review to examine the role of modifiable risk factors and military exposures in the progression of MS, as well as methods to reduce progression that are directed at modifiable risk factors.

The Key Questions (KQ) were:

- (1) What modifiable epidemiologic factors are related to multiple sclerosis progression following diagnosis?
- (2) What environmental exposures prior to or during military service are related to multiple sclerosis progression following onset symptoms?
- (3) Among identified risk factors for progression, what treatment/risk factor modification therapies have been shown to delay or hasten the progression of multiple sclerosis once it has initiated?

SEARCH STRATEGY

We searched the electronic databases PubMed (medical literature); EMBASE (biomedical literature); AMED (Allied and Complementary Medicine Database); SCOPUS and Web of Science (broad research databases indexing conference papers and innovations); GreenFILE (environmental factors); DTIC (Defense Technical Information Center), and ProQuest Military Collection (databases for military research) for primary research studies published in English to March 2015 without date restriction. Dates of database inception varied; for example, PubMed systematically indexes research published since 1966, with some earlier publications.

For KQ1, we employed a search strategy that combined known presumed risk factors, and a more general search for prognostic study designs based on a published search filter¹⁴ applied to PubMed, SCOPUS, Web of Science, and GreenFILE.

The KQ2 search strategy used search terms for military populations to identify MS studies without further study restrictions in the databases PubMed, EMBASE, AMED, SCOPUS, Web of Science, GreenFILE, DTIC, and ProQuest Military Collection.

For KQ3 we applied a search filter for randomized controlled trials (RCTs) to search the databases PubMed, AMED, SCOPUS, and Web of Science, to target eligible studies. The PubMed search encompassed all indexed RCTs in MS patients and was not restricted to a set of pre-defined interventions, to avoid missing relevant studies targeting uniquely-named or novel interventions.

Furthermore, we screened references of pertinent reviews and consulted with topic experts to ensure that all relevant studies were identified.

STUDY SELECTION

Two independent reviewers screened titles and abstracts of retrieved citations and recorded decisions in an electronic database. Citations deemed potentially relevant by at least one of the reviewers were obtained as full text. The full-text publications were screened against the specified inclusion criteria by 2 independent literature reviewers; disagreements were resolved through discussion within the review team. The literature flow was documented in an electronic database and reasons for exclusion of full text publications were recorded.

To be included in the systematic review, studies had to meet the following criteria, organized in the PICOTS framework.

Participants: Studies in human adult participants with a clinical diagnosis of MS were eligible for inclusion for KQ1 and KQ3. KQ2 was limited to active military personnel and Veterans with MS. Studies exclusively focusing on pediatric MS in children and adolescents were excluded. Studies targeting a range of clinical conditions were included as long as data on MS progression was reported separately. The sample composition of MS populations was not restricted but risk factor studies excluding all progressive forms and not reporting on MS progression were excluded (*eg*, studies describing disease severity in explicitly non-progressive forms).

Intervention: Studies reporting on modifiable epidemiologic factors and environmental exposures potentially associated with MS progression (“risk factors”) were eligible for inclusion for KQ1 and KQ2. Eligible risk factors included (but were not limited to) the geographic region of residence, sun exposure, vitamin D intake, polyunsaturated fatty acid intake, diet, smoking, alcohol, exercise behavior, vaccinations, anesthesia exposure, radiation therapy exposure, use of oral contraception, fertility treatment, childbirth delivery variables, breastfeeding, salt intake, use of milk products, water sources intake, trace elements intake, mercury exposure, trauma exposure, military service/deployment, and military exposures. Non-modifiable risk factors such as genetic predispositions, physiological correlates, or demographic characteristics at MS onset were excluded. Descriptive factors such as quality of life or vitality with unclear modifiability, comorbidities, and concurrent psychological correlates of disability status that are more likely to be a reaction to than a predictor of MS (*eg*, coping strategies and perceptions of body image) were excluded. Factors directly associated with known MS medication, such as the use of disease-modifying treatment, type of medication, medication combinations, dosing schemes, adherence, and timing of therapy onset were also excluded.

Intervention studies evaluating the effect of modifying the intake or exposure to potential risk factors (*eg*, smoking cessation, weight loss, or exercise programs; nutritional interventions targeting vitamin D or Omega-3), alone or in combination with other therapies, were eligible for KQ3. Treatment studies testing potential risk factors were eligible for inclusion regardless of the current strength of association in empirical studies, but studies evaluating unspecific interventions not associated with potential or identified MS risk factors (*eg*, acupuncture) were excluded. Treatment studies evaluating the effect of existing, FDA-approved MS medications that aim to modify the disease course of MS (*eg*, interferon beta-1a), or aim to manage MS relapses (*eg*, prednisone), other suggested medication for MS (*eg*, laquinimod), treatments for autoimmune and immunodeficiency diseases (*eg*, corticosteroids), and medication given for their immunomodulatory properties (*eg*, statins) or tested for their use in MS (*eg*, lithium) were excluded regardless of any underlying risk factor hypotheses (*eg*, infection, hygiene hypothesis).

Comparator (design): Observational studies (*eg*, case-control, cohort studies comparing 2 cohorts, or cross-sectional studies including surveys), and experimental studies analyzing factors associated with MS progression were eligible for KQ1 and KQ2. Non-randomized experimental studies had to have a non-treated concurrent control group to identify standard progression rates and provide a power calculation to determine *a priori* whether differences between experimental groups could be identified. Risk factor studies had to report data on 10 or more participants with MS. Case studies speculating about associations were excluded.

RCTs in adults regardless of the comparator were eligible for KQ3. Only primary research studies were eligible for inclusion. Pertinent reviews and secondary data analyses were retained as background paper for reference mining.

Outcome: Studies reporting on the progression of MS were eligible for inclusion in the review. The primary outcome was Expanded Disability Status Scale (EDSS) scores or progression classifications based on EDSS score cut-offs. Studies reporting on earlier versions of the EDSS scale; other global patient-centered, clinical MS progression measures (*eg*, Multiple Sclerosis Functional Composite [MSFC], multiple domain assessments of the Functional System Score [FSS], Patient Determined Disability Scale [PDDS]); the clinical course of MS (*eg*, progression defined by clinical judgment, time to secondary progression); or comparing MS subgroups relevant to progression (*eg*, relapsing-remitting versus secondary-progressive stage) were eligible for inclusion. Studies reporting on disability measures focusing on the general ability to walk (*eg*, MS Progression: Disease Steps [DS]) were included. Studies only reporting on individual characteristics of walking (*eg*, gait, muscle strength, speed) were excluded. Studies reporting on other individual symptoms (*eg*, fatigue or depression) or individual diagnostic markers (*eg*, lesions shown with imaging techniques) without reporting on patient outcomes of MS progression were excluded. Studies reporting disability measures not specific to MS (*eg*, receiving a disability pension) were excluded. Studies reporting on MS-associated mortality were included if the endpoint was part of a continuum of progression and not an incidence measure of MS. Studies reporting on all-cause mortality in MS patient samples, for example investigating whether associations between epidemiologic factors and mortality found in the general population ('smoking predicts mortality') also apply to the MS population, were excluded. Studies exclusively reporting on the onset, rather than the progression of MS, and studies only reporting on the prevalence and incidence of MS without differentiating MS subtypes relevant to MS progression (*eg*, primary progressive MS) were excluded.

Timing: Risk factor studies were not limited by exposure duration and timing (*eg*, childhood exposure) and any follow-up points were eligible for inclusion in KQ1, but investigator-initiated exposures (*ie*, interventions) were restricted to long-term interventions if they did not report a statistical power calculation indicating that the study had sufficient power to show a difference between exposed groups. We included prospective (measuring the exposure before the outcome), retrospective (measuring the exposure of a past event retrospectively at the time of measuring the outcome), and concurrent (measuring the exposure status and the outcome at the same time point) studies. Studies eligible for KQ2 were limited to exposures prior to or during military service. Intervention RCTs including any intervention duration, regardless of the intervention timing, and any follow-up points were eligible for inclusion for KQ3.

Setting: Studies of any settings were eligible for inclusion in the review.

Other limiters: English-language studies were included.

The review was registered in PROSPERO, the international registry for systematic reviews PROSPERO <http://www.crd.york.ac.uk/PROSPERO/>. (PROSPERO 2015:CRD42015016461)

Protocol Deviations

Due to the overwhelming size of the literature identified through our literature searches that exceeded the available time and resources needed to complete the project, we removed comorbidities such as stress, anxiety, depression, infections, sleep problems, or obesity regardless of their treatability and modifiability status from the eligibility criteria. We also excluded the large body of literature on pregnancy and parity given that the decision to have children may be directly associated with disease severity and anticipated progression (reverse causality is discussed in more detail in the discussion section). Finally, we excluded studies that reported on the physiological or clinical status of patients, such as body weight or serum fatty acid levels, without information on the intake or patient behavior (*eg*, diet regime) other than vitamin D. In sum, we excluded factors that could either be a reaction to, an independent comorbidity, or a predictor of MS progression, and concentrated primarily on behavior and choices or exposures somewhat under the control of the patient or their families.

DATA ABSTRACTION

Studies underwent standardized abstraction of study-level data in an electronic database. Data collection forms were designed by the project lead and discussed in the review team.

For KQ1 (risk factors) studies, we extracted information on the MS population (*eg*, proportion of patients with relapsing-remitting, secondary progressive, or primary progressive MS; age; % male; race/ethnicity distribution). We documented the number of participants in the study sample and the number of cases (*ie*, patients with progressive MS). We recorded the geographic region of the sample. We documented the study design (*eg*, cohort study), methods used to analyze the results (*eg*, linear mixed effects model, partial correlations), and the predictive timeframe (concurrent, retrospective, prospective data). We extracted analyzed, potential, modifiable risk factors of interest together with the time of exposure (*eg*, alcohol consumption in last 2 years). We recorded all independent variables entering the prediction model. We extracted the point estimate of effects and statistical significance of risk factors on MS progression. The evidence table differentiates predictions for EDSS scores and other clinical course characteristics relevant to MS progression.

Concurrent studies were defined as measuring the exposure status and the outcome at the same time point, such as current alcohol intake. Retrospective studies assessed at least some outcomes retrospectively (*eg*, cod liver oil consumption during childhood). Prospective studies had to report on at least 2 different points in time assessing the risk factor prior to the MS progression outcome to be classified as prospective.

For studies relevant to KQ2 (military service exposures), we extracted the information on the study population including: MS characteristics and military service status; number of study participants and cases, geographic region; study design; analytic method; assessed prior or post military service exposures; assessed military service exposures; other analyzed independent variables; predictive time frame; EDSS score results; and other clinical course results.

For intervention studies (KQ3, risk factor modification therapies), we extracted the study design and methodological characteristics, number of randomized participants per intervention group and proportion of participants with progressive MS, characteristics of participants, intervention components and co-interventions, comparator details, outcomes, followup points, statistical power analysis, EDSS results, other disease progression results, and adverse events.

Some studies were reported on in more than one publication. Studies, defined by the included participants, were only counted once, regardless of the number of publications the results were published in. The data extraction considered data from all publications available for the study.

QUALITY ASSESSMENT

For KQ1 and KQ2 we distinguished concurrent, retrospective, and prospective studies. Prospective studies were assessed with QUIPS (Quality In Prognosis Studies), a critical appraisal tool for prognostic studies.¹⁵

Intervention studies (KQ3) were assessed with the Cochrane risk of bias tool assessing selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias (where appropriate).

Quality criteria definitions and scoring guidelines for all domains are documented in Appendix C together with the assessment results.

DATA SYNTHESIS AND ANALYSIS

The evidence tables provide information on each included study to allow a comprehensive overview. Summary of findings tables summarize results for analyzed modifiable risk factor in the general population (KQ1) and military samples (KQ2), and results for individual interventions (KQ3) across all identified studies.

The evidence tables and summary of findings tables differentiated results based on EDSS scores, the primary outcome of the review, and other MS progression results. The EDSS¹⁶ is widely used to assess the disability and the progression of MS. Scores range from 1 (no disability) to 10 (death due to MS). A milestone often used in research is EDSS 6, characterized by the need for a cane or other constant assistance to walk 100 meters.

Where possible, variables were pooled across studies in meta-analyses to identify reliable and valid effects across studies. We pooled studies where at least 3 studies were available for the risk factor of interest and the effect measure of interest (*eg*, correlations, time to event data, count data). Continuous outcomes were reported as standardized mean differences (SMD) to facilitate the comparison of effect sizes across outcome measures. We calculated weighted mean differences (WMD) to determine the clinical importance of the effect for studies reporting on the primary outcome EDSS scores. Dichotomous data were presented as relative risks (RR). For time to event data we computed hazard ratios (HR). Correlations (*r*) transformed to *z* statistics (using the Fisher transformation) to pool across studies. Point estimates were calculated together with the 95 percent confidence interval (CI). We used a restricted maximum-likelihood estimator and the Hartung-Knapp-Sidik-Jonkman method for random-effects models to pool across studies.

All studies relevant to KQ1 were summarized narratively. When at least 3 studies were available that reported on the same risk factor and the same outcome measure, we performed meta-analysis. The synthesis differentiated variables assessed as potential risk factors, and results indicating a statistically significant association with MS disability and progression. The synthesis addressed negative and positive associations indicating worsening of progression status or protective factors. In addition, it also documented the absence of associations.

Due to the diversity in study designs, analytic methods, and effect measures, and the small number of studies, studies in military personnel and Veterans relevant to KQ2 were summarized narratively. We differentiated assessed variables and statistically significant effects. The narrative synthesis emphasizes risk factors identified in more than one individual study.

Intervention studies (KQ3) were summarized narratively, grouped by intervention category. When at least 3 studies were available for the same intervention group and outcome measure (*eg*, EDSS scores, number of patients progressing, time to progression), we performed meta-analysis. Data were based on intention-to-treat results, where available. For continuous outcomes results were based on unadjusted post-intervention scores. Results of studies in military personnel and Veterans were an *a priori* planned subgroup analysis.

RATING THE BODY OF EVIDENCE

We rated the quality of the evidence for individual risk factors across all identified studies (KQ1), in military and Veteran populations (KQ2), and for individual interventions (KQ3) across all identified pertinent studies. Based on GRADE guidelines¹⁷ the quality of the evidence was categorized as follows:

High: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Given the complexity of epidemiological data collection and interpretation, the synthesis focused on factors that have been assessed in more than one study. Other, unique assessment results were reported in evidence tables but not further documented in the summary of findings tables for KQ1 and KQ3 to provide a concise overview. Given the relevance to the VA, all available evidence was documented for KQ2.

For KQ1 and KQ2 we took the following criteria into account to determine the level of evidence quality. These are based on an adaptation of the GRADE framework for prognostic factor research.¹⁸ The “phase of investigation” criterion was used as a starting point (high or moderate quality of evidence). The criteria “study limitations,” “inconsistency,” “indirectness,” “imprecision,” and “publication bias” were used to decrease the quality of evidence. The criteria

“moderate / large effect size” and “exposure-response gradient” were used to increase the evidence grade where applicable.

For KQ3 we took the number of identified studies and the criteria “risk of bias,” “inconsistency,” “imprecision,” and “publication bias” into account. The starting point was high evidence because the data are based on RCTs.¹⁷

Publication bias was assessed with the regression test (Egger test) and the rank test (Begg test). Results indicating evidence of publication bias were reanalyzed using the trim-and-fill method to adjust for potentially missing studies.

TECHNICAL EXPERT PANEL

The technical expert panel (TEP) for the project included Mitchell T. Wallin MD, MPH, Clinical Associate Director, VA MS Center of Excellence-East; Glenn D. Graham, MD PhD, Deputy National Director for Neurology, Specialty Care Services, VA Central Office, Christopher Bever, Jr., MD, MBA, Director of the MS Center of Excellence-East, Professor, Departments of Neurology, Pharmacology and Physical Therapy, University of Maryland School of Medicine; Jodie Haselkorn, MD, MPH, Director, MS Center of Excellence-West, Professor, Rehabilitation Medicine, VA Puget Sound Health Care System; W. Joel Culpepper, MA, PhD, Associate Director of Epidemiology and Outcomes for the MS Center of Excellence-East; John W. Rose, M.D., Chief, Division of Neuroimmunology, VA Salt Lake City Health Care System; Gary M. Franklin, MD, MPH, Research Professor, Department of Environmental and Occupational Health Sciences Medicine (Neurology) and Health Services, University of Washington; Vijayshree Yadav, MBBS, MCR, Associate Professor, Neurology, Clinical Director, MS Center, Oregon Health & Science University; John F Kurtzke MD, FACP, FAAN, Professor Emeritus of Neurology, Georgetown University, Consultant in Neurology and Neuroepidemiology, Veterans Affairs Medical Center, Washington, DC; and Aaron Turner, PhD, Mental/Behavioral Health Psychology, VA Puget Sound Health Care System.

PEER REVIEW

A draft version of the report was reviewed by technical experts, clinical leadership, and additional peer reviewers where appropriate. Reviewer comments and how we have addressed them is documented in Appendix D.

RESULTS

LITERATURE FLOW


The literature search identified a large number of citations (N = 8,594). We selected 455 potentially relevant publications to be obtained as full text in order to screen them against the predetermined inclusion criteria.

We obtained a large number of publications as full text and checked studies for the outcome of interest after piloting the inclusion criteria in the first set of citations. Publications did not systematically mention progression in the title or abstract of the publication; hence, a large number of studies was obtained as full text and results sections were carefully screened for data relevant to MS progression.

In total, 300 publications were excluded because they did not meet one or more of the inclusion criteria. The list of excluded studies and the reasons for exclusion are documented in Appendix B. A large proportion of the studies was excluded because the full-text review showed that the study did not report on MS progression. The second-largest reason for exclusion was associated with studies not reporting on modifiable risk factors (Exclude-Intervention/Exposure).

In total, 95 studies¹⁹⁻¹¹² met inclusion criteria and contributed to answering the review questions. Of these, 59 studies contributed to KQ1. Despite the extensive search in general and specialist databases for military research, we only identified 4 studies that provided data for KQ2. In total, 36 RCTs were identified that contributed to KQ3.

Figure 1: Literature Flow Chart



Note: Some included studies contributed to more than one KQ.

KEY QUESTION 1: What modifiable epidemiologic factors are related to multiple sclerosis progression following diagnosis?

Risk factor studies meeting inclusion criteria were published between 1973 and 2015, with a large proportion of studies having been published in the last 3 years. Of note, no study was excluded due to the publication year for this review and all databases were searched without date restriction.

Studies were conducted in the US, Canada, Australia, Japan, Iran, Italy, Belgium, UK, the Netherlands, France, Sweden, Germany, Turkey, and Finland, and some were international samples based on online surveys. Studies identified participants through hospital records or surveyed members of MS registries. Most studies used unselected samples that included a range of MS forms.

Studies assessed a large variety of modifiable epidemiological factors and used different operationalizations of potential risk factors (*eg*, average number of cigarettes smoked per day, exercise / physical activities assessed with the revised Health Promoting Lifestyle Profile [HPLP-II]). Some studies assessed the current status while others assessed lifetime prevalence (*eg*, ever smokers).

Included studies used a broad range of outcome measures such as EDSS scores, other patient-reported scale scores, correlations with EDSS scores or other measures of disease status, time to EDSS 6, time to EDSS 4, time to secondary progression, or time to wheelchair dependency. Some studies used standardized scales such as the EDSS while others reported on clinician-defined outcomes (*eg*, clinical deterioration).

The research study pool included 13 prospective studies.^{20,30,35,69,72,76,87,91,96-98,112,113} These studies assessed participants at 2 or more different points in time and are better suited to make predictions (rather than establish concurrent associations, or relying on retrospective assessments from memory about factors experienced in the past).

Details of all included studies are presented in the evidence tables. We grouped studies exclusively reporting on vitamin D or sun exposure, studies reporting on childbirth-related factors, studies investigating the role of smoking, studies reporting on diet and nutrition, and studies reporting on unique factors such as childhood trauma. The last evidence table summarizes studies that investigated more than one risk factor of interest for this review.

Of the single-factor studies, the largest group addressed vitamin D. Vitamin D can be absorbed from exposure from sunlight, from diet, or from dietary supplements. The first evidence table for KQ1 documents how published studies have operationalized this potential risk factor for MS progression.

Table 1. Evidence for KQ1 (MS Progression Risk Factors): Vitamin D or Sunshine Exposure

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Ascherio, 2014 ²⁰ prospective	18 European countries, Israel, and Canada	Sample from BENEFIT trial, presenting with first episode of neurological dysfunction suggestive of MS Form N/A; Poser criteria, McDonald 2001 criteria	EDSS changes	465	Time series Multivariate analysis	25(OH)D level	Sex, age at baseline, treatment group, baseline T2 lesion score, type of clinically isolated syndrome (BMI and steroid use explored)	A 50-nmol/L increase in 25(OH)D levels was associated with a reduction of 0.16 steps in EDSS scores (p = 0.11); 25(OH)D concentrations \geq 50nmol/L predicted lower EDSS during subsequent 4 years (p = 0.004)	
Dastagir, 2013 ³³ concurrent	US	MS center patients Relapsing MS patients (R-R or SP); criteria N/A	EDSS score	100	Cross-sectional Multiple regression	Vitamin D levels	Race, age, disease duration, time of onsite of Rx	Vitamin D level showed significant inverse correlation with EDSS (data N/A)	
Fragoso, 2012 ³⁹ retrospective	South America	Patients with MS from Argentina, Brazil, Chile, and Peru, mean age 40.8 (SD 12.6) years, mean disease duration 8.2 (SD 15.5) years, 29.1% female Form N/A, mean EDSS 2.48 (SD 2.34); Poser criteria, McDonald 2005 criteria, McDonald 2001 criteria	Progression to EDSS 6	1207 cases, 1207 controls	Case-control ANOVA, chi-square test, linear regression, correlation	Month of birth in different latitudes of South America	Latitude, age, disease duration, gender	No difference in disease progression in relation to the month or season of birth (numerical data N/A)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Gelfand, 2011 ⁴¹ concurrent	US	African Americans with MS, mean age 21.9 (SD 11.2) years, 55.9% female, 18.7% European genetic ancestry Form N/A, MSSS 6.1(CI 4.8, 8.1); McDonald 2001 criteria	MSSS score	339 cases, 342 controls	Cross-sectional Correlation	25(OH)D levels	Age, gender, HLA-DRB1*15 status, latitude		No linear association between MSSS and vitamin D status (p = 0.57), no association between low vs high MSSS and deseasonalized or unadjusted vitamin D (OR 0.79, p = 0.86; OR 1.01, p = 0.97)
Hatamian, 2013 ⁴⁵ concurrent	Iran	Patients of MS Society with R-R confirmed by clinical findings and MRI, mean age 28.4 yrs, 70% female R-R with EDSS score < 5.5 and in remission; criteria N/A	EDSS score	52 MS patients, 52 healthy participants	Case-control Multiple linear regression analysis	25(OH)D level	Duration of disease, sex, age	Vitamin D was not associated with EDSS (beta = -0.01, p = 0.34) in univariate analysis; in adjusted model duration of disease was the only significant contributor to EDSS	
Lucenti, 2014 ⁵⁸ retrospective	Italy	MS patients, mean age 32 (SD 10.4) years, mean disease duration of 8.8 (SD 7.8) years, 65% female, 84% R-R and SP, 16% PP, median MSSS 3.86 (CI 3.55, 4.14); criteria N/A	MSSS score	1782	Cross-sectional Quantile regression	Month of birth	Gender, age at onset, clinical form		Month of birth had no impact on disease progression
Knippenberg, 2011 ⁵⁰ concurrent	The Netherlands	Outpatients with MS, 73% female, mean age 44.2 R-R, SP, PP; criteria N/A	EDSS score	59	Cross-sectional Correlation	25(OH)D serum level	N/A	Vitamin D did not reach statistical significance (r = -0.198)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Koch, 2008 ⁵¹ retrospective	Canada, The Netherlands	Canadian MS database 29.6% males, mean age at onset 30.6, mean disease duration 20.1 years (SD 9.9); Dutch database 33.3% males, mean age at onset 32.9, mean disease duration 17.98 years (SD 10.4) Canadian: 12.4% PP, 87.2% R-R; Dutch 29.4% PP, 87.6% R-R; Poser criteria	Time to EDSS 6, time from MS onset to secondary progression, age at secondary progression	N = 2837; N = 810	Cross-sectional Kaplan-Meier survival analysis	Month of birth	N/A	No association between the month or season of birth and disease progression could be found that was reproducible in both cohorts	
Kragt, 2009 ⁵³ concurrent	Europe, The Netherlands	MS patients 68% female, 98% Caucasian, and mean 11.2 years duration, 98% born in the Netherlands, 64% of women premenopausal Definitive MS; Poser criteria	EDSS score	103 MS and 110 healthy controls	Case-control Correlation	Summer and winter serum 25(OH)D concentrations	N/A	No significant correlation between summer and winter vitamin D and summer and winter EDSS in sample; but in women $r = -0.25$ (summer, $p = 0.044$) and $r = -0.29$ (winter, $p = 0.020$)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Niino, 2013 ⁷⁰ concurrent	Japan	MS patients from Medical Center and Neurology Clinic, 90% female, mean age 40.8, mean age onset 30.1 years, mean and median age of disease duration 10.8 and 10.5 years 69% remitting phase, 33% relapsing phrase, 21% SP; McDonald 2010 criteria	Decreasing EDSS score and MSSS	43 cases, 34 controls	Case-control ANOVA	1,25(OH)2D, 25(OH)D, Vitamin D-binding protein	N/A	Negative correlation between 25(OH)D and EDSS ($r = -0.53$, $p < 0.01$)	25(OH)D levels in SPMS patients were decreased compared with R-R patients at remitting phase ($p < 0.01$); serum 25(OH)D correlates negatively with disease severity in R-R in the remitting phase and SP MS
Shahbeigi, 2013 ⁸⁶ concurrent	Iran	Neurology clinic patients, 76% women, mean age 34 (SD 9.1), mean disease duration 6 years (5.14) Mild (73%), moderate (11%), and severe (16%) MS; mean EDSS score 2.76 (SD 1.93); McDonald 2005 criteria	EDSS score	98	Cross-sectional Correlation	25(OH) Vitamin D3 concentration	N/A	Significant inverse correlation between EDSS and vitamin D level ($r = -0.168$, $p = 0.049$)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Smolders, 2008 ⁹⁰ concurrent	The Netherlands	Outpatient clinic patients, 75% female R-R 47%, SP 32%, PP 18%, unknown 3%; McDonald 2001 criteria	EDSS score	267	Cross-sectional T test, Mann-Whitney U test, linear regression model, poisson regression model	25(OH)D serum levels, 1,25(OH)2D	Sex, age, disease course (years)	Raw 25(OH)D levels correlated negatively with EDSS, there was no association between EDSS score and raw 1,25(OH)2D levels (p = 0.065); when vitamin D levels were tested as predictors of EDSS score, only the adjusted 25(OH)D level was an independent predictor, when the levels were considered as dependents of disability, only 25(OH)D was independently predicted by EDSS score (OR=3.155, CI -4.936, -1.374); 1,25(OH)2D level was not dependent upon disability	
Soilu-Hanninen, 2008 ⁹¹ prospective	Finland	MS patients, mean age 34.1 (SD 1.5 years), mean time from the diagnosis of definite MS 5.6 years (range 6-15 years); healthy laboratory personnel living in the same area Form N/A, Mean EDSS 2.4 (range 0-5); criteria N/A	EDSS progression during 1 year	Treatment 23, Control 23	Case-control Logitudinal analysis	Vitamin D (25(OH)D) level	Grouped by winter, spring, summer, and autumn serum 25(OH)D levels	No correlation between vitamin D nutrition and EDSS progression (p = 0.07)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Sternberg, 2013 ⁹⁵ retrospective	US	MS patients: 75.7% female, mean age 55.6 (SD 11.5) years, mean disease duration 19.0 (SD 9.8) years 61% R-R, 31.6% SP, 7.4% PP; EDSS 4.1 (SD 2.2); criteria N/A	EDSS, MSSS score	206	Case control Regression analyses	Vitamin D3 plasma level	Cardiovascular drugs, smoking	Vitamin D level was inversely associated with EDSS (p = 0.05) and MSSS (p = 0.04)	
Thouvenot, 2014 ¹⁰⁰ concurrent	France	Files from MS clinic, age 45.3, 12.1 average years of disease, 72% women PP, SP, R-R; McDonald 2005 criteria	EDSS score	181	Other retrospective cohort analysis Kruskal-Wallis to compare vitamin D levels between MS types, Wilcoxon test comparing vitamin D levels in different origins	25(OH)D plasma level	N/A	Vitamin D level associated with EDSS score in bivariate model OR = 2.87 (p = 0.0012)	

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Van der Mei, 2007 ¹⁰³ concurrent, retrospective	Australia	Recruitment at local MS societies, eligible cases had cerebral MRI abnormalities and clinically definite MS RRMS, SPMS, PPMS; Poser criteria	EDSS score	136 MS patients, 272 matched community controls	Case control ANOVA F test Linear regression	25(OH)D status, time in the sun in summer and winter on leisure days in last 3 years, time in the sun in summer during work hours in the last year, past sun exposure, dietary intake last 12 months	Month serum sample was taken, duration of MS since first symptom	EDSS and 25(OH)D level correlation $r = -0.38$ ($p < 0.0001$); recent sun exposure was significantly associated with high EDSS (leisure $r = 0.39$, $p < 0.01$; during work hours $r = 0.40$, $p < 0.01$); no statistically significant correlation with past sun exposure or dietary intake	
Weinstock-Guttman, 2011 ¹⁰⁸ concurrent	US	MS patients mean age 46.6 (SD 10.6) years, disease duration 13.8 (SD 10.3) years, 71.9% female, 15.2% statin use 85.4% R-R, 11.8% SP, 2.8% PP; median EDSS 2.5, MSSS 3.5 (SD 5.43); McDonald 2010 criteria	EDSS and MSSS score, EDSS 4 or greater	178	Cross-sectional Stepwise regression	Vitamin D levels	Age, gender, race, statin use, lipid indicator variables	Deseasonalized 25-hydroxy vitamin D3 associated with MSSS ($p = 0.021$) but not included in EDSS prediction	

Note: N/A not available, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus



The 17 identified studies provided data on patients in different European countries, the US, Canada, Iran, Japan, Israel, and Australia. Several studies recruited patients through MS registries. Total sample sizes ranged from 46 and 2,837. The majority of studies were concurrent studies, measuring the current status of the proposed risk factor and the outcome of interest simultaneously. Four studies assessed retrospective data (*ie*, predicted outcomes from exposures in the past).^{39,51,58,95} Two studies were prospective studies^{20,114} reporting on the risk factor and outcome sequentially, with the exposure preceding the outcome measure.

Assessed potential risk factors (as reported) were serum or plasma 25(OH)D levels at the time of assessment, 25(OH)D levels in the summer and winter, 1,25(OH)2D, vitamin D-binding protein, vitamin D levels not further specified, dietary vitamin D intake, sun exposure in the summer, sun exposure in the winter, time in the sun on leisure and on work days, and the month of birth.

Several studies reported on the correlation between 25(OH)D levels and EDSS scores, either reporting the correlation coefficient, the p-value, or paraphrasing the association. No other specific risk factor (*eg*, sun exposure) and specific outcome (*eg*, MSSS score) combination was assessed in more than one study. Only one study reported on the change between relapsing-remitting MS to secondary progressive MS. Koch et al⁵¹ analyzed the month of birth and the time from MS onset to secondary progression in sample of patients with primary progressive or relapsing-remitting MS. Half the studies adjusted for potential confounders, such as age and duration of disease.

One of the prospective studies reported that 25(OH)D levels of 50nmol/L at up to 12 months predicted lower disability during the subsequent 4 years.²⁰ The other prospective study reported a statistically non-significant correlation between vitamin D nutrition and EDSS progression, but it was unclear whether the study had sufficient power to detect an effect.⁹¹ The quality assessment of the two prospective studies is shown in the appendix. The study by Ascherio et al was a clinical trial sample,²⁰ rather than derived from a large and broader in scope MS registry sample. The study by Soilu-Hanninen was very small (23 patients with MS) and may also not be a good representation of the population of interest.¹¹⁴

Another large group of studies reported on smoking and effects on disease progression, as documented in the next evidence table.

Table 2. Evidence for KQ1 (MS Progression Risk Factors): Smoking

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Healy, 2009 ⁴⁶ retrospective	US	1465 out of 1745 patients who completed questionnaire at MS center R-R (N = 1020), SP (N = 212), primary progressive (PP) (N = 63), progressive relapsing (PR) (N = 24), CIS (N = 106), unspecified demyelinating disease (N = 39), or suspected MS (N = 1); McDonald 2005 criteria	EDSS score, MSSS, time to conversion from R-R to SP, proportion of patients who progressed on EDSS after 2 years/ after 5 years (increase in EDSS score)	1465	Cross-sectional Kruskal-Wallis, Wilcoxon, chi-square test, Cox proportional hazard model	Smoking history (smoking status, age of starting and quitting, average number of cigarettes smoked per day)	Age, disease duration from first symptom, gender	EDSS was significantly higher in current smokers (p < 0.0001) but not significantly different in ex-smokers (p = 0.22) compared to never smokers; EDSS was significantly lower in the light smoking group compared to the moderate smoking group (p = 0.040) and compared to the heavy smoking group (p = 0.025)	Conversion from R-R to SP occurred at faster rate in current smokers than never smokers (HR 2.50, CI 1.42, 4.41) but was similar in ex-smokers and in never smokers (HR 1.05, CI 0.59, 1.84); MSSS was significantly higher in the heavy smoking group compared to the light smoking group (p = 0.038) and the moderate smoking group (p = 0.048); probability of a PP course was higher among current smokers (OR 2.42; CI 1.09, 5.35) or ex-smokers (OR 1.91; 95% CI 1.02, 3.58) than never smokers



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Hernán, 2005 ⁴⁷ retrospective	UK	Individuals with a confirmed diagnosis of MS and 2 years or more of medical history prior to diagnosis available R-R; Poser criteria	R-R converting to progressive course (continuously worsening disability lasting 6 months or more as determined by 2 independent reviewers)	201	Case-control Cox proportional hazards regression	Current, past or never smokers; ever vs never smokers; according to medical records	Age at first symptoms, sex, first symptoms including motor deficits		Incidence rate ratio of secondary progression was 3.6 (CI 1.3, 9.9) for ever smokers compared with never smokers; 80% of progression occurred by 4.6 years of follow-up in smokers and by 5.3 years in nonsmokers
Jansons, 2011 ⁴⁸ retrospective	US	Patients with progressive MS Established progressive MS; criteria N/A	Time to progression from onset of MS in patients with relapsing-remitting MS; age at progression onset; time to EDSS 6 after progression onset	756	Cross-sectional Cox regression	Smoking (ever vs never; current vs previous; higher vs lower than mean pack-years)	Gender, age, number of 1st two year relapses, immune-therapy, PPMS vs SAPMS vs SPMS, post-progression relapses, symptoms at MS onset, CSF positivity		More than 19 pack-years of smoking was independently associated with shorter time to progression (p = 0.015); smokers reached EDSS 6 ~5 years earlier than never smokers (p < 0.001); smoking alone very strongly predicts an earlier onset of progression and disability after progression in MS



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Koch, 2007 ⁵² retrospective	The Netherlands	Patients in MS database, definitive MS meeting Poser criteria Benign relapsing-remitting, R-R, SPMS, PPMS;	Benign relapsing-remitting, R-R, SPMS, PPMS; age at onset of SP, age at onset of PP disease; time from disease onset to EDSS 4, time from disease onset to EDSS 6; EDSS score	364	Case-control Conditional logistic regression and Cox hazard ratio	Smoking history: current status, starting and quitting dates, nonsmoking periods, number of cigarettes smoked, number of smoked pack-years before and after onset	Gender	No significant differences in the time to EDSS scores 4 and 6; total pack-years were not significantly correlated with EDSS in the total sample but in women (r = -0.16, p = 0.01)	In patients with PPMS, none of the variables had a significant effect on the age of progression
Maghzi, 2011 ⁵⁹ retrospective	Iran	Patients from MS registry; smoking group: 78.5% female, mean age 32.75 (SD 8,68) years, mean age at onset 27.42 (SD 7.91) years; control group: 46.5% female, mean age 32.86 (SD 9.65) 83.2% R-R, 2.9% PP, 13.9% SP course in the smoking group; McDonald 2005 criteria, McDonald 2001 criteria	Progression (EDSS/ disease duration)	516	Cross-sectional Conditional logistic regression	Ever/never smoker, smoking history, smoking duration, pack-years smoked	Age, gender	No difference in disease progression (EDSS/ disease duration) between smokers and nonsmokers (0.54, SD 0.42 vs 0.49, SD 0.48) in male patients	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Manoucherhri nia, 2013 ⁶¹ retrospective	UK	<p>Patients registered in MS specialist clinic database, 270 male, 625 female, mean age 49 years, mean duration of illness 17 years</p> <p>CIS, suspected MS, R-R, SP, PP; Lublin & Reingold criteria</p>	Reaching EDSS 4, reaching EDSS 6	895	Cross-sectional Linear regression, Cox proportional hazard regression model	Smoking status (nonsmoker, stopped before onset, stopped after onset, current smoker)	Sex, onset age, use of DMT, initial course (R-R, PP)	<p>RR of reaching EDSS 6 was higher in smokers compared to nonsmokers; risk of reaching EDSS 4 and 6 in ever-smokers vs never-smokers was 1.34 (CI 1.12,1.60) and 1.25 (CI 1.02, 1.51); current smokers showed 1.64 (CI 1.33, 2.02) and 1.49 (CI 1.18, 1.86) times higher risk of reaching EDSS 4 and 6 compared with nonsmokers; ex-smokers had a significantly lower risk of reaching EDSS 4 (HR 0.65, CI 0.50, 0.83) and 6 (HR 0.69, CI 0.53, 0.90) than current smokers, and there was no significant difference between ex-smokers and nonsmokers in terms of time to EDSS 4 or 6</p>	No association between smoking status and PP vs R-R type at onset



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Pittas, 2009 ⁷⁶ prospective	Australia	Patients with MS, female 69.2%, mean age 48.2 years (SD 11.4), median age of MS onset 33.5 years, mean disease duration 14.1 (SD 10.3) years R-R at cohort entry 75%; mean EDSS 3.7 (SD 2.3); Poser criteria, McDonald criteria	MS progression (MS Severity Scale [MSSS])	203	Experimental Mixed effects linear regression	Pack-years smoked in the past 6 months at entry, ever smoker, total pack-years prior to MS, pack-years from onset, current smoker	Entry MSSS and EDSS, age, gender, IMT use, education level, and month of review		Cumulative pack-year smoked after cohort entry was associated with an increase in longitudinal MSSS (p < 0.001)

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Roudbari, 2013 ¹¹⁵ retrospective	Iran	Patients registered in the MS Society (Guilan, Iran) database; mean age 34.8 (SD 9.5) years, 74% female, mean age at disease onset 1.7 (SD 2.3) years, 14% smokers, 86% nonsmokers R-R 64%, SP 36%; McDonald 2005 criteria	Risk of progression	524 included, 400 responded	Cross-sectional Cox regression	Smoking (pack-years smoked; 20 cigarettes smoked per day for 1 year = pack-year; nonsmokers vs < 10 pack-years vs > 10 pack-years)	Age on disease onset, number of relapses per year, gender		Compared with nonsmokers, current smokers who continued smoking after MS diagnosis and patients who started smoking after MS diagnosis showed a RR of 2.43 (CI 1.2, 4.8; p < 0.001) and RR 3.55 (CI 1.3, 9.2; p = 0.007) for MS progression; HR for smokers vs nonsmokers was 2.25 (CI 1.3, 3.99; p = 0.004); risk of SP was 2.43 times higher (CI 1.28, 4.6; p = 0.007) for greater numbers of cigarettes smoked per day vs nonsmokers



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Sundström, 2008 ⁹⁷ prospective	Sweden	Respondents MS epidemiological survey and interviews, 64% female R-R, SP, progressive from onset; criteria N/A	Progressive disease (PP, SP, or progressive relapsing) determined during interview, neurological exam, and medical records; progressive disease from onset, conversion to progressive disease (R-R, SP), time to progressive disease based on EDSS	122	Cross-sectional Multivariate Cox regression	Self-reported smoking habits; ever smoker (had to have started before MS onset to be included), never smoker; early start (15 or younger) or later start	Gender, age at disease onset, relapsing-remitting MS cases		After a median of 6 years disease duration, progressive disease was significantly more likely to occur in ever smokers compared to never smokers (p = 0.006); progression was most likely in patients who started smoking early compared to later (p = 0.005) or never smokers (p < 0.001); cases with late disease onset had 3x higher risk and ever smokers had 2x as high a risk for progression
Tepavcevic, 2010 ¹¹² prospective	Serbia	Patients with MS, age 18-60 years EDSS < 8; McDonald criteria	EDSS score	98	Prospective followup T-test, linear regression	Cigarette smoking status at baseline	Baseline EDSS, gender	The baseline smoking status showed independent predictive value on development of physical disability (p = 0.001)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Zivadinov, 2009 ¹¹¹ retrospective	US	Patients with MS at MS center with MRI exam, age 18-80 years, mean age 44 (SD 10.2), mean disease duration 12.1 years (SD 9.1), 93% white, 6% black; 79% female R-R: 68.6%, CIS: 5.7%, SP: 22.9%, PP: 2.8%; criteria N/A	EDSS score	368	Cross-sectional Polytomous universal model ordinal regression method	Smoking: never-smoker, ever-smoker, active smoker; mean duration; average number of packs per day	Age, disease duration, treatment duration	Median EDSS for the ever-smokers was 3.0 compared with 2.5 for the never-smokers; association of EDSS score with never-smoker/ever-smoker status (p = 0.004)	

Notes: N number of participants, N/A not available, SD standard deviation, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, RR relative risk, vs versus



We identified 11 studies that exclusively evaluated the effect of smoking on disease progression. Studies from the US, different European countries, Iran, and Tasmania contributed research. All but 3 studies were retrospective analyses. Participants were recruited at MS centers and registries. The number of included participants ranged from 98 to 1,465.

Specific assessed risk factors were: current smoking status; smoking status as baseline; age of starting and quitting; early (15 years or younger) or later smoking start; number of cigarettes smoked per day; current, past, or never smokers; ever versus never smokers; number of cigarette pack-years in total; pack-years smoked in past 6 months; smoking status before and after onset of MS; nonsmoking periods; and smoking duration in years. Information came from self-reported survey data or medical records. All studies used multivariate methods controlling for demographic and disease characteristics.

Studies used a range of outcome predictors, assessing continuous outcomes, dichotomous status variables, and time to event data. The individual measures were EDSS scores, MSSS scores (measure of rate of disease progression, standardized for disease duration), EDSS score divided by disease duration, time to conversion to secondary progression from onset, time from disease onset to EDSS 4, time to EDSS 6, reaching EDSS 4 during study period, reaching EDSS 6, experiencing progression, age at onset of secondary progression, and proportion of patients who progressed on EDSS after 2 years/ after 5 years (increase in EDSS score).

Three prospective studies were identified. All reported a statistically significant effect of smoking on MS but reported on different outcome measures.^{76,97,112} The detailed quality assessment of the prospective studies is shown in Appendix C. Two of the studies did not indicate major flaws. One was published as an abstract only and lacked detail.

The following evidence table shows studies that investigated childbirth-related factors such as the use of epidural analgesia during childbirth.

Table 3. Evidence for KQ1 (MS Progression Risk Factors): Childbirth-associated Factors

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Confavreux, 1998 ^{30,116} prospective	Europe, multiple countries	Women had MS before pregnancy and were pregnant, referred by European neurologist; duration of MS before pregnancy 6 years, age at beginning of pregnancy 30 96.6% R-R, 3.14% SP; mean EDSS at baseline 1.32; Poser criteria	EDSS or DSS	254	Time series Logistic regression	Epidural analgesia, breast feeding	Age, duration of disease, occurrence of relapses before and during pregnancy		No acceleration of the progression according to use of epidural analgesia (p = 0.66) or breast-feeding (p = 0.27); same finding 2 years post-partum
Gava, 2014 ⁴⁰ retrospective	Italy	Women with MS at an academic medical center SP and R-R; McDonald 2010 criteria	EDSS score	174	Cross-sectional Logistic regression analysis	Oral contraceptives use	Age, duration of disease, age of menarche, use of DMT, parity	Ever users of combined oral contraceptives had lower EDSS scores compared to never users (p = 0.044)	
Lu, 2013 ⁵⁷ retrospective	Canada	Female MS patients with live births, British Columbia Perinatal Database Registry, mean age 32 years 99% relapsing-onset, 1% PP; Poser criteria, McDonald 2005 criteria	EDSS 1-1.5 vs 2-2.5 vs 3 or higher	431	Cross-sectional Multivariate models	Obstetrical epidural and spinal anesthesia use during delivery	Age, parity, comorbidities, mode of delivery, birth weight, gestational age in weeks	EDSS was not associated with use of either type of anesthesia (p > 0.1)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Pastò, 2012 ⁷² prospective	Italy	Women with pregnancies between 2002 and 2008 in 21 MS centers, mean age at conception 31.8, mean age at onset 24.7, mean disease duration at conception 7.1 years Form N/A, mean EDSS at conception 1.5 (SD 1.0); McDonald 2010 criteria	Progression on EDSS	415	Cross-sectional Multivariate analysis	Epidural analgesia delivery, cesarean delivery	Age at MS onset, age, disease duration, EDSS at conception, DMT before pregnancy, number of relapses in year before pregnancy / during pregnancy, exclusive breastfeeding	Epidural analgesia delivery and cesarean delivery were not associated with disability progression after delivery	
Sena, 2012 ⁸⁵ retrospective	Europe	Female MS patients registered with hospital, with R-R MS, median disease duration 6.2 (SD 5.1) years, never-users vs past-users vs after-users: mean age 37.3 (SD 10.2) vs 38.6 (SD6.8) vs 32 (SD6.6) years, mean age at disease onset 29.9 (SD 9.8) vs 34.6 (SD R-R; McDonald 2005 criteria	EDSS, MSSS scores; benign course (MSSS < 2.5)	132 (53 never-users, 26 post-users, 54 after-users)	Cross-sectional Multivariate linear and logistic regression	Oral contraceptive use	Age, gender, smoking, childbirths, age at disease onset, disease duration, relapse rate, age of menarche, age at onset of OC use, OC use duration	After-user patients had lower EDSS and MSSS scores than never users (p < 0.001, p = 0.002) and past users (p = 0.015 and p = 0.002)	Patients who took oral contraceptives after disease onset were more likely to have a more benign disease course (MSSS < 2.5) than never / past users (OR: 2.97; CI 1.24, 6.54; p = 0.011)

Notes: DMT disease modifying treatment, N number of participants, N/A not available, SD standard deviation, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus



We identified 5 studies reporting on pertinent risk factors. Study sample sizes in the studies varied widely, ranging from 174 to 2,105 included women. Studies used different outcomes measures: EDSS, DSS, or MSSS scores. One study included only patients with relapsing-remitting MS. It predicted EDSS and MSSS scores and reported on the odds ratio of having a more benign disease course defined as MSSS below 2.5.⁸⁵

The studies evaluated a number of potential risk factors that may be associated with MS progression: epidural and/or spinal analgesia during delivery, breast feeding, use of oral contraceptives, and cesarean delivery. All studies adjusted for covariates in the analyses, in particular the age at the time of the first child and age at MS onset.

Three studies were retrospective analyses but 2 studies assessed women at the time of pregnancy and followed them for a number of years.^{30,72} The quality assessment of the prospective studies are shown in the appendix. The main source of potential bias was confounding due to selection bias. It is possible that participants self-selected the exposure or intervention, such as breast feeding, because of their EDSS scores. Hence studies may show reverse causality with EDSS scores (the outcome) influencing the variable assessed as the risk factor.

We also identified studies that exclusively reported on diet and its effects on disability and progression of MS, as documented in the following evidence table.

Table 4. Evidence for KQ1 (MS Progression Risk Factors): Diet

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Aupperle, 2005 ²¹ concurrent	US	Patients with MS, 84% female R-R; criteria N/A	EDSS	38	Case-control Analysis N/A	Red blood cell fatty acids, dietary fatty acids intake	N/A	None of the fatty acids were related to disability	
Foster, 2012 ³⁸ retrospective	US	MS patients, mean age 47.8 (SD 12.5) years, mean disease duration 15.2 (SD 10.5) years, median EDSS 3.0 (SD 4.0) 93.5% Caucasian American, 4.5% African American, and 5% other races, 76% female 66.2% R-R, 22.4% SP, 7% relapsing SP, 4.4% PP or primary relapsing; McDonald 2001 criteria	EDSS and MSSS scores	272 cases, 151 controls	Cross-sectional Regression analyses	Duration of alcohol consumption after MS diagnosis 15 years or fewer (compared to no consumption of alcohol or consumption for > 15 years)	Age, age of onset, sex, disease duration	EDSS scores were lower in patients who had consumed for 15 years or fewer after MS onset compared to those who did not consume alcohol or consumed it for > 15 years; pattern of non-linear dependence suggests that moderate duration of alcohol use does not have adverse effects	
Kurtzke, 1973 ⁵⁴ retrospective	US	Men first diagnosed with MS in US Army hospitals during World War II Form N/A; Schumacher criteria	DSS score change (better, same, worse after hospitalization)	517	Other Count comparison	Diet	N/A		Diet: 28% better, 56% the same, 16% worse; patients with hospital routine without specific treatments: 19% better, 74% same, 8% worse.



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Plow, 2012 ⁷⁷ concurrent	US	N/ARCOMS registry, 292 respondents out of 1000 randomly selected surveyed patients, 79.7% female, average duration since diagnosis 15 (SD 8.30) years 63% R-R, 20% SP, 8.1% PP, 6.6% progressive relapsing MS; criteria N/A	Type of MS (R-R, progressive, unknown)	292	Cross-sectional Logistic regression	Healthy nutritional behavior indicator defined by whether participants answered 4 out of 5 questions with the response of "often": 1) make good food choices, 2) eat 5 servings of fruits and vegetables a day, 3) limit fat intake, 4) read labels, 5) eat regularly	Gender, optimism/pessimism, BMI, physical activity, emotional self-management, communication with physician		Nonsignificant correlation type of MS-nutritional behavior (p = 0.38)
Swank, 1990 ^{98,117} prospective	US, Canada	Patients who maintained contact with MS clinic Form N/A, minimum, moderate, and severe disability; other criteria	Average worsening in disability grade, percentage of deaths due to MS	144	Case series t-test	Good dieters (fat consumption = < 20 g/day) vs poor dieters (consumption > 20 g/day), period checks of eating habits (presumably) self-reported	N/A		In each of the disability groups the average worsening in disability grade and the percentage of deaths of the poor dieters significantly exceeded those of the good dieters; greatest difference occurred for minimum disability at study entry (p < 0.0001)

Notes: N number of participants, N/A not available, N/ARCOMS North American Research Committee on Multiple Sclerosis, SD standard deviation, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus

We identified 4 studies that exclusively looked at dietary behavior. All studies were conducted in the US or the US and Canada.

One study reported concurrent data, meaning current dietary fatty acid intake, in patients with relapsing-remitting MS. The study, published as a conference abstract, lacked detail but stated that none of the assessed fatty acids were related to disability.²¹

Two studies were retrospective analyses.^{38,54} One reported on the duration of alcohol consumption after MS diagnosis. The other focused on men on active duty in the US Army and reported on the disease course for patients that were put on a specific diet in the hospital, compared to patients without administration of a specific therapy.⁵⁴ The study did not report a statistical analysis but, applying Fisher's exact test to the raw data, we find that the difference between groups was not statistically significant. No information was available on the specific diet and approaches may have varied across patients and hospitals.

A fourth study reported on the Swank diet in multiple publications.^{98,118,119} The prospective study compared "good dieters," meaning people with fat consumption of 20g per day or less, and "poor dieters" who exceeded the fat consumption limit. Patients who were given the diet advice were followed for 34 years. The study reported that in each of the disability groups, the average worsening in disability grade and the percentage of deaths of the poor dieters significantly exceeded those of the good dieters. The detailed quality assessment of the study is shown in Appendix C. The main concern is the ascertainment of the risk factor, which in this case is the compliance of the participants with the diet and self-reports that determined the classification into good or poor dieters.

A small group of studies exclusively reported on exercise behavior as shown in the following evidence table.

Table 5. Evidence for KQ1 (MS Progression Risk Factors): Exercise

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Marrie, 2009 ⁶² retrospective	US, Canada	N/ARCOMS questionnaire respondents, 94.5% white, 75.8% women, mean age 52.7; mean age at onset 31.2, mean age of diagnosis 31.2, mean disease duration 21.5 Form N/A, PDDS mild disability 35.4%, moderate disability 11.95, severe disability 52.7%; criteria N/A	PDDS category	8983	Cross-sectional Multivariate regression	Physical activity, leisure-time activity (scale from 1 = inactive to 4 = heavy activity) in the last year	Smoking status, physical activity level		Physical activity decreased steadily with increasing disability
Milivojevic, 2013 ⁶⁴ retrospective	US	MS patients, 65.1% female, mean age 38 (range 21-58), mean disease duration 5.4 years (range 1-16) Form N/A, mean EDSS 1.7 (range 0-5.5); neurological evaluation	EDSS score	63	Cross-sectional T-tests	Use of physical rehabilitation	N/A	Patients who used inpatient, outpatient, and home-based rehabilitation had higher levels of impairment compared to patients who were not rehabilitated (p = 0.002, p = 0.004, p = 0.0021)	
Motl, 2012 ⁶⁸ prospective, retrospective	US	MS patients recruited through National MS Society, mean age 45.9 (SD 9.6) years, mean disease duration 8.8 years (SD 7.0), median PDDS 2, 86.6% female, 91% Caucasian, well-educated R-R; criteria N/A	Progression in PDDS	269	Time series Latent growth curve modeling	Premorbid physical activity	Gender, age disease duration since diagnosis, disease-modifying therapies		Premorbid physical activity predicts the linear change in disability scores (PDDS) (p < 0.005)



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Shammas, 2014 ⁸⁷ prospective	Germany	Patients with definite MS and EDSS < 5, 64% female, mean age 41 years (SD 9.3), mean disease duration 12.18 years (SD 10.67), recruited in MS clinic 8/11 R-R, 1/11 PP, 2/11 SP, mean EDSS 3.6 (SD 1.66); McDonald 2010 criteria	EDSS score	11	Other Correlation	Total number of steps taken during study period	Age, gender, weight, height, shoe sizes	Number of steps negatively correlated with EDSS score (r = -0.54, p = 0.01)	
Stuifbergen, 2006 ⁹⁶ prospective	US	Patients from MS Society patients and advertisements in rural newspapers, mean age 49.4 years, 83% women R-R, PP, SP, PR; criteria N/A	Incapacity Status Scale (ISS) scores	611	Time series Multivariate latent curve modeling	Exercise behavior (HPLP-II exercise/physical activity subscale)	Age, sex, years since diagnosis, residency type, attrition		Exercise behaviors and functional limitations were negatively correlated (r = -0.34); time 1 exercise scores were negatively correlated with annual change rate in functional limitations (r = -0.17); increasing rates of change in functional limitations correlated with decreasing rates of change in exercise behavior (r = -0.25)

Notes: N number of participants, N/A not available, N/ARCOMS North American Research Committee on Multiple Sclerosis, SD standard deviation, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus



The 5 studies addressing exercise were conducted in the US, US and Canada, and Germany. The number of included participants ranged from 11 to 8,983. The studies included retrospective and prospective analyses.

A large retrospective study used data from 8,983 survey respondents.⁶² It reported an association between self-reported physical activity in the last 12 months and disability measured with the Patient Determined Disease Steps (PDDS), indicating that physical activity decreased steadily with increasing disability. The PDDS is a self-report measure of disability using a scale of 0 (normal) through 8 (bedridden), developed as a surrogate for the EDSS. Another retrospective study assessed the use of physical rehabilitation and reported that patients who had used inpatient, outpatient, or home-based rehabilitation had higher levels of impairment compared to patients who were not rehabilitated.⁶⁴

A very small, prospective study in 11 participants reported a negative correlation between objectively measured physical activity over one year and EDSS scores.⁸⁷ No other data were reported that may inform the temporal association between the 2 variables, such as the effect of physical activity at baseline on MS progression.

A prospective study by Stuifbergen et al, on the other hand, assessed exercise behavior in a sample followed for 5 years. Exercise scores at the first assessment time point were negatively correlated ($r = -0.17$) with annual change rate in functional limitations due to MS (Incapacity Status Scale, ISS; self-reported degree of impairment).⁹⁶ A prospective study by Motl et al⁶⁸ reported that participants with higher premorbid physical activity levels reported less change in disability over time (PDDS scores) compared with those who reported lower premorbid physical activity.

The risk of bias evaluation for the prospective studies is shown in the Appendix C. The objectively measured study only included 11 patients and data were not prospectively analyzed.⁸⁷ The other prospective studies were higher quality but neither reported on EDSS scores, the primary outcome of this review.

The next evidence table summarizes studies that addressed other exposures not captured in previous evidence tables, such as exposure to trauma.

Table 6. Evidence for KQ1 (MS Progression Risk Factors): Other

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Baghizadeh, 2013 ²² retrospective	Iran	Neurology and MS clinic-attending patients, 78% female, mean age 34 yrs, mean age of onset 24 yrs R-R, SP, PP; McDonald criteria	MSSS scores (chronic, mild-moderate, advanced-accelerated, aggressive-malignant disease severity)	338	Cross-sectional Ordinal logistic regression	Education	Unclear		Education did not predict getting worse (p = 0.074)
Detels, 1982 ³⁵ prospective	US	MS onset between Jan 1, 1960 and Dec 31, 1969, born in the US, white, residents in 1970 in either a low-prevalence (Los Angeles County, CA) or in a high-prevalence area (King and Pierce Counties, WA); LA: 67.7% female, WA: 74.8% female; mean age at onset 33.4 yrs Form N/A; Schumacher criteria	3-point scale: 1) walking without aids; 2) walking with aids such as braces, crutches, or canes; and 3) restricted to wheelchair or to bed (self-reported)	560 cases in LA, 326 cases in WA	Cross-sectional Multivariate regression	Geographic regions (high- vs low-prevalence area)	Age at onset, residence, sex, disability status at intake		Progression to a non-ambulatory status or death was significantly greater among patients who lived in LA county (low-prevalence area)
Sibley, 1990 ⁸⁹ retrospective	US	Patients in the community with clinically definitive MS, mean age 43 years, female to male ratio 1.6 to 1 Form N/A; Schumacher criteria	Mean increase in DSS/year	170 MS patients	Other design Chi-square test	Trauma, different subtypes (dental procedures, minor surgery, major surgery, fractures, sprains, burns, head injuries, abrasions/lacerations/contusions)	N/A		Peripheral trauma is not a risk factor for MS progression



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Covariates	EDSS results	Other results
Spitzer, 2012 ⁹³ retrospective	Germany	Patients with definite MS attending a MS outpatient clinic, age 18-50 years, mean age 39.7, 73% women, mean MS onset 29.2 years, mean MS duration 10.5 years, mean relapse rate 0.66% 70% R-R, 7% PP, 23% SP, mean EDSS score 3.2; McDonald 2001 criteria, McDonald 2005 criteria	EDSS score, disease progression (EDSS scores divided by years of disease duration)	234 with MS	Case-control Logistic and multiple linear regression	Self-reported childhood maltreatment (CTQ total score, emotional abuse, physical abuse, sexual abuse, emotional neglect and physical neglect)	Age, sex, education, current depression		Childhood trauma was not associated with disease progression or EDSS
Tuzun, 2010 ¹⁰² retrospective	Turkey	MS patients with R-R or SP MS; earthquake victim vs control: 66.7% vs 58.8% female, mean age of onset 26.8 (SE 1.3) vs 24.8 (SE 1.2), 68.6% R-R, 31.2% SP, EDSS 3.09 (SE 0.3) (earthquake); 64.7% R-R, 35.3% SP, 3.01 (SE 0.4) (control); McDonal criteria	EDSS score	82	Cross-sectional Logistic regression	Earthquake experience	N/A	Comparable EDSS scores between groups after the earthquake	
Vollmer, 2002 ¹⁰⁴ retrospective	US	US Veterans and non-veterans from NARCOMS patient registry Relapsing, PP; criteria N/A	PDDS score	2150 Veterans, 2107 non-VHA Veterans, 16119 non-veterans	Matched controls Paired t-test	VHA Veteran, non-VHA Veteran, non-veteran	N/A		PDDS scores 5.0 in VHA, 4 in non-VHA Veterans, 3.6 in non-veterans (p < 0.001 VHA Veteran vs non-veteran)

Note: N number of participants, N/A not available, N/ARCOMS North American Research Committee on Multiple Sclerosis, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, SD standard deviation, vs versus



We identified 6 studies that reported on unique risk factors of interest. Three were US studies, one was conducted in Iran, one in Turkey, and one in Germany. All but one were retrospective studies; one followed patients prospectively.³⁵ Where reported, studies included a range of MS subtypes. The largest study compared 2,150 VHA Veterans with 2,107 non-VHA Veterans and 16,119 non-veterans.

In terms of risk factors, studies reported on education, peripheral trauma (*eg*, surgery, head injuries), childhood maltreatment, geographic regions with high or low MS prevalence, recent earthquake exposure, and being a VHA Veteran.

A prospective study reported that progression to a non-ambulatory status or death was significantly greater among patients who lived in LA county, a low-prevalence area for MS.³⁵ The detailed risk of bias assessment for this study is shown in the appendix. Of note, the study measured disability status at follow-up by a self-administered mailed questionnaire; hence, the progression data are not based on physician assessments.

One study used a VA-relevant dataset and reported that VHA Veterans had higher PDDS scores than non-veterans.¹⁰⁴

The other studies reported no associations between assessed predictors and outcome measures.

The last KQ1 evidence table summarizes all those studies that reported on more than one group of risk factor of interest for this review, for example studies reporting the effect of smoking *and* exercise.

Table 7. Evidence for KQ1 (MS Progression Risk Factors): Multiple

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
Bombardier, 2004 ²⁷ concurrent	US	Survey respondents with diagnosis of MS by MRI, 77% female, mean age 48.7 years, mean EDSS 5.7, mean disease duration 11.8 years Form N/A; criteria N/A	EDSS score	739 respondents (out of 1374 surveyed)	Cross-sectional T-test	Possible, current alcohol problems during preceeding month (4 items) vs no alcohol problems; drug or medication misuse during the past month (1 item) vs not	N/A	Respondents with possible alcohol-related problems (p = 0.001) and respondents with drug misuse (p < 0.05) had lower EDSS scores	

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
D'hooghe, 2012 ^{36,120-122} retrospective	Belgium	Flemish MS Registry, relapsing vs progressive onset patients: mean age 50.3 vs 58.6, mean age onset 31.5 vs 37.3, mean disease duration 18.8 vs 21.4, female 75.6% vs 62.2%, 33.3% relapsing onset, 34.9% progressive onset, EDSS >= 6 35.9% vs 80%; Poser criteria	Time from onset or from birth to sustained EDSS 6	1431 respondents (out of 3320 invited); 704 with EDSS 6 or more	Cross-sectional Kaplan-Meier survival and Cox proportional hazard regression	Alcohol, coffee, and fish consumption (compared to no consumption); smoking; sun exposure in summer (hours daily), sun exposure in winter, sun exposure compared to peers, sunscreen/protection, working place (inside, both, outdoors); age at starting oral contraception, duration of oral contraceptive intake; health promoting lifestyles profile II (HPLP total score, health responsibility, physical activity, nutrition, spiritual growth, interpersonal relationships, stress management)	Gender, age at MS onset, IMT use	In relapsing MS, alcohol, wine, coffee, and fish consumption were associated with a reduced risk to reach EDSS 6; in progressive onset MS, all n.s. Smoking was associated with an increased risk to reach EDSS 6 in relapsing onset MS; in progressive onset MS, all n.s. except for type of fish (fatty fish associated with increased risk to reach EDSS 6 compared to lean fish). In relapsing onset MS, respondents reporting equal or higher levels of sun exposure than peers had a decreased risk of reaching EDSS 6. In progressive onset MS, the use of oral contraceptives was related to an increased risk. For relapsing onset, HPLP (p = 0.030), health responsibility (p = 0.218),	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
								physical activity (p < 0.001), and nutrition (p < 0.001) were predictive of time from onset to EDSS 6 but not spiritual growth (p = 0,048); time from birth analyses showed physical activity and nutrition to be significant (p < 0.001); for progressive onset, all n.s.	
Goodin, 1999 ⁴³ concurrent	US	Survey respondent with definite MS, 78.6% female, 92.5% Caucasian, 2% African American, 2.5% Asian, 3.0% Hispanic, mean age 48.1, mean age at MS onset 31.1, mean duration of symptoms 17.1 years 57.8% R-R, 22.6% SP, 20.1% PP; mean EDSS 4.8 (SD 2.3); diagnosed by a physician, any criteria	EDSS score	168	Cross-sectional Multiple regression	Exercise, consumption of alcohol (5-point scale from never to daily), insurance coverage, physical therapy, getting a 2nd opinion, being happy with medical care or coverage, being denied medical coverage or treatment, other dietary factors	unclear	Exercising (p = 0.001) and consumption of alcohol (p < 0.001) associated with lower EDSS scores; medical insurance coverage (p < 0.001) and physical therapy (p < 0.001) associated with higher EDSS scores; getting a second opinion, being happy with or being denied medical coverage, other dietary factors not associated with EDSS (p > 0.05)	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
Lauer, 1992 ⁵⁵ retrospective	Germany	MS patients, 64.1% female 64.2% benign, 35.8% malignant MS	MS patients with benign (DSS = < 2.0 after 11 or more years' duration) vs malignant (DSS > = 7.0 after less than 16 years' duration) course	81 (52 benign, 29 malignant)	Cross-sectional Logistic regression	Ether anesthesia, brain trauma, vaccination (poliomyelitis, diphtheria, tetanus, influenza), childhood diet breast fed, diet rich in animal fat, predominantly butter, domestic slaughtering, milk daily, unpasteurized milk, 3 or more eggs per week, animal brain, often brain sausage; childhood animal exposures (dog, cat, bird, pig, rats, mice, other rodents, cattle); animal exposure within 5 years before onset (dog, cat, bird, domestic rodents, cattle, pigs); childhood coal heating, wood heating, humid flats, no sewage system, no piped water; frequent environments (farm, industrial plant, fields,	Covariates	Associated with benign course: milk daily (OR 3.03, p = 0.03), grew up with chickens (OR 2.77, p = 0.03), frequent environment meadows/pastures (OR 3.88, p = 0.007), close contact to wood (OR 3.31, p = 0.017); not associated with ether anesthesia, vaccination (poliomyelitis, diphtheria, tetanus, influenza), brain trauma, childhood diet breast fed, diet rich in animal fat, predominantly butter, domestic slaughtering, unpasteurized milk, 3 or more eggs per week, animal brain, often brain sausage, dog, cat, bird, pig, rats, mice, other rodents, cattle, within 5 years before onset dog, cat, bird, domestic rodents, cattle, pigs, childhood coal heating, wood heating, humid flats,	



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
						meadows/pastures, natural waters, forest, close to wood)		no sewage system, no piped water, other frequent environments (farm, industrial plant, fields, natural waters, forest)	
Mandia, 2014 ⁶⁰ retrospective	Italy	MS patients mean age 45 (SD 11.0) years, disease duration 13.6 (SD 9.1) years Form N/A, mean EDSS 3.0 (SD 2.4), MSSS 3.2 (SD 2.6); McDonald 2001 criteria	MSSS score, MSSS 1 or less (mild) vs MSSS 6 or more (severe)	131	Cross-sectional Multiple linear regression	Smoking (ever, never, ex, current smoker, active/passive exposure), sunlight exposure (frequent vs rare, > 2h/day vs < 2h/day, sunscreen use), diet (vegetarian, egg consumption, fish consumption, consumption of dairy products, liver consumption, vitamin supplementation, fortified foods) in previous 2 years	Age, sex, covariates		Severe MS was predicted by vitamin D (p = 0.001) and sun exposure (p = 0.005) but not smoking or diet

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
McDowell, 2011 ⁶³ retrospective	US	<p>Patients with progressive MS, mean age 61 (SD 9.6), between 18 and 65 years old at time of onset, 77% male, born and raised in the USA, registered in the VHA Multiple Sclerosis Surveillance Registry</p> <p>Progressive MS (progressively worsening from symptom onset with or without any recovery from symptoms later in the course), PP, and progressive relapsing MS; McDonald criteria 2001</p>	Time to PDDS 8	219	Other Kaplan-Meier analysis, log rank tests, Cox proportional hazards models	Average fall/winter sun exposure before MS onset, cod liver oil intake at ages 6-15, fish consumption at ages 6-15	Age at symptom onset, MS subtype, onset symptoms, demographics, mononucleosis before symptom onset, smoking before disease onset, type of skin		<p>Median time from disease onset to PDDS 8 was 20 years (CI 16, 29) for low average fall/winter sun exposure compared to 29 years (CI 14, 42) for higher exposure; fall/winter sun exposure HR 2.13 (CI 1.20, 3.78, p = 0.01), cod liver intake HR 0.44 (CI 0.20, 0.96; p = 0.04), fish consumption HR 0.79 (CI 0.45, 1.41; p = 0.43)</p>



ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variates	EDSS results	Other results
Mowry, 2012 ⁶⁹ prospective	US	EPIC cohort (5-year longitudinal MS cohort), white MS patients over 18, with EDSS score < 8 from MS center MS or CIS; McDonald 2001 criteria, McDonald 2005 criteria	EDSS score	469	Time series Multivariate regression	25 hydroxyvitamin D level, smoker at baseline (5 years earlier)	Age, sex, ethnicity, DMT	EDSS was not associated with smoking at baseline (IRR 0.09, p = 0.49) but each 10 ng/mL higher vitamin D level was associated with lower subsequent disability (IRR - 0.047, CI -0.091, - 0.003; p = 0.037)	
Teter, 2008 ⁹⁹ retrospective	US	Female MS patients age 45 and older, NYSMSC registry, mean age 54.2 (SD 7.3), mean disease duration 18 (SD 10.8) years 48% progressive disease at enrolment; criteria N/A	EDSS > 6	2935	Cross-sectional Logistic regression	Educational attainment, sun exposure	Age, disease duration, MS type	Lower educational attainment (OR 1.5, 95% CI 1.2, 2.8) and less sun exposure (OR 1.8, 95% CI 1.2, 2.8) predict EDSS > 6	
Wallin, 2015 ¹⁰⁵ retrospective	US	Gulf War-era MS cohort with US military service between 1990-2007 Form N/A; criteria N/A	Progression to DSS 6 and DSS 7	2691	Cross-sectional Cox proportional hazard model	Geographic location and occupational status at entry to the military, deployment to a war theater			Deployment to a war theater, geographic location and occupational status at entry to the military were not predictors of progression to DSS 6 and DSS 7

ID Assessment timing	Region	Sample MS form	Predicted outcome	N	Design Analysis	Risk factors	Co-variables	EDSS results	Other results
Weiland, 2014 ^{106,123,124} retrospective, concurrent	Australia, US, Europe	Internet survey, adults diagnosed with MS by a physician Form N/A, physician diagnosis	PDDS converted to normal/ some disability, gait/ cane disability, major mobility support	2469	Cross-sectional Multiple regression	Alcohol (frequency of alcohol use, amount; non-drinker, low level vs high level of consumption, binge drinking; moderate drinking [up to 30g/day for women, up to 45g/day for men] vs low or no alcohol consumption); smoking (current, former, or never smoker; frequency, time since quitting; physical activity; meditation practice, frequency	Gender, age		Disability associated with moderate alcohol consumption (p < 0.001) and smoking status (p < 0.001); being a current smoker increased odds of requiring major mobility support (OR1.9, CI 1.44, 2.5; p < 0.001), being a former smoker associated with increased odds of 1.24 (CI 1.0, 1.5, p = 0.23) compared with never smokers. Those with higher disability had a lower level of physical activity and vice versa (p < 0.001) No association between those who did and did not meditate in PDDS scores but significant association with frequency of meditation and PDDS (more-disabled respondents were more likely to meditate, p < .001)

Note: IRR incidence rate ratio, N/A not available, n.s. not statistically significant, NYSMSC New York State Multiple Sclerosis Consortium, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, RR relative risk, vs versus



The 10 studies that each addressed multiple risk factors of interest were 6 US studies, one which included the data from the Flemish MS registry, one study which was conducted in Germany, one in Italy, and one study which reported on an internet survey which international responders.

The studies addressed a wide range of potential risk factors such as alcohol, wine, coffee, fish, cod liver oil, and fat consumption. Studies also addressed health-promoting nutrition and other dietary factors; alcohol-related problems, drug misuse, smoking; vitamin D levels, sun exposure; oral contraceptive intake; physical activity; meditation practices, spiritual growth; interpersonal relationships; and stress management behaviors. Some studies associated MS progression with insurance coverage and treatment-associated factors; latitude and geographic location; and deployment to a war theater.

Three studies primarily reported on concurrent data^{27,43,106} (that is, linking current behavior such as current alcohol intake to EDSS scores). Most studies assessed the effects of prior events, exposures, or behaviors in retrospective studies.^{36,55,63,105,106 60,99} The retrospective study by D'hooghe was based on a 2009 survey of people registered in the Flemish MS society, and the data were reported in multiple publications focusing on the effects of alcohol, coffee, fish, and smoking,³⁶ sunlight exposure,¹²⁰ and menarche, oral contraceptives, and self-reported health promotion behaviors.¹²² A German study assessed a catalogue of potential risk factors, ranging from exposure to vaccines, childhood diet, exposures to pets and livestock, and environmental factors such as living near an industrial plant.⁵⁵


One prospective study addressed vitamin D levels and smoking. The longitudinal US study reported that EDSS scores were not associated with smoking at baseline but each 10ng/mL higher vitamin D level was associated with lower subsequent disability.⁶⁹ The detailed risk of bias assessment for this high-quality study is documented in Appendix C.

Summary of Findings and Quality of Evidence

We identified a large number of studies reporting on potential modifiable risk factors for MS progression. However, studies assessed very specific risk factors (*eg*, vitamin D serum level, sun exposure in the summer 2 hours or more daily, *etc*) and predicted very specific outcomes (*eg*, EDSS scores, time to reach EDSS 6, *etc*). The following summarizes the available evidence for individual risk factors across all identified risk factor studies.

Vitamin D

Vitamin D and sun exposure-associated variables have been addressed in a large number of studies; however, the risk factor analyses used many different approaches, as documented in the evidence tables (see Table 1 and Table 7). The following figure summarizes the correlation between EDSS scores and the physiological vitamin D level of participants. The figure shows a risk factor and outcome measure that was reported in multiple studies that all reported a correlation as the measure of association or allowed computing a correlation from the reported data.

Figure 2: Correlation between EDSS Score and Vitamin D Level

Eleven included studies reported a correlation between vitamin D levels and EDSS scores. Across all available data, there was a weak negative correlation of -0.22 (CI -0.32, -0.12; 11 studies) indicating that lower vitamin D levels are associated with higher EDSS scores. All individual studies suggested the same direction of effects but not all were statistically significant and there was evidence of heterogeneity (I^2 66%). We also identified evidence of publication bias (regression test $p = 0.045$, rank test $p = 0.087$). Using the trim-and-fill method of correcting for potentially missing studies, the estimate was slightly lower but still statistically significant ($r = -0.20$; CI -0.29, -0.11).

Eight data points in the meta-analysis came from concurrent data analyses, assessing current vitamin D level and EDSS scores at the time of data assessment. One retrospective chart review also reported an association.⁹⁵ Of the 2 included prospective studies, one highlighted that there was not a statistically significant negative correlation between vitamin D nutrition and EDSS progression.⁹¹ However, the finding is likely to be linked to the small sample size; the reported correlation is in range with other reported results seen in the forest plot. The other prospective study showed higher vitamin D levels to be associated with lower subsequent disability in a multivariate analysis.⁶⁹

An additional prospective study assessing on vitamin D was identified that could not be added to the meta-analysis because it reported on other measures of association. The study reported that values greater than or equal to 50nmol/L at up to 12 months predicted lower EDSS scores ($p = 0.004$).²⁰

The evidence suggesting a correlation between vitamin D levels and EDSS scores was downgraded to only moderate quality of evidence due to *indirectness*. For this systematic review, the correlation between the physiological measures of vitamin D serum or plasma level is an indirect outcome. The review evaluated patient-modifiable risk factors, such as exposure, intake, or behavioral risk factors. The meta-analysis shows a correlation between the physiological level and a progression measure and whether the physiological levels can be directly influenced by the participant is an unresolved question. We did not identify more than one study reporting on intake of vitamin D and a measure of MS progression.

Sun Exposure

Five studies reported on sun exposure and MS progression.^{36,60,63,99,103} All were retrospective studies. Four reported a negative association of sun exposure and MS progression or a positive association of increasing disability and reduced sun exposure. One reported an association in patients with relapsing onset MS but not in progressive onset MS. However, all studies used different assessment tools (EDSS, PDDS, and MSSS) and different predictors (time to sustained EDSS 6, time to PDDS 8, a score of MSSS 6 or above, odds of reaching an EDSS score greater than 6, EDSS scores). Hence it was not possible to estimate the size of the potentially protective effect across studies and the quality of the evidence base is currently insufficient for concrete effect estimates.

Sunscreen Use


Sunscreen use has been addressed in 2 studies.^{36,60} Both reported no association with MS progression but both used different outcome measures (reaching EDSS 6, MSSS scores), precluding concrete evidence statements.

Month of Birth

Three studies assessed whether the month of birth was associated with disease progression, often hypothesizing this affects the amount of sunshine a newborn is exposed to.^{39,51,58} One study reported on the time from onset to secondary progression, one on progression to EDSS 6, and one on MSSS scores. All reported no impact on disease progression but studies did not report on the same outcome measure and did not report numerical results other than the statistical significance of the association that would allow further analyses. The quality of the evidence base was determined to be insufficient for specific evidence statements.

Smoking

A large number of studies reported on smoking but studies used a variety of operationalizations of the risk factor and a range of different outcome measures. The forest plot summarizes the studies that reported on disease progression, either operationalized as time to reach EDSS 6, time to conversion to secondary progression, or time to progressive disease. The studies compared current and/or ever smokers with nonsmokers and/or never smokers. Data are primarily based on retrospective data collections.

Figure 3: Time to Progression and Smoking

Across studies we identified an increased risk of faster progression in smokers than nonsmokers (HR 1.55; CI 1.10, 2.19; I^2 72%; 7 studies, 8 datasets). However, there was evidence of substantial heterogeneity (that is, unexplained variation in results across studies). A subgroup analysis restricting to studies predicting time to secondary progressive MS (rather than progression to EDSS 6 or progression in all samples) showed a larger effect estimate, but the pooled effect was not statistically significant in this subset and substantial heterogeneity remained (HR 1.90; CI 0.73, 4.94; I^2 77%; 4 RCTs). There was also evidence of publication bias (rank test $p = 0.179$, regression test $p = 0.038$). A sensitivity analysis computing the trim-and-fill method to account for potentially missing studies estimated a smaller effect (HR 1.33, CIs 1.05, 1.85; 2 estimated missing studies), but nonetheless a still statistically significant effect.

The forest plot includes one out of 4 identified prospective studies.⁹⁷ The other prospective studies could not be added to the meta-analysis because they reported on different measures. These studies reported conflicting results: one found no association between smoking status at baseline and EDSS scores over a period of 5 years (incidence rate ratio [IRR] 0.09; -0.17, 0.36)⁶⁹ while another one found baseline smoking status to be a predictor of physical disability after 6 years.¹¹² The third reported that the cumulative cigarette pack-years smoked after cohort entry was associated with an increase in longitudinal MSSS scores ($p < 0.001$).⁷⁶

The body of evidence regarding an effect of smoking on the risk of progression was downgraded to moderate evidence quality due to unexplained heterogeneity in effect estimates across studies (*inconsistency*).

Diet

Evidence on dietary regimen was sparse and lacked detail.^{21,36,38,54,60,63,98} We did not identify more than one study reporting on the same diet or diet variable except fish consumption (see below). Studies addressing fat consumption did not report on the same outcome measure. Results across individual studies varied, with some studies showing associations with MS progression, others not; and results also varied within studies (comparing relapsing and progressive onset MS).³⁶

The only identified prospective study reported on the Swank diet for MS patients and showed that for poor dieters, operationalized as participants with an intake of more than 20g fat per day, the average worsening significantly exceeded those of the good dieters, but the size of the effect was not reported.⁹⁸ The quality of the evidence base was judged to be insufficient overall.

Fish Consumption

Fish consumption specifically, which is associated with vitamin D as well as fatty acid intake, has been evaluated in 3 studies: the Flemish registry survey, a study in patients with progressive MS registered in the VHA Multiple Sclerosis Surveillance Registry, and an Italian cohort.^{36,60,63} The studies differed in risk factor timing (current; in the last 2 years; intake as a child) and used different outcome measures. The existing retrospective studies reported conflicting results with regard to the presence or absence of a negative association with MS progression. The quality of evidence was determined to be insufficient for specific evidence statements.

Alcohol

Alcohol consumption or alcohol misuse has been addressed in 5 studies in total.^{27,36,38,43,106} Possible alcohol-related problems,²⁷ moderate duration of alcohol use after MS onset (15 years or less as compared to those who did not consume alcohol or consumed it for more than 15 years),³⁸ higher levels of alcohol consumption (using a 5-point scale ranging from never to daily)⁴³ have been associated with lower EDSS score categories, that is less disability in participants consuming alcohol, in 3 identified studies. One study found an association of alcohol consumption (compared to no consumption) with a reduced risk to reach EDSS 6 in relapsing MS patients but not in patients with progressive onset MS.³⁶ One study found that engaging in moderate alcohol consumption (up to 30g/day for women, up to 45g/day for men) compared to low or no alcohol consumption was associated with reduced odds of increased disability based on the PDDS (OR 0.59, $p < 0.001$).

No prospective study exists, and the identified studies reported predominantly on concurrent associations (measuring current intake and current disability status). We did not identify more than one study reporting on the same operationalization of alcohol consumption and the same progression or disability measure; hence, the quality of evidence was insufficient for effect estimates across studies.

Exercise

Although a handful of studies on physical exercise is available, we did not identify more than one study reporting on the same specific exercise variable and the same measure of MS progression.^{36,43,62,64,68,87,96,123} All identified studies reported an association between exercise and EDSS score or another measure of progression or disability, but the direction of effects varied by study design.

Only 2 identified studies were prospectively analyzed, predicting later progression from baseline physical activity.^{68,96} Both highlighted the possible role of premorbid or baseline physical activity on future progression. Neither reported on the primary outcome of the review. One reported that premorbid physical activity statistically significantly predicted the linear change in PDDS scores in patients with relapsing-remitting MS and emphasized the possible role of physical activity for lessening disability progression.⁶⁸ The other reported that baseline exercise scores were negatively correlated with the annual change rate in functional limitations assessed

with a self-reported incapacity status scale and discussed the potential positive impact of exercise on MS progression.⁹⁶ The overall quality of evidence was determined to be insufficient for concrete evidence statements, given the differences in outcome and predictor measures.

Trauma

Two studies addressed exposure to brain trauma.^{55,89} Both reported that it is not a risk factor for MS progression, but studies used different outcome measures (mean increase in DSS per year, benign MS defined as DSS equal or lower than 2 after 11 or more years of MS duration). No concrete evidence statement could be formulated for an individual outcome that has been shown in more than one study.

Epidural Analgesia

The association with MS progression and epidural analgesia has been addressed in 3 studies, including 2 prospective and one retrospective study.^{30,57,72} None reported a statistically significant association with EDSS or DSS scores. We did not identify studies that reported on the change to secondary progression.

The quality of the evidence for the statement that epidural analgesia does not affect progression was downgraded due to *phase of investigation* and *imprecision*. The risk factor was identified in exploratory, not confirmatory, studies and the point estimate of the association was not reported in either study. Hence, the strength of association is not known (studies only reported the statistical significance of the association).

Oral Contraception

Three studies reported on oral contraceptive use with conflicting results within and across studies.^{36,40,57} The Flemish registry survey reported that use of oral contraceptives was related to an increased risk of reaching EDSS 6 in progressive but not in relapsing onset MS.³⁶ A second study reported that patients who had used combined oral contraceptives continuously for at least one year had lower EDSS scores compared to never users, indicating a protective effect.⁴⁰ A third study reported that women who started oral contraceptives after disease onset had lower EDSS scores than both never users and past users. A benign disease course was predicted by current oral contraceptive use compared to never or past users.⁸⁵ Given that none of the studies compared an identical combination of risk factor and outcome measure operationalization, the quality of evidence was determined insufficient for concrete evidence statements.

Geographic Region

Two studies addressed geographic regions but in different operationalizations (*eg*, high vs low MS prevalence areas; geographic region of military personnel at entry to the military) and studies used different outcome measures (3-point scale differentiating walking without aids, walking with aids, and restricted to wheelchair; progression to DSS 6 and DSS7).^{35,105} Only one of the studies reported an association; progression to a non-ambulatory status or death was significantly greater among patients who lived in Los Angeles County (a low-prevalence area). The different outcome measures, risk factor operationalizations, and conflicting results cannot be combined to a concrete evidence statement.

Education

Two studies investigated an association between education and MS progression.^{22,99} Both studies were retrospective analyses, they reported on EDSS greater than 6 or MSSS scores, and they reported conflicting results. One study assessing MSSS did not find that education predicted getting statistically significantly worse in a sample of 338 patients, the other one reported that lower educational attainment predicted EDSS scores above 6 (OR 1.5; CI 1.2, 2.8). Given the lack of replication on outcome measures and the conflicting results, the quality of evidence was rated insufficient.

Other Factors

All other factors have been addressed in only one of the included studies and have not been replicated yet. The study details together with the results are shown in the evidence tables.

KQ1 Summary

The summary of findings table documents the available evidence for specific risk factors and specific outcome measures that were reported in more than one study. We did not include results that were based on a single study without replication by another, independent author group, given the complexity of epidemiological data collection.

Results (strength and statistical significance of the association) for EDSS scores and for other MS progression-relevant findings were summarized across studies. For each outcome, the GRADE summary is documented. The summary of findings tables is organized by outcome and where outcomes were not identical or not compatible across studies, no effect estimate could be determined and the evidence was consequently graded as insufficient for concrete evidence statements. The table shows the presence and the absence of associations, and factors delaying as well as hastening progression have been considered.

Table 8. Summary of Findings for KQ1

Risk factor and Outcome measure	Study Design, # of Studies	EDSS Findings: Direction, Magnitude of Effect	Other Progression Findings: Direction, Magnitude of Effect	GRADE
Vitamin D				
Correlation 25(OH)D level and EDSS	8 concurrent, 1 retrospective, 1 prospective study	Weak correlation (r -0.22; CI -0.28, -0.10) indicating lower levels of vitamin D are associated with higher EDSS scores		Moderate (indirect)*
Sun Exposure				
No outcome assessed in > 1 study	5 retrospective studies	N/A (see text)	N/A	Insufficient
Sunscreen Use				
No outcome assessed in > 1 study	2 retrospective studies	N/A (see text)	N/A	Insufficient
Month of Birth				
No outcome assessed in > 1 study	3 retrospective studies	N/A (see text)	N/A	Insufficient
Smoking				
Risk of progression comparing smokers and nonsmokers	6 retrospective, 1 prospective study	N/A	Smoking is associated with an increased risk of progression (HR 1.55; CI 1.10, 2.19)	Moderate (heterogeneity)*
Diet				
No outcome assessed in > 1 study	2 concurrent, 4 retrospective, 1 prospective study	N/A (see text)	N/A	Insufficient
Fish Consumption				
No outcome assessed in > 1 study	3 retrospective studies	N/A (see text)	N/A	Insufficient
Alcohol-related Variables				
No outcome assessed in > 1 study reporting on the same operationalization	3 concurrent, 2 retrospective studies	N/A (see text)	N/A	Insufficient
Exercise				
No outcome assessed in > 1 study	2 retrospective, 3 prospective studies	N/A (see text)	N/A	Insufficient
Trauma				
No outcome assessed in > 1 study	2 retrospective studies	N/A (see text)	N/A	Insufficient
Epidural Analgesia				

EDSS scores	2 prospective studies, 1 retrospective study	2 studies showed no association with EDSS scores (sign. N/A) or 3 EDSS score categories ($p > 0.1$)	One study showed no statistically significant association with EDSS or DSS ($p = 0.66$)	Low (exploratory, no point estimate)**
Oral Contraception				
No outcome assessed in > 1 study	3 retrospective studies	N/A (see text)	N/A	Insufficient
Geographic Region				
No outcome assessed in > 1 study	1 retrospective, 1 prospective study	N/A (see text)	N/A	Insufficient
Education				
No outcome assessed in > 1 study	2 retrospective studies	N/A (see text)	N/A	Insufficient

Note: The table only shows risk factors that were reported in more than one study; * quality of evidence downgraded by 1 level, ** quality of evidence downgraded by 2 levels

KEY QUESTION 2: What environmental exposures prior to or during military service are related to multiple sclerosis progression following onset symptoms?

Despite the extensive search, very few relevant studies were identified. In addition, only some of the studies addressed environmental exposures during military service. The remaining studies addressed other factors in samples of Veterans.

One of the studies has been presented in the context of diet risk factors (evidence table 4). The study evaluated MS in men on active duty in the US Army. It reported on the disease course for patients that were put on a specific diet in the hospital, compared to patients without administration of a specific therapy.⁵⁴ The reported data were not statistically significantly different between groups. However, no information was available on the specific diet and approaches may have varied across patients and hospitals.

A second study focused on disability and treatment patterns of MS patients in Veterans and non-veterans. The concurrent study reported that VHA Veterans had statistically significantly higher PDDS scores than non-veterans.¹⁰⁴ More information is presented in table 6, the evidence table summarizing “other” MS progression risk factors.

Two additional studies reported on multiple risk factors of interest and are shown in more detail in evidence table 7. One study reported on a Gulf War-era MS cohort which includes 2,631 patients.¹⁰⁵ The study reported that deployment to a war theater, geographic location, and occupational status at entry to the military were not predictors of progression to DSS 6 and DSS 7. The study was reported in a conference abstract and data on the exact point estimate and measure of dispersion were not available.

The fourth study addressed vitamin D exposure and reported on the average fall/winter sun exposure before MS onset, cod liver oil intake as a child (ages 6 to 15), and fish consumption between the age of 6 and 15.⁶³ The study reported on 219 Veterans with progressive MS registered in the Multiple Sclerosis Surveillance Registry. The study used the PDDS to assess

progression and predicted hazard ratios for the time to reach a PDDS score of 8 from disease symptom onset. This stage indicates that a wheelchair or scooter is the main form of mobility. The study reported low average sun exposure in the fall/winter before disease onset was associated with an increased risk of progression (HR 2.13; CI 1.20, 3.78) and cod liver oil during childhood and adolescence was associated with a reduced risk (HR 0.44; CI 0.20, 0.96). Fish consumption was not statistically significantly associated with PDDS progression in this sample. The study concluded that exposure to vitamin D before MS onset may slow disease-related neurodegeneration and thus delay progression to disability in patients with progressive MS.

Summary of Findings and Quality of Evidence for Key Question 2

The summary of findings table showing KQ2 evidence is grouped by exposures prior to or post military service and exposures during military service. All studies relevant to KQ2 also contribute to KQ1 and were already included in KQ1 evidence statements.

Table 9. Summary of Findings for KQ2

Risk Factor	Study Design, # of Studies	EDSS Findings: Direction, Magnitude of Effect	Other Progression Findings: Direction, Magnitude of Effect	GRADE
Prior or Post Military Service in Veterans				
Geographic location at entry to the military	1 retrospective study, N = 2631	N/A	Geographic location was not a predictor of progression to DSS 6 and DSS 7 (magnitude of effect N/A)	Insufficient
Occupational status at entry to the military	1 retrospective study, N = 2631	N/A	Status was not a predictor of progression to DSS 6 and DSS 7 (magnitude of effect N/A)	Insufficient
Average fall/winter sun exposure before MS onset	1 retrospective study, N = 219	N/A	Low sun exposure was associated with faster progression (HR 2.13; CI 1.20, 3.13)	Insufficient
Cod liver oil intake at ages 6-15	1 retrospective study, N = 219	N/A	Cod liver oil intake was associated with slower progression (HR 0.44; CI 0.20, 0.96)	Insufficient
Fish consumption at ages 6-15	1 retrospective study, N = 219	N/A	No statistically significant association with progression (HR 0.79; CI 0.45, 1.41)	Insufficient
Exposure During Military Service				
Deployment to a war theater	1 retrospective study, N = 2631	N/A	Deployment to a war theater was not a predictor of progression to DSS 6 and DSS 7 (magnitude of effect N/A)	Insufficient
Being a Veteran	1 concurrent study; N = 2150	N/A	VHA Veterans had higher PDDS scores than non-veterans ($p < 0.001$)	Insufficient
Diet in hospital	1 retrospective study, N = 517	N/A	Diet group: 28% better, 56% the same, 16% worse; patients with hospital routine without specific treatments: 19% better, 74% same, 8% worse ($p = 0.131$)	Insufficient

Note: N/A not reported, not available

None of the identified studies were prospective studies, which allow more confident interpretations of associations. In addition, all associations were based on only one study, and

without any replication in independent studies, the available evidence was graded as insufficient. Some of the factors shown in this summary of findings table were uniquely addressed in the KQ2-relevant studies, such as deployment. Other investigated factors, such as sun exposure, have been addressed in other studies documented in the KQ1 evidence synthesis; however, the exact operationalization of the factors, for example sun exposure during childhood and teenage years, also has not been replicated in other available studies by independent author groups.

KEY QUESTION 3: Among identified risk factors for progression, what treatment/risk factor modification therapies have been shown to delay or hasten the progression of MS once it has initiated?

We identified a substantial number of intervention evaluations; however, they addressed only a small range of interventions. Despite the comprehensive search and inclusive inclusion criteria, all identified studies evaluated either vitamin D supplementation, exercise interventions, or dietary interventions.

Details of included studies contributing to KQ3 are presented in 3 evidence tables in the following text.

The largest group of interventions addressed physical exercise.

Table 10: Evidence for KQ3: Effects of Exercise Interventions on MS Progression

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Armutlu, 2001 ¹⁹	26 No power calculation	Patients with ataxic MS, intervention group mean age 32.61 (23-44), 9 female, 4 male, EDSS 4.53 (3.5-5.5); control group mean age 34.61, (range 26-45), 7 female, 6 male; PP and SP; Poser criteria	Neuromuscular rehabilitation with pressure splints, 3x / week for 4 weeks		Neuromuscular rehabilitation alone	Significant improvements in EDSS scores in both groups, no difference between groups (p > 0.05)		N/A
Bjarnadottir, 2007 ²⁶	16 (6 treatment, 10 control) No power calculation	Patients with mild MS aged 18-50 years with definite MS and EDSS < 4, and with the ability to ride a stationary bicycle; mean age 38.7 vs 36.1, mean EDSS 2.1 vs 1.8, mean duration of MS 8.7 vs 8.3 years; Poser criteria	Training 3x / week for 5 weeks or a total of 15 hours; aerobic exercise, resistance exercise and stretching and relaxation		No treatment	No change in EDSS was detected and groups did not differ in pre-post difference (-0.07, CI -0.7, 0.61)		1 patient in each group developed a relapse and was withdrawn, transient increase in symptoms was not observed
Carter, 2013 ¹²⁵	28 No power calculation	Patients with MS, mean age 40 years (24-49) with mild to moderate EDSS = < 5.5; treatment vs usual care: female 87.5% vs 85.7%, mean age 39.5 (SD 6.5) vs 40.9 (SD 8.7), mean EDSS 3.0 (SD 1.1) vs 3.1 (SD 1.7); McDonald 2010 criteria	10 week pragmatic exercise intervention (2 supervised and 1 home-based session / week)		TAU	Lower EDSS scores in intervention group after 10 weeks (p = 0.07) and 3 months post-intervention (p = 0.48) compared to control		N/A
Conklyn, 2010 ³¹	10 No power calculation	Adult MS patients with gait disturbance, able to walk 100 feet without physical assistance; treatment vs control: mean age 47 (SD 10.51) vs 50.2 (SD 5.45), 60% vs 80% female, relapsing-remitting 80% vs 60%, SP 0% vs 40%, primary progressive 20% vs 0%; criteria N/A	2 week Rhythmic Auditory Stimulation		No treatment		No statistically significant changes in PDDS scores	N/A



ID, Trial type ⁵⁶	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Dalgas, 2009 ³² cross-over	38 Power unclear	Moderately impaired patients with MS, treatment vs control: female 10/16 vs 10/15, mean age 49.1 vs 47.7, mean EDSS 3.9 vs 3.7, mean time since diagnosis 8.1 vs 6.6; McDonald 2001 criteria	Biweekly 12-week lower extremity progressive resistance training program, participants encouraged to continue training afterwards		No treatment	EDSS remained unchanged in both groups		N/A
DeBolt, 2004 ³⁴	36 (19 treatment, 17 control) No power calculation	Healthy adults with MS and the ability to walk (with or without assistive devices) at least 20m without rest, EDSS scores ranged from 2 to 6, 29 women (mean age, 50.3, SD 8.5) and 8 men (mean age 51.1, SD 7.1); criteria N/A	Home-based resistance exercise (8-week)		No treatment	No significant differences between groups after intervention (p = 0..552)		N/A
Fimland, 2010 ³⁷	14 No power calculation	Maximal strength training vs control group: female 75% vs 75%, mean age 53 vs 54, mean EDSS 4.6 vs 3.5, years since diagnosed 8 vs 8; criteria N/A	A rehabilitation program, maximal strength training using high loads and few repetitions, 5 days/wk for 3 wks		No treatment	No changes were observed for the EDSS between groups., scores remained unchanged in all participants		No adverse effects
Golzari, 2010 ⁴²	20 No power calculation	Women from MS society and clinic, age 20-50, with clinically diagnosed R-R and EDSS 0-4; exercise vs control: mean age 32.5 (SD 7.57) vs 33.75 (SD 8.18), mean EDSS 2.14 (SD 1.06) vs 1.96 (SD 1.06); criteria N/A	Combined exercises for 24 sessions during 8 wks; 1-hour session with warm-up, stretch, aerobic, endurance, and resistance training, and relaxation		No treatment	Score was decreased in intervention group 8 weeks after training (p < 0.43) but not control group		N/A
Lo, 2008 ⁵⁶ cross-over	13 No power calculation	R-R, SP, and PP MS patients, mean age 49.8 (SD 11.1), EDSS 4.9 (SD 1.2), female 6/13, R-R 8/13, PP 5/13; McDonald 2001 criteria	Body weight supported treadmill training with or without robotic assistance training sessions, 2/week for 3 weeks, a total of 6 sessions of 40 mins		Reversed treatment order	Significant improvement in EDSS scores in both groups: -0.83 (SD 0.61, p = 0.06) and -1.1 (SD 0.7, p = 0.03)		No adverse events occurred

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Miller, 2011 ⁶⁶	30 Insufficient power	Patients with PP or SP MS and EDSS scores 6.5-8; intervention vs control: 26.7% vs 46.7% female, mean age 56.3 vs 52.9, time since diagnosis 13 vs 18.7, EDSS 7 vs 7.1; definitive diagnosis, criteria N/A	8 week physiotherapy		TAU	EDSS: no interaction effect over time (p = 0.803) or group effect (p = 0.074)		None
Petajan, 1996 ¹²⁶	46 No power calculation	Ambulatory MS patients recruited through MS society and physician referrals, exercise vs non-exercise: female 71.4% vs 76%, mean age 41.4 (SD 2) vs 39 (SD 1.7), EDSS 3.8 (SD 0.3) vs 2.9 (SD 0.3), years since first symptoms 11.6 (SD 1.7) vs 10.5 (SD 1.6), years since diagnosis 9.3 (SD 1.6) vs 6.2 (SD 1.1); Poser criteria	15 weeks aerobic training with 3 supervised training sessions per week (5 minute warm-up, 30 mins at 60% maximum aerobic capacity, 5 min cooldown)		No treatment	Overall EDSS scores did not change (-0.1 in exercise group, -0.1 in nonexercise group)		N/A
Pfalzer, 2011 ⁷⁵	39 No power calculation	Ambulatory patients with clinically diagnosed MS; 22 with R-R, 5 SP, 5 PP, 3 PR, 4 unknown; clinically diagnosed, criteria N/A	Home-based exercise training (10 weeks)		No treatment	Intervention: EDSS mean 4.3 (SD 1.9, improvement pretest-posttest 0.2 (0.7)), Control: 3.7 (SD 1.6); pre-post 0.5 (SD 1.2) post-intervention		2 dropped out due to medical illness unrelated to MS
Rampello, 2007 ⁷⁹ cross-over	19 No power calculation	Patients aged 20-55 years with MS on waiting list for rehabilitation program with EDSS < 7; treatment vs control: mean age 44 vs 37, female 8/11 vs 6/8, mean disease duration 6 vs 10 years, mean EDSS 3.5 vs 3.25; Poser criteria	Aerobic training (8 weeks)		Other: neurological rehabilitation	No change over time was found in EDSS (p = 1.0)		2 dropped out due to perception of breathlessness and fatigue



ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Romberg, 2004 ⁸¹ cross-over	114 Sufficient power	Patients aged 30-55 with definite MS and EDSS ≤ 5.5; exercise vs control: female 30/47 vs 41/48, mean age 43.8 vs 43.9, mean years after 1st symptoms 9.7 vs 9.6, mean years after diagnosis 6.0 vs 5.5, mean EDSS 2.0 vs 2.5; Poser criteria	Strength and aerobic training initiated during 3-week inpatient rehabilitation and continued for 23 weeks at home		TAU	No change ($p = 0.93$) over time in EDSS		No exercise-related injuries; 5 relapses in intervention group and 6 in control group in 9 patients
Sangelaji, 2014 ⁸³	147 Power unclear	MS patients, EDSS score 0-4; criteria N/A	Aerobic, strengthening, balancing, and stretching exercises (10 weeks)		No treatment	No significant changes in EDSS at any follow-up, but both control and intervention increased EDSS scores at 1-year follow-up (intervention: 0.5 points, $p = 0.001$; control: 0.72 points, $p = 0.001$)		1 dropped out due to muscular pain in cuff muscles, 1 due to new attack and nonresponding symptoms
Schwartz, 2012 ⁸⁴	32 Insufficient power	MS patients with chronic progressive pattern or relapsing-progressive with no relapse for 3 months (RP, SP, and PP); robot-assisted vs conventional: female 41% vs 43%, mean age 50.5 (SD 11.5) vs 46.8 (SD 11.5), disease duration 14.9 (SD 8.1) vs 11.3 (SD 6.7), EDSS 6 (SD 0.6) vs 6.2 (SD 0.5); McDonald 2001 criteria	12 sessions of robot-assisted gait training (gait orthosis) or conventional walking treatment 2-3 times a week (30 min net treatment) for 4 weeks		Conventional walking treatment	EDSS scores improved significantly post-treatment with no difference between the groups; mean changes in EDSS robot-assisted vs conventional post-intervention: -0.29 (SD 0.4) vs -0.31 (SD 0.3); at 3 months -0.22 (SD 0.4) vs -0.27 (SD 0.3); at 6 months -0.21 (SD 0.4) vs -0.25 (SD 0.4)		N/A

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Solari, 1999 ⁹²	50 Sufficient power	MS patients aged 18-65, EDSS 3-6.5, mean EDSS 5.5; treatment vs control: 63 vs 48% female, mean age 44.6 (SD 10.2) vs 44.9 (SD 10.9), R-R 22.2 vs 21.7%, PP 14.8 vs 17.4%, SP 63 vs 60.9%; clinically definite or laboratory-supported MS	3 week inpatient physical therapy		Exercise at home	No changes in impairment occurred in either group (EDSS scores)		N/A
Wiles, 2011 ¹⁰⁹ cross-over	42 Power unclear	MS patients with walking difficulties, able to walk 5 meters without any physical assistance, mean age 47.2 (28.2-68.8), 35.7% female, mean duration of disease onset 4.4 (SD4.6); Poser criteria	Allocation to one of 6 permutations of three 8-week treatment periods separated by 8-week intervals: physiotherapy at home or no therapy		No treatment		Effects favored hospital- or home-based therapy over no therapy	N/A

Notes: AE adverse events, Co co-intervention, N/A not available, TAU treatment as usual, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus

§ All studies are RCTs unless otherwise noted.

The 18 studies tested a range of physical interventions, including aerobic exercise, resistance training, physiotherapy, or rehabilitation with maximal strength training. Settings were home-based or rehabilitation centers. The majority of studies compared the program to no treatment; 3 studies compared to treatment as usual.^{29,66,81} Two studies assessed the comparative effectiveness of a robot-assisted intervention^{84,56} and one the effect of adding pressure splints to the training.¹⁹ The training duration ranged from 2 to 26 weeks.

Studies enrolled between 10 and 147 participants. The majority of included studies was small and did not report a statistical power calculation. Four studies reported a power calculation but for a different outcome than MS progression or disability scores.^{32,81,83,109} Two studies reported that power was insufficient even for the primary outcome.^{66,84} Only one study took EDSS scores into account for the power calculation; the study reported no changes in impairment occurred in either group after 3-week inpatient physical therapy or exercise training at home.⁹²

The identified studies were primarily in patients with mild MS who were ambulatory. However, 2 of the included studies were specifically designed to test the comparative effectiveness of robot-assisted gait training compared to conventional walking treatment or adding pressure splints to the training in patients with progressive MS; EDSS scores improved in both intervention arms.^{19,84}

All included studies reported on disability of MS measured by the primary outcome of this review – EDSS scores. However, in none of the studies was MS progression a primary outcome, and only selected studies reported EDSS assessments to be a secondary outcome^{42,74,75,83,84} to evaluate the intervention. Given the short duration of the intervention, many studies reported no substantial changes in EDSS levels after the intervention.

Half the studies did not report on adverse events. Reported adverse events were relapses,^{26,81,83} breathlessness and fatigue,⁷⁹ muscular pain,⁸³ and unrelated illnesses.⁷⁵ Two studies assessed adverse events and reported that none occurred.^{37,56}

The risk of bias assessment for the identified studies is shown in Appendix C. Performance bias was a prominent source of bias in the identified interventions because blinding of participants and personnel was not possible given the nature of the intervention. In addition, only selected studies ensured that the outcome assessors were blind to the treatment condition. Two studies, Fimland et al and Petajan et al, had noticeable imbalanced samples at baseline, with intervention patients that had higher EDSS scores than the control group.^{37,127} While the internal validity of included studies varied, several studies were not particularly suitable to assess the outcome of interest due to the short duration of the intervention. Only 11 out of 18 studies reported on an intervention with a duration of 2 months or more.^{29,32,34,42,66,74,75,79,81,83,109}

The second group of intervention studies reported on dietary interventions. The details of included RCTs are shown in the following evidence table.

Table 11: Evidence for KQ3: Effects of Dietary Interventions on MS Progression

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Bates, 1977 ²⁴	152 No power calculation	Patients with chronic progressive non-relapsing MS; criteria N/A	Group A: 8 capsules of 360mg linolenic and 3-42 g of linoleic acid daily; group B: placebo capsules (oleic acid oil); group C received 11.5 g/day of linoleic acid spread; group D placebo spread (oleic acid) for [presumably] 24 months		Placebo		No statistically significant difference between groups in the number of patients who improved, deteriorated, or remained unchanged	N/A
Bates, 1978 ²⁵	116 (29 for each of 4 groups) No power calculation	Patients with remitting MS; Group A vs B, C vs D: female 19/29 vs 19/29, 24/29 vs 18/29; mean age 35 vs 32, 34 vs 33; mean duration of disease 7 vs 6, 7 vs 6; criteria N/A	Group A: 8 capsules daily (2 92g linoleic acid, 0 34g gamma-linolenic acid); Group B: 8 similar capsules (4 g oleic acid, control); Group C: 23g linoleic acid daily in a spread; Group D: 16g oleic acid in a spread (control) for [presumably] 24 months		Placebo		After 2 years, the number of patients who had deteriorated (DSS and additional assessment) in intervention group A was significantly greater than that in the control group B (p < 0.05)	N/A
Bates, 1989 ²³	312 No power calculation	Patients aged 16-45 years with definite MS, suffered at least 2 relapses with 1 during last 24 months, EDSS =< 6.0, treatment vs control: female 102/155 vs 109/157, mean age 34 vs 33, mean duration of disease 6.5 vs 6.6; McDonald & Halliday criteria	20 capsules of 0.5 g of omega-3 fatty acid (1.71 g C20:5 and 1.14 g C22:6 per day) for [presumably] 24 months		Placebo	Intervention: 51% better, 43% worse, 1 patient died; placebo (olive oil): 41% better, 52% worse, no deaths (difference p = 0.07)		1 patient died



ID, Trial type ⁶⁶	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Harbige, 2007 ⁴⁴	36 No power calculation	Patients with active MS; international MS criteria	High or low dose of gamma-linolenic acid (18:3n-6)-rich borage oil (high in sn-2 GLA, low in monoenes, natural levels of vitamin E) for 18 months		Placebo	High-dose treatment significantly reduced disability progression (EDSS) compared with placebo and low dose treatment (no numerical results)		N/A
Millar, 1973 ⁶⁵	87 (36 treatment, 39 control) No power calculation	MS patients, treatment vs control: mean age 37.8 vs 35.5, female 56% vs 64%, average age at onset 38 vs 36, mean duration of symptoms before entry 7.7 vs 9.2, mean disability score 2.9 vs 2.7; criteria N/A	Linoleate supplementation (30 ml sunflower seed oil, 8-6g of linoleic acid, 2/day) for 2 years		Placebo		Placebo (olive oil) deteriorated from 2.7 to 3.3 at the end of the trial, treatment group from 2.9 to 3.1 (n.s.)	N/A
Pantzaris, 2013 ⁷¹	80 (20 each in 4 groups) No power calculation	R-R patients aged 18-65 years, EDSS 0-5, with at least 1 documented clinical relapse; McDonald criteria	Intervention A: omega-3 and omega-6 polyunsaturated fatty acids at 1:1 wt/wt; Intervention B: combination of A and gamma-tocopherol; intervention C: gamma-tocopherol; Control: placebo (olive oil).; 19.5 ml / day for 30 months		Placebo	The cumulative probability of progression of EDSS with 1 point increase at 2 years was 10% in the combination group and 35% in the placebo group (p = 0.052), adjusted HR 0.22 (CI 0.04, 1.07; p = 0.06)		No significant AE, nausea N = 2, no abnormal values in biochemical and blood tests, no allergic reactions

ID, Trial type ⁶	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Paty, 1978 ⁷³	96 No power calculation	Patients with definite MS, ambulatory (either on their own or with ambulatory aids); treatment vs control: mean age 45 for both, mean age onset 32 vs 30, duration of disease 13 vs 16, mean DSS 4.24 vs 4.26; Schumacher criteria	Linoleic acid (1 oz, 2/day, sun flower seed oil, 66.2% linoleic acid) for 30 months		Placebo		Final disability scale score for intervention vs placebo (olive oil): 3.52 vs 3.85, changes from baseline: -0.72 vs -0.41 (n.s.)	N/A
Ramirez-Ramirez, 2013 ⁷⁸	50 Power unclear	Patients with R-R, at least 1 relapse in year before, EDSS score 0-5, treated with interferon beta-1b; intervention vs placebo: female 17% vs 18%, mean age 35 (SD 7.6) vs 35 (SD 7.8), mean EDSS 2.1 (SD 0.98) vs 2.06 (SD 0.84), years with disease 7.1 (SD 4.8) vs 6.7 (SD 6.7); McDonald 2005 criteria	Fish oil (4 g/day, 0.8g EPA, 1.6g DHA, and excipient) for 12 months	Interferon beta-1b	Placebo	EDSS changes from baseline to 12 months: 0.1 in intervention, 0.2 in placebo group (group differences n.s.)		No serious adverse effects; no changes in liver and renal tests, platelets, blood count, bleeding; fishy taste; < 5% reported nausea, stomach pain, diarrhea

ID, Trial type ⁵⁶	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Rezapour-Firouzi, 2013 ⁸⁰	100 No power calculation	R-R; group A vs B vs C: mean age 34.2 (SD 7.5) vs 35.9 (SD 7.8) vs 33.7 (SD 7.8); average age at onset 25 (SD 7.5) vs 30.3 (SD 8.1) vs 27.6 (SD 6.4); disease duration 6.23 (SD 3.9) vs 7.55 (SD 5.08) vs 6.6 (SD 4.0); female 69.6% vs 50% vs 75%; baseline EDSS 2.76 (SD 1.39) vs 3.45 (SD 1.41) vs 3.25 (SD 1.9); criteria N/A	Group A: hemp seed and evening primrose oils with Hot nature diet (foods with Hot nature; low intake of cholesterol, hydrogenated / trans fatty acids and saturated fats (fried food), olive / grape seed oil, fresh fruit and vegetables, nuts and seeds, fish and seafood, unrefined carbohydrates, plenty of water, cutting down sugar and refined starch, dairy products with honey or date, removing foods with Cold nature); Group B: hemp seed and evening primrose oils for 6 months		Placebo	Significant improvements in EDSS in intervention groups, significant increase in EDSS score in control group (olive oil)		No serious adverse effects in any of the patients
Torkildsen, 2012 ¹⁰¹ multi-center	92 Power unclear	R-R patients, 18-55 years, EDSS = > 5.0; fatty acids vs placebo: female 30/46 vs 29/45, mean age 28.8 vs 28.3, mean EDSS at baseline, 1.94 vs 1.86, mean disease duration 5.4 vs 5.8 years, mean relapses the year prior 1.7 vs 1.6, mean time since diagnosis 2.2 vs 1.7; McDonald 2001 criteria	Oral omega-3 fatty acids (270mg EPA, 170mg DHA) and 4 units of alpha-tocopherol per gram for 18 months	Interferon beta-1a	Placebo	After 24 months, EDSS increased to 2.22 (1.34) in the fatty acids group and 2.19 (1.34) in placebo group (p = 0.63); 30% in the fatty acids group vs 30% in the placebo group had experienced disease progression (p > 0.99)	No differences in changes of MS Functional Composite scores after 6 (p = 0.53) or 24 (p = 0.57) months	74% intervention, 63% placebo experienced AE (eg, influenza-like symptoms, injection site reaction), n.s. between groups; 1 intervention patient (nausea) and 2 placebo patients (allergic reaction) withdrew

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	Other results	AE
Weinstock-Guttman, 2005 ¹⁰⁷ cross-over	31 No power calculation	MS patients, 18-60 years; intervention vs placebo: female 85.7% vs 84.6%, mean age 45.1 vs 39.9, mean disease duration 6.9 vs 4.6, mean EDSS 1.9 vs 2.0; Poser criteria	Very low-fat diet dietary advice (not to exceed 15% of total daily calories) plus fish oil supplement (6 capsules / day, 1.98g EPA, 1.32 DHA); control group received AHA diet advice (30% fat) plus placebo		Other	Weak trend towards an increase in EDSS (+0.35) in the control group vs a decrease of 0.07 points in the intervention group after 1 year		2 could not tolerate the diet (1 per group)
Yadav, 2014 ¹¹⁰	61 No power calculation	R-R (mean EDSS 2.5; mean age 41, range 24-55); criteria N/A	Low-fat plant-based diet (1 year)		Waitlist	After baseline difference adjustment, the groups showed no significant change in EDSS		"study demonstrated safety"

Notes: AE adverse events; Co co-intervention, N/A not available, n.s. not statistically significant, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus

§ All studies are RTCs unless otherwise noted.



The majority of the 12 dietary intervention studies addressed effects of fatty acid supplementation. Three studies evaluated the effects of advice for a diet of foods with “Hot nature” according to traditional Chinese medicine, a very low-fat diet plus fish oil, and a low-fat plant-based diet.^{80,107,110} Studies compared interventions primarily to placebo. One study compared to patients assigned to waitlist (patients will receive the intervention eventually).¹¹⁰ Another compared to different, not very low-fat diet advice plus placebo instead of fish oil supplementation.¹⁰⁷ All studies tested long-term interventions; the duration ranged from 6 to 30 months.

Studies enrolled between 31 and 312 patients. Studies either reported no power calculation to determine the sample size necessary to detect a statistically significant difference between treatment groups, or it was computed for a different outcome than MS progression or disability scores. One of the included studies tested the intervention specifically in chronic progressive non-relapsing MS,²⁴ while other studies used unrestricted MS samples or did not report on the form and stage.

Several studies reported on EDSS results but not all reported EDSS endpoint values to allow a comparison between intervention and control groups. Some studies only stated the statistical significance of the difference, reported the statistical significance of the difference between baseline and endpoint for each group, or reported no specific numbers. Four included studies were published before the development of the EDSS and reported on the number of patients who deteriorated.^{24,25,65,73} The adverse event assessment was sparse; 5 included studies did not report on adverse events at all, 3 reported adverse events but did not specify the treatment group patients were assigned to, and 2 gave no details on the experienced events. Only 2 studies reported on adverse events by intervention group and reported that one or 2 patients withdrew from the study.

The risk of bias assessment for the identified studies is shown in Appendix C. There was insufficient detail to assess the risk of bias in a number of dietary intervention studies, in particular the studies that were published 40 years ago, presumably due to differences in reporting standards.^{24,25,65,73} Compliance in diet advice studies was judged to be a source of other bias, given the long duration of the intervention that required the participants to adhere to a demanding dietary schedule.^{80,107,110}

Studies reporting on vitamin D supplementation are shown in the following, final evidence table. Studies exclusively gave dietary supplements to patients, rather than addressing more complex nutritional changes or dietary habits.

Table 12. Evidence for KQ3: Effects of Vitamin D Supplementation Interventions on MS Progression

ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	AE
Burton, 2010 ²⁸ multi-center	49 Power unclear	MS clinic patients, mean age 40.5 years, EDSS 1.34, and 25(OH)D 78 nmol/L; treatment vs control: female 84% vs 70%, R-R/SP 23/2 vs 22/2, mean disease duration 8.2 vs 7.4; patients already taking > 4,000 IU/day were excluded; McDonald 2001 criteria	Escalating vitamin D doses up to 40,000 IU/day over 28 weeks followed by 10,000 IU/day, and further downtitrated to 0 IU/day; calcium 1,200 mg/day; for 52 weeks		Placebo	Treatment vs control EDSS (p > 0.5), % change in EDSS - 0.23 vs 0.30 (p > 0.5), proportion completing with increased EDSS 0.88 vs 0.375 (p = 0.019) at end of trial	No adverse events observed
Kampman, 2012 ⁴⁹	68 (35 treatment, 33 placebo) No power calculation	Patients aged 18-50 with clinically definite MS and EDSS = < 4.5; vitamin D vs placebo: female 69% vs 73%, mean age 40 vs 41, mean duration from first symptom (range) 11 (1-27) vs 10 (2-26) years, mean EDSS 2.5 vs 2.0, mean MSSS 3.6 vs 3.2; McDonald 2001 criteria	20,000 IU vitamin D3 once a week in capsule for 96 weeks		Placebo	No significant difference in EDSS between treatment and placebo groups (absolute difference -0.01, CI -0.35, -0.35, p = 0.091)	1 placebo patient dropped out due to nephrolithiasis
Mosayebi, 2011 ⁶⁷	62 (28 treatment, 34 placebo) No power calculation	MS patients, 18-60 years, at least 1 relapse in the previous 12 months; > 3 lesions on spinal or brain-MRI or both; EDSS 0-3.5; vitamin D vs placebo: female 17/26 vs 25/33, mean age 37 vs 35, mean duration of disease 4.15 vs 6.4 years; patients with progressive MS were excluded; McDonald 2001 criteria	300,000 IU vitamin D3 as intra-muscular injections every month for 6 months		Placebo	EDSS increased by 0.21 from 2.10 after 6 month intervention and by 0.17 from 2.5 in placebo group	N/A
Shaygannejad, 2012 ⁸⁸	50 Sufficient power	MRI, clinical, or laboratory-supported R-R, EDSS < 7, average age 38.6; PP and SP MS excluded; McDonald 2005 criteria	Low-dose vitamin D (calcitriol) for 1 year	DMT	Placebo	Intervention: EDSS 1.63 (SD 0.70, difference pre-post 0, CI -0.15, 0.15); Placebo: 1.94 (SD 1.41, difference pre-post -0.24, CI -0.40, -0.08; p < 0.01) at 12-month follow-up	Vitamin D was well-tolerated; most AE were mild. Most common in intervention vs placebo group: constipation (N = 6 vs 4), dyspepsia (N = 6 vs 2), fatigue (N = 4 vs 5), headache (N = 2 vs 1)



ID, Trial type [§]	N Power	Participants	Intervention	Co	Comparator	EDSS results	AE
Soilu-Hanninen, 2012 ¹²⁸ multi-center	66 (34 treatment, 32 placebo) Power unclear	R-R patients age 18-55 years with IFNB-1b use for at least 1 month and EDSS = < 5.0; vitamin D vs placebo: female 21/34 vs 20/32, mean age 39 vs 35, mean EDSS 2.0 vs 2.4, mean disease duration 3.0 vs 2.4, mean annual relapse rate from the 2 years before the study onset 0.49 vs 0.52, patients with relapses during the year preceding baseline 12/34 vs 13/32; McDonald 2005 criteria	Vitamin D3 (20,000 IU or 0.5 mg of vitamin D3 in capsule, once weekly) for 1 year		Placebo	EDSS score decreased in the vitamin D group by -0.2 from 1.8 and remained the same in the placebo group (-0.02) after the 12 months intervention (p = 0.071)	No hypercalcaemia or significant differences in any clinical chemistry parameters or AE between groups; diarrhea (intervention N = 5 vs control 2), fever (2 vs 5); SAE: 1 case of erysipelas treated with antibiotics in intervention, 2 hospitalizations in control group (elective hip surgery, elbow fracture)
Stein, 2011 ⁹⁴	23 No power calculation	Patients with R-R older than 18 years, relapse within the preceding 24 months; intervention vs placebo, mean age 34 (29.5-49) vs 44.5 (39.5 -47), female 63% vs 75%, duration of MS, 6 (1.5-10.5) vs 6 (2-12), EDSS 2.5 (2-4) vs 2 (1-3); PP and SP excluded; McDonald 2001 criteria	High-dose D2 group received 1,000 IU vitamin D2 daily plus a high-dose vitamin D2 supplement for 6 months		Other: low-dose D2 received 1000 IU vitamin D2 daily plus a placebo	OR for lower exit EDSS comparing high-dose with low-dose: 0.16 (CI 0.02, 1.34, p = 0.09)	N/A

Notes: AE adverse events, Co co-intervention, DMT disease-modifying therapy, N/A not available, R-R relapsing-remitting, PP primary progressive, SP secondary progressive, vs versus

§All studies are RCTs unless otherwise noted.



We identified 6 RCTs addressing vitamin D supplementation. Studies provided patients with different doses, and some studies explicitly tested high- or low-dose supplementation. Most studies administered vitamin D as a capsule. One study provided intramuscular injections. One study provided vitamin D and calcium.²⁸ All but one study compared intervention effects to placebo; 1 study provided the control group with a low-dose supplement.⁹⁴ The duration of interventions ranged from 6 to 24 months.

Samples were small and ranged from 23 to 68 randomized patients. One study⁸⁸ reported a power calculation for EDSS score differences. Two studies reported a power calculation, but for a different outcome, and 3 reported no power calculation; hence, it is unclear whether studies were adequately powered to detect a difference in MS progression. Only one study explicitly reported that the sample included 4 (out of 49) patients in secondary progression²⁸ and patients with progressive MS were excluded in 3 of the identified studies.^{67,88,94}

All but one of the identified studies reported mean EDSS scores at the end of the trial for both experimental groups, some together with a statistical significance test for differences between groups. One study reported the proportion of patients completing the trial with increased EDSS, but none of the studies reported on the number of patients who entered progression, or reported on the time to progression. Adverse events were addressed in 4 out of 6 studies: one RCT reported no adverse events; one reported nephrolithiasis but did not specify the group; and 2 studies reported on minor adverse events.


The risk of bias assessment for the individual studies is shown in Appendix C. Studies gave supplements with matching placebos or injections with matching placebo injections, thereby reducing the risk of performance bias.

Summary of Findings and Quality of Evidence for Key Question 3

Results for KQ3 studies (risk factor modification therapies) are grouped by identified intervention type: exercise, diverse dietary interventions, and vitamin D supplementation.

Exercise

Across all identified physical exercise intervention studies, 7 reported post-intervention EDSS scores for both treatment arms. The results are shown in the following forest plot.

Figure 4: Effect of Exercise Interventions on EDSS Scores

None of the individual studies reported a statistically significant effect, and the pooled result also did not provide evidence of statistically significant improvements in EDSS scores for exercise relative to an untreated control group (SMD 0.02; CI -0.40, 0.44; I^2 0%; 7 RCTs). However, several studies showed baseline imbalances, where intervention participants had higher EDSS scores than the control group. Using baseline-adjusted data for a sensitivity analysis, the result favored the exercise intervention (SMD -0.19; CI -0.34, -0.03; I^2 0; 7 RCTs). There was no indication of publication bias (rank test $p = 0.562$, regression test $p = 0.850$).


The quality of the evidence for the result of no difference between exercise interventions and untreated control groups on EDSS scores was downgraded by 2 due to severe *study limitations* and by 1 due to conflicting results in a sensitivity analysis (*imprecision*). Our confidence in the evidence summary showing the absence of an effect is limited because most studies were not designed to assess EDSS changes, study sample sizes were very small which could only detect a large treatment effect, and there were baseline imbalances. The intervention duration was not long-term but ranged between 4 weeks and 3 months, which may be too short to achieve, and to detect changes with standard diagnostic criteria. In addition, the difference between intervention and control groups was statistically significant when adjusting for baseline scores; hence an intervention effect in better-designed studies cannot be ruled out. Nonetheless, any treatment effect is likely to be very small; even adjusting for baseline imbalances, the estimate was an average of 0.20 points of improvement on the EDSS scale.

None of the studies reported on other outcome measures such as the change from relapsing-remitting to secondary progressive MS.

Dietary Interventions


Across studies, 4 dietary intervention studies reported on the number of patients deteriorating and entering progression in each group. The figure shows that none of the included studies reported a statistically significant effect between fatty acids supplementation compared to placebo. The intervention duration ranged from 18 to 24 months.

Figure 5: Effect of Fatty Acid Supplementation Interventions on the Relative Risk of Progression



The pooled relative risk of experiencing progression was not statistically significantly lower in intervention groups (RR 0.86; CI 0.67, 1.05; I^2 0; 4 RCTs). Of note, Bates et al (1977) exclusively addressed patients with chronic progression.²⁴

A similar result was shown for differences in EDSS scores between treatment and control groups across 3 dietary intervention studies testing fatty acids supplementation or Hot nature diet advice.

Figure 6: Effect of Dietary Interventions on EDSS Scores

None of the individual interventions demonstrated a statistically significant effect on EDSS scores. Across studies, the difference in EDSS scores was not systematically different between intervention and control groups (SMD -0.13, -83, 0.56; I^2 5%; 3 RCTs).


One identified dietary intervention study reported a significant intervention effect, but this study could not be included in the meta-analysis. The study concluded that high-dose treatment of gamma-linolenic acid significantly reduced disability progression compared with placebo and low-dose treatment, but it did not report numerical data.⁴⁴

The quality of evidence for the dietary intervention results showing the absence of an effect on MS progression (measured as the relative risk of progression [see figure 5] or based on EDSS scores [see figure 6]) were both downgraded to moderate due to study limitations. The early studies lack reporting detail while the more recently published studies were small and did not report statistical power calculations to determine whether studies were designed to detect an effect of the intervention on MS progression.

We did not identify studies reporting on other MS progression outcomes such as the time to secondary progression.

Vitamin D

The 5 RCTs comparing vitamin D supplementation to placebo and reporting on the same outcome measure are shown in the figure. All reported on EDSS scores.

Figure 7: Effect of Vitamin D Interventions on EDSS Scores

None of the individual studies reported a statistically significant effect of the specific intervention under evaluation. While the pooled result indicated a positive trend, we also could not show a significant difference in EDSS scores between intervention and control group across all studies using standardized mean differences (SMD -0.15; CI -0.33, 0.02; I^2 0; 5 RCTs). However, analyzing weighted mean differences to determine the clinical importance of the difference showed a statistically significant effect of vitamin D supplementation on EDSS scores (WMD -0.22; CI -0.39, -0.05; I^2 0; 5 RCTs). The result indicates a difference in EDSS scores of 0.22 between intervention and control groups. There was no evidence of publication bias for this result (rank test $p = 0.82$, regression test $p = 0.99$).

The quality of evidence for a non-significant effect of vitamin D supplementation on EDSS scores was downgraded by 2 due to *study limitations* and by 1 due to *imprecision*. The included studies were small and the lack of reported power calculations makes it unclear whether the studies were sufficiently powered to be able to detect small treatment effects. The statistical significance is dependent on the effect measure, showing that the effect estimate is not very robust.

Studies on vitamin D did not report on other MS progression-relevant outcomes.

Summary for KQ3

The following summary of findings table documents the results for all interventions or class of interventions for outcomes that were reported in at least 2 studies.

Table 13. Summary of Findings for KQ3

Intervention Outcome	# of RCTs	Findings: Direction, Magnitude of Effect	GRADE
Exercise Interventions			
EDSS score differences	7 RCTs	No statistically significant difference between exercise intervention and control group (SMD 0.02; CI -0.40, 0.44)	Very low (study limitations, ** imprecision*)
Dietary Interventions			
Number of patients progressing	4 RCTs	No statistically significant difference between fatty acids supplementation intervention and control group (RR 0.86; CI 0.67, 1.05)	Moderate (study limitations*)
EDSS score differences	3 RCTs	No statistically significant difference between dietary intervention (fatty acids or Hot nature diet) and control group (SMD -0.13; CI -0.83, 0.56)	Moderate (study limitations*)
Vitamin D Supplements			
EDSS score differences	5 RCTs	No statistically significant difference between vitamin D supplementation and placebo (SMD -0.15; CI -0.33, 0.02)	Very low (study limitations, ** imprecision*)

Note: * quality of evidence downgraded by 1 level, ** quality of evidence downgraded by 2 levels

VA Subgroup Analysis

The participants in Lo et al were recruited either from the MS clinic at the VA Connecticut Healthcare System or through chapters of the National Multiple Sclerosis Society.⁵⁶ The study compared body weight supported treadmill training, with or without robot assistance, and found an improvement in EDSS scales for both groups across the 13 participants.

The author affiliation of the study by Yadav et al¹¹⁰ suggests that the participants were US Veterans. Patients were assigned to a one year low-fat, plant-based diet. The study reported no significant changes in EDSS scores in the groups after baseline difference adjustment. Only few study details were available; the study was published as a conference abstract.

SUMMARY AND DISCUSSION

Our systematic review focused on modifiable risk factors, such as health behaviors of patients with MS. We systematically searched for, documented, and synthesized studies available in the international literature on modifiable risk factors and the effect of modification therapies.

The review addressed a broad and very complex research field and a large number of studies contributed to this review. Literature searches were comprehensive and exploratory in nature and were not limited to a narrow set of known risk factors. Few prospective studies were identified to inform the association between modifiable risk factors and MS progression, limiting the conclusions that can be drawn from the existing literature for KQ1. Furthermore, while the review made every effort to locate studies relevant to KQ2 (exposure during military service), only a very small number of studies was identified. Although a number of interventions have been tested in RCTs, many were not designed to assess the effect on MS progression, also limiting the conclusions that can be drawn from the intervention literature addressed in KQ3.

We did not find variables that were identified as valid risk factors of MS progression and that have been shown in intervention studies to improve MS progression. However, the review systematically explores and catalogues what is currently known in this research field, highlights promising areas, and identifies future research needs to address the progression of MS.

SUMMARY OF EVIDENCE FOR KQ1: What modifiable epidemiologic factors are related to multiple sclerosis progression following diagnosis?

Our literature review identified a large number of modifiable epidemiologic factors that have been assessed in the context of MS progression. However, study designs, operationalizations of risk factors, and outcome assessment measures varied widely.

A substantial amount of research has been dedicated to the role of vitamin D in MS progression. Our synthesis shows a weak but consistent negative correlation between 25(OH)D levels and EDSS scores across studies. Evidence comes primarily from concurrent studies which assess the physiological level and the disability status at the same time. Hence, this result should be interpreted as an association without causal interpretation. Low vitamin D levels may be the cause, the effect, or a covariate of EDSS levels. In addition, whether the physiological levels can be directly influenced by patients is an unresolved question. The association has also been shown in 2 prospective studies that reported on this outcome and although there was some evidence of publication bias, an adjusted analysis found a very similar effect. We did not find studies reporting on other operationalizations of the role of vitamin D, such as sun exposure or use of supplements, that could be combined, and we did not find studies reporting on the effect of vitamin D on the change from relapsing-remitting to secondary progressive MS. The international literature has linked MS to vitamin D deficiency and suggests additional functions outlining why high levels of vitamin D may be beneficial for MS patients (*eg*, anti-inflammatory aspects of vitamin D).^{4,129}

Smoking has also been addressed in a large number of studies and was associated with an increased risk of progression in MS patients. The association was shown in studies predicting time to EDSS scores of 6 (use of cane, crutch, or brace) as well as conversion to secondary

progression. Our confidence in the exact size of effect is somewhat limited due to unexplained heterogeneity (moderate quality of evidence). Our pooled estimate was statistically significant but lower than that reported by a 2011 meta-analysis. The earlier existing meta-analysis was based on fewer studies and did not find a statistically significant effect, and concluded at the time that smoking is important in determining MS susceptibility but the effect on the progression of disease is less certain.¹³⁰ The now available literature suggests that smoking is an important modifiable risk factor for MS progression. This is of particular importance as it is a risk factor that can be directly influenced by MS patients.

There is low quality of evidence that epidural analgesics during childbirth are associated with EDSS scores. This outcome has been addressed in retrospective as well as prospective studies but all existing studies report on disability levels across study samples, not direct measures of progression in individuals such as time to secondary progression.

The risk factors sun exposure, month of birth, diet, fish consumption, alcohol-related predictors, exercise, oral contraception, and education have been addressed in more than one study and were documented in detail in the summary of findings section. It was not possible to derive specific evidence statements due to the unique operationalization of risk factors and outcome measures; however, in particular the role of sun exposure and alcohol-related variables should be investigated further.

The evidence tables document a large range of potential risk factors such as: cesarean delivery; breast feeding; having been breast fed; obstetrical and spinal anesthesia; childhood maltreatment; working outdoors; individual health promoting lifestyle domains; meditation practice; insurance coverage; medical care satisfaction variables; exposure to different types of animals; coal heating; wood heating; humid living space; no sewage system; no piped water; type of environment (*eg*, farm); specific diet factors such as coffee consumption, liver consumption, vitamin supplementation, fortified foods, vegetarian diet; cod liver oil intake; occupational status; deployment to a war theater; being a Veteran; and earthquake experience. These were addressed in single studies and have not been replicated in other studies.

The review explored a large number of potential risk factors but shows that in many cases, the existing evidence base investigating an association is insufficient to make evidence statements for specific outcomes and results. This is illustrated by the following examples. Our systematic review showed that the evidence for an association between progression of MS and dietary factors is sparse. We did not identify more than one study reporting on the same diet and reporting on the same outcome measure. Similarly, a Cochrane review on dietary interventions in MS highlighted that a number of diets for MS (*eg*, Swank Diet) have been proposed; however, dietary habits in MS patients have not been extensively studied or reported.¹² Furthermore, physical exercise has been addressed in a number of published studies, both as a correlate of disability and its predictive validity for MS progression. Study results varied by analytic design. Lower physical exercise can be the cause, the effect, or a covariate of higher EDSS scores. We did not identify more than one study reporting on the same risk factor operationalization and MS progression outcome measure. Hence, the existing evidence base is still very limited. Approaches to offer physical exercise to MS patients are traditionally based on optimizing daily functioning, but whether exercise has a role in slowing progression of MS has also been raised as a research question.¹³¹⁻¹³³

SUMMARY OF EVIDENCE KQ2: What environmental exposures prior to or during military service are related to multiple sclerosis progression following onset symptoms?

Only very few studies were identified that reported on exposures prior to and during military services associated with MS progression (KQ2) in active military personnel or Veterans. Evaluated risk factors in existing studies include only a small number of potentially relevant exposures such as deployment.

The quality of the evidence across studies was determined to be insufficient for evidence statements. None of the studies employed a prospective study design and risk factors were addressed in single studies without replication in other studies. All potential risk factors were reported in only one included study without replication in another participant sample. Hence, the available evidence is not suitable to answer the review question.

SUMMARY OF EVIDENCE KQ3: Among identified risk factors for progression, what treatment / risk factor modification therapies have been shown to delay or hasten the progression of MS once it has initiated?

Our literature searches identified a substantial number of studies that have addressed modifiable risk factors; however, all addressed exercise programs, dietary interventions, or vitamin D supplementation.

Exercise interventions did not demonstrate a statistically significant effect on EDSS scores comparing intervention and untreated control groups across all studies reporting on this outcome. However, sensitivity analyses indicated that, adjusting for baseline imbalances, small effects on EDSS become apparent (0.20 point difference between treatment groups). Studies were not designed to assess EDSS changes or other measures of progression, study sample sizes were very small with indications of baseline imbalances, and the interventions may have been too short to achieve and to detect changes with standard diagnostic criteria. The negative results should not be interpreted as exercise not being beneficial in MS in general. Exercise in MS patients may have many positive effects¹³² and a recent systematic review¹³⁴ addressing a range of outcomes concluded that exercise may be recommended for rehabilitation. Our review aimed to detect an effect for a very specific outcome – progression of MS.

The identified data did not indicate a statistically significant positive effect of dietary interventions that affected the progression of MS. This result mirrors the conclusion of an existing Cochrane review on dietary interventions for MS that included studies published to November 2011.¹² The review reported that polyunsaturated fatty acids seem to have no major effect on disease progression but cautioned also that evidence statements are limited due to uncertain quality of the studies.

Individual studies and the pooled result showed a trend for an effect favoring vitamin D supplementation in MS patients but the statistical significance depended on the effect measure. Our confidence in the evidence for the absence of an effect is limited given that the existing studies were small and they may lack statistical power to detect small treatment effects. A Cochrane review that searched for intervention studies in May 2010 identified only one study; all

additional studies shown in our meta-analysis were published after this date. The review concluded that the level of evidence for the effectiveness of vitamin D supplementation does not allow confident decision-making about the use of vitamin D in MS.⁴ Any potential treatment effects are likely to be small, with an estimated difference of 0.22 points in EDSS scores between intervention and control groups.

Finally, smoking, a risk factor for progression with a stronger evidence base, has not been addressed in RCTs to assess the effects of smoking cessation interventions on progression in MS patients. This is unfortunate because some risk factor studies suggested that negative consequences of smoking can be reversed in ex-smokers, suggesting that this risk factor could be amenable to intervention.⁴⁶

LIMITATIONS

It should be noted that this review was restricted to patient-reported measures of MS progression and disability. Other progression measures such as MRI results are also of interest to clinicians and can make additional contributions to this complex research field.

Furthermore, due to resource constraints, this review was limited to English-language publications. Although we included several international studies, the language restriction will have missed some studies, in particular older studies contributing to research on MS progression.

This review identified a large number of studies contributing to the evidence base on modifiable risk factors associated with MS progression. However, the evidence base is limited due to the small number of prognostic studies and the small number of studies reporting on direct measures of progression (*eg*, conversion to secondary progressive MS) rather than proxies such as MS disability status.

We converted statistics to the extent possible for this review. Nonetheless we were often not able to summarize results across studies due to lack of reporting of key variables, such as point estimates and measures of dispersion, in addition to the statistical significance of the presence or absence of associations. Due to the timeframe and lack of resources the review is entirely based on published literature and did not contact authors for missing information or additional data; furthermore, several included studies have been published decades ago, making it unlikely that additional data is still available.

Applicability of Findings to the VA Population

We found no indication that risk factor results and treatment effects are not applicable to the VA population. However, the existing evidence does not permit analyses to test this hypothesis by identifying moderator effects linking study populations to differential effects. There are very few risk factor or intervention studies reporting specifically on VA samples.

RESEARCH GAPS/FUTURE RESEARCH

Our systematic review showed that more prospective research studies are needed to allow predictions and meaningful interpretation of risk factor analyses. Furthermore, it is imperative that risk factor studies report more details (*eg*, mean EDSS scores and a measure of dispersion), more measures of progression, and/or more analyses (*eg*, reporting on EDSS scores means as well as time to progression to specific EDSS benchmarks). While many individual studies do not

have sufficient statistical power to detect small effects of risk factors on progression, studies may contribute to future meta-analyses. We identified a number of areas with published research on a risk factor of interest, but due to the unique operationalization of predictor and outcome measure, it was not possible to adequately synthesize results across studies.

Although our review addressed a broad research field, there are other potential risk factors that were outside the scope of this review, such as comorbidities.¹¹ There is a growing literature on MS comorbidities, including obesity and the associations of body weight and MS progression, which warrants an individual systematic review.^{135,136} Future reviews should in particular address the role of treatable comorbidities in MS progression. Scoping searches also identified a large literature base evaluating the effect of pregnancies. However, any association needs to be interpreted with caution. While the data may suggest a protective effect, reverse causality cannot be ruled out – a MS diagnosis and perceived progression may affect reproductive decision making.¹³⁷

Furthermore, this review did not target psychological variables, such as depression, anxiety, coping strategies, social functioning, distress, anger, and other emotions and cognitive styles, which may be reactions to MS progression and/or contributing factors to MS progression. Although variables have been assessed in the literature, very often, these have been studied as correlates of the disease, and while many studies have tried to predict psychological variables with MS progression, some have used the psychological variables as predictors for MS progression. These variables should be assessed in prospective risk factor studies to establish the temporal chain of events in order to establish a prognostic link between these variables and MS progression. However, even if a link can be established, it is a different matter to show that the psychological variables can a) be modified and b) the modification has an effect on progression; hence, intervention studies testing the modification therapy will be subsequently needed.

Generally, more prospective risk factor studies are needed that allow determining a temporal sequence of events and that address the direction of associations. For example, a number of studies have reported on alcohol-related measures and showed better outcomes associated with specific operationalizations of alcohol use or misuse, but the available studies used primarily concurrent data (correlating current alcohol intake and current disability) and an alternative interpretation of this “protective” effect of alcohol is that more disabled people drink less alcohol because of their disability. Sun exposure should also be evaluated further in order to replicate identified associations of specific operationalizations of the predictor variable and MS disability and progression measures. Prospective studies are needed to provide more information on the role of sun exposure and alcohol consumption (and the optimum amount) in MS progression.¹¹

Finally, intervention studies testing the effect of interventions on MS progression should determine the statistical power needed to detect a difference between treatment groups. This is in particular needed for vitamin D supplementation trials. In addition, more research on exercise interventions is warranted with studies that are adequately powered and interventions of sufficient duration to potentially influence MS progression. Effects of smoking cessation interventions should be determined in intervention studies given the association between smoking and MS progression. Furthermore, while a substantial number of intervention studies exist that have reported on disease status and disability measures, larger studies reporting on direct progression measures are urgently needed.

CONCLUSIONS

A large number of studies is available to contribute to the growing research literature on modifiable risk factors and MS progression but the research field is very complex.

Risk factor studies used diverse operationalizations of risk factors and different outcome measures, and more prospective studies are needed. Most consistent results were shown for the association between EDSS scores and vitamin D levels. Smoking was associated with a faster progression of MS in smokers compared to nonsmokers.

Risk factors in Veterans and active military personnel were one of the key questions for this review but very few studies are available to inform on this participant subgroup.

We did not identify interventions that showed a statistically significant effect of exercise, diet, or vitamin D supplementation on EDSS scores across studies. However, studies were not designed to assess effects on MS progression. More research is needed, in particular, on interventions for smoking cessation, adequately powered vitamin D supplementation RCTs, and RCTs testing the effects of long-term exercise interventions.

REFERENCES

1. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med*. Nov 16 2000;343(20):1430-1438.
2. Multiple sclerosis - management of multiple sclerosis in primary and secondary care. October 2014.
3. Veterans Health Administration The Office of Patient Care Services: Medical-Surgical Services. VHA HANDBOOK 1011.06 Multiple Sclerosis System of Care Procedures. Washington, D.C. December 7, 2009.
4. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. *Cochrane Database Syst Rev*. 2010(12):CD008422.
5. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. *Brain: a Journal of Neurology*. Oct 2002;125(Pt 10):2202-2212.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Annals of Neurology*. Mar 1983;13(3):227-231.
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Annals of Neurology*. Jul 2001;50(1):121-127.
8. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. Jul 15 2014;83(3):278-286.
9. Herndon RM. Medical hypothesis: why secondary progressive multiple sclerosis is a relentlessly progressive illness. *Archives of Neurology*. Feb 2002;59(2):301-304.
10. Compston A, Coles A. Multiple sclerosis. *Lancet*. Apr 6 2002;359(9313):1221-1231.
11. D'Hooghe M B, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jul 2010;16(7):773-785.
12. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev*. 2012;12:CD004192.
13. Faridar A, Eskandari G, Sahraian MA, Minagar A, Azimi A. Vitamin D and multiple sclerosis: a critical review and recommendations on treatment. *Acta Neurol Belg*. Dec 2012;112(4):327-333.
14. Altman DG. Systematic reviews of evaluations of prognostic variables. *BMJ*. Jul 28 2001;323(7306):224-228.
15. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. *Annals of Internal Medicine*. Feb 19 2013;158(4):280-286.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology*. Nov 1983;33(11):1444-1452.
17. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology*. Apr 2011;64(4):401-406.

18. Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst Rev.* 2013;2:71.
19. Armutlu K, Karabudak R, Nurlu G. Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. *Neurorehabil Neural Repair.* 2001;15(3):203-211.
20. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurology.* Mar 2014;71(3):306-314.
21. Aupperle R, Denney D, Lynch S. Omega 3 fatty acid levels in multiple sclerosis: correlation of diet, disability, and depression. *Multiple Sclerosis.* Sep 2005;11:S28-S28.
22. Baghizadeh S, Sahraian MA, Beladimoghadam N. Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. *Iranian Journal of Neurology.* 2013;12(1):1-8.
23. Bates D, Cartlidge NE, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry.* Jan 1989;52(1):18-22.
24. Bates D, Fawcett PR, Shaw DA, Weightman D. Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. *British Medical Journal.* Oct 8 1977;2(6092):932-933.
25. Bates D, Fawcett PR, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. *British Medical Journal.* Nov 18 1978;2(6149):1390-1391.
26. Bjarnadottir OH, Konradsdottir AD, Reynisdottir K, Olafsson E. Multiple sclerosis and brief moderate exercise. A randomised study. *Multiple sclerosis (Houndmills, Basingstoke, England).* Jul 2007;13(6):776-782.
27. Bombardier CH, Blake KD, Ehde DM, Gibbons LE, Moore D, Kraft GH. Alcohol and drug abuse among persons with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England).* Feb 2004;10(1):35-40.
28. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. *Neurology.* Jun 8 2010;74(23):1852-1859.
29. Carter AM, Daley AJ, Kesterton SW, Woodroffe NM, Saxton JM, Sharrack B. Pragmatic exercise intervention in people with mild to moderate multiple sclerosis: a randomised controlled feasibility study. *Contemporary Clinical Trials.* Jul 2013;35(2):40-47.
30. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. *N Engl J Med.* Jul 30 1998;339(5):285-291.
31. Conklyn D, Stough D, Novak E, Paczak S, Chemali K, Bethoux F. A home-based walking program using rhythmic auditory stimulation improves gait performance in patients with multiple sclerosis: a pilot study. *Neurorehabil Neural Repair.* Nov-Dec 2010;24(9):835-842.
32. Dalgas U, Stenager E, Jakobsen J, et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. *Neurology.* Nov 3 2009;73(18):1478-1484.

33. Dastagir A, Alqallaf A, Bao F, et al. Vitamin D Levels in African-Americans and Caucasian with Relapsing Multiple Sclerosis: Relationship with Disease Course. *Neurology*. Feb 2013;80.
34. DeBolt LS, McCubbin JA. The effects of home-based resistance exercise on balance, power, and mobility in adults with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Feb 2004;85(2):290-297.
35. Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP. Factors associated with a rapid course of multiple sclerosis. *Archives of Neurology*. Jun 1982;39(6):337-341.
36. D'Hooghe M B, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. *European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies*. Apr 2012;19(4):616-624.
37. Fimland MS, Helgerud J, Gruber M, Leivseth G, Hoff J. Enhanced neural drive after maximal strength training in multiple sclerosis patients. *European Journal of Applied Physiology*. Sep 2010;110(2):435-443.
38. Foster M, Zivadinov R, Weinstock-Guttman B, et al. Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. *Journal of Neuroimmunology*. Feb 29 2012;243(1-2):61-68.
39. Fragoso YD, Adoni T, Almeida SM, et al. Multiple sclerosis in South America: month of birth in different latitudes does not seem to interfere with the prevalence or progression of the disease. *Arq Neuropsiquiatr*. Sep 2013;71(9a):573-579.
40. Gava G, Bartolomei I, Costantino A, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. *Fertility and Sterility*. Jul 2014;102(1):116-122.
41. Gelfand JM, Cree BAC, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. *Neurology*. May 2011;76(21):1824-1830.
42. Golzari Z, Shabkhiz F, Soudi S, Kordi MR, Hashemi SM. Combined exercise training reduces IFN-gamma and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. *Int Immunopharmacol*. Nov 2010;10(11):1415-1419.
43. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. *Multiple sclerosis (Houndmills, Basingstoke, England)*. Apr 1999;5(2):78-88.
44. Harbige LS, Sharief MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. *The British Journal of Nutrition*. Oct 2007;98 Suppl 1:S46-53.
45. Hatamian H, Bidabadi E, Seyed Saadat SM, et al. Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis? *Iranian Journal of Neurology*. 2013;12(2):41-46.
46. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. *Archives of Neurology*. Jul 2009;66(7):858-864.

47. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. *Brain: a Journal of Neurology*. Jun 2005;128(Pt 6):1461-1465.
48. Jansons L, Tutuncu M, Tang J, et al. Does smoking really impact progression in multiple sclerosis? *Mult. Scler. J*. Oct 2011;17:S138-S138.
49. Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Aug 2012;18(8):1144-1151.
50. Knippenberg S, Bol Y, Damoiseaux J, Hupperts R, Smolders J. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. *Acta Neurologica Scandinavica*. Sep 2011;124(3):171-175.
51. Koch M, De Keyser J, Tremlett H. Timing of birth and disease progression in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jul 2008;14(6):793-798.
52. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. *Neurology*. Oct 9 2007;69(15):1515-1520.
53. Kragt J, van Amerongen B, Killestein J, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jan 2009;15(1):9-15.
54. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on the natural history of multiple sclerosis. 7. Correlates of clinical change in an early bout. *Acta Neurologica Scandinavica*. 1973;49(3):379-395.
55. Lauer K, Firnhaber W. Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study. *Journal of Neurology*. Feb 1992;239(2):93-97.
56. Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. *Neurorehabil Neural Repair*. Nov-Dec 2008;22(6):661-671.
57. Lu E, Zhao Y, Dahlgren L, et al. Obstetrical epidural and spinal anesthesia in multiple sclerosis. *Journal of Neurology*. Oct 2013;260(10):2620-2628.
58. Lucenti A, Galimberti S, Barizzone N, et al. Multiple sclerosis progression is not associated with birth timing in Italy. *Journal of the Neurological Sciences*. Nov 2014;346(1-2):194-196.
59. Maghzi AH, Etemadifar M, Heshmat-Ghahdarjani K, et al. Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran. *Neuroepidemiology*. 2011;37(3-4):238-242.
60. Mandia D, Ferraro OE, Nosari G, Montomoli C, Zardini E, Bergamaschi R. Environmental Factors and Multiple Sclerosis Severity: A Descriptive Study. *Int. J. Environ. Res. Public Health*. Jun 2014;11(6):6417-6432.
61. Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. *Brain: a Journal of Neurology*. Jul 2013;136(Pt 7):2298-2304.

62. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jan 2009;15(1):105-113.
63. McDowell TY, Amr S, Culpepper WJ, et al. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. *Neuroepidemiology*. 2011;37(1):52-57.
64. Milivojevic I, Adamec I, Habek M. Utilization of physical rehabilitation among people with multiple sclerosis. *Irish Journal of Medical Science*. Sep 2013;182(3):429-432.
65. Millar JH, Zilkha KJ, Langman MJ, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. *British Medical Journal*. Mar 31 1973;1(5856):765-768.
66. Miller L, Paul L, Mattison P, McFadyen A. Evaluation of a home-based physiotherapy programme for those with moderate to severe multiple sclerosis: a randomized controlled pilot study. *Clin Rehabil*. Aug 2011;25(8):720-730.
67. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. *Immunological Investigations*. 2011;40(6):627-639.
68. Motl RW, Dlugonski D, Pilutti L, Sandroff B, McAuley E. Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis. *Journal of the Neurological Sciences*. Dec 15 2012;323(1-2):123-127.
69. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. *Annals of Neurology*. Aug 2012;72(2):234-240.
70. Niino M, Fukazawa T, Miyazaki Y, et al. Association of serum vitamin D levels in Japanese patients with multiple sclerosis. *Clinical and Experimental Neuroimmunology*. December 2013;4 SUPPL. 1:92.
71. Pantzaris MC, Loukaides GN, Ntzani EE, Patrikios IS. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. *BMJ open*. 2013;3(4).
72. Pasto L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. *BMC Neurol*. 2012;12:165.
73. Paty DW, Cousin HK, Read S, Adlakha K. Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit. *Acta Neurologica Scandinavica*. Jul 1978;58(1):53-58.
74. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. *Annals of Neurology*. Apr 1996;39(4):432-441.
75. Pfalzer L, Fry D. Effects of a 10-week inspiratory muscle training program on lower-extremity mobility in people with multiple sclerosis: a randomized controlled trial. *International Journal of MS care*. Spring 2011;13(1):32-42.
76. Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. *Journal of Neurology*. Apr 2009;256(4):577-585.

77. Plow M, Finlayson M, Cho C. Correlates of nutritional behavior in individuals with multiple sclerosis. *Disabil. Health J.* Oct 2012;5(4):284-291.
78. Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, et al. Efficacy of fish oil on serum of TNF alpha , IL-1 beta , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. *Oxidative Medicine and Cellular Longevity.* 2013;2013:709493.
79. Rampello A, Franceschini M, Piepoli M, et al. Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. *Physical Therapy.* May 2007;87(5):545-555.
80. Rezapour-Firouzi S, Arefhosseini SR, Ebrahimi-Mamaghani M, et al. Erythrocyte membrane fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils. *African Journal of Traditional, Complementary, and Alternative medicine: AJTCAM / African Networks on Ethnomedicines.* 2013;10(6):519-527.
81. Romberg A, Virtanen A, Ruutiainen J, et al. Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. *Neurology.* Dec 14 2004;63(11):2034-2038.
82. Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan. *Journal of the Neurological Sciences.* Jul 15 2013;330(1-2):52-55.
83. Sangelaji B, Nabavi SM, Estebarsari F, et al. Effect of combination exercise therapy on walking distance, postural balance, fatigue and quality of life in multiple sclerosis patients: a clinical trial study. *Iranian Red Crescent Medical Journal.* Jun 2014;16(6):e17173.
84. Schwartz I, Sajin A, Moreh E, et al. Robot-assisted gait training in multiple sclerosis patients: a randomized trial. *Multiple Sclerosis (Houndmills, Basingstoke, England).* Jun 2012;18(6):881-890.
85. Sena A, Couderc R, Vasconcelos JC, Ferret-Sena V, Pedrosa R. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. *Journal of the Neurological Sciences.* Jun 15 2012;317(1-2):47-51.
86. Shahbeigi S, Pakdaman H, Fereshtehnejad SM, Nikravesh E, Mirabi N, Jalilzadeh G. Vitamin d3 concentration correlates with the severity of multiple sclerosis. *International Journal of Preventive Medicine.* May 2013;4(5):585-591.
87. Shamma L, Zentek T, von Haaren B, Schlesinger S, Hey S, Rashid A. Home-based system for physical activity monitoring in patients with multiple sclerosis (Pilot study). *Biomedical Engineering Online.* 2014;13:10.
88. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. *Multiple Sclerosis International.* 2012;2012:452541.
89. Sibley WA, Bamford CR, Clark K, Smith MS, Laguna JF. A prospective study of physical trauma and multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry.* Jul 1991;54(7):584-589.

90. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Nov 2008;14(9):1220-1224.
91. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Feb 2008;79(2):152-157.
92. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. *Neurology*. Jan 1 1999;52(1):57-62.
93. Spitzer C, Bouchain M, Winkler LY, et al. Childhood trauma in multiple sclerosis: a case-control study. *Psychosomatic Medicine*. Apr 2012;74(3):312-318.
94. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. *Neurology*. Oct 25 2011;77(17):1611-1618.
95. Sternberg Z, Leung C, Sternberg D, et al. The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients. *CNS & Neurological Disorders Drug Targets*. Feb 1 2013;12(1):104-111.
96. Stuifbergen AK, Blozis SA, Harrison TC, Becker HA. Exercise, functional limitations, and quality of life: A longitudinal study of persons with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Jul 2006;87(7):935-943.
97. Sundstrom P, Nystrom L. Smoking worsens the prognosis in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Sep 2008;14(8):1031-1035.
98. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. *Lancet*. Jul 7 1990;336(8706):37-39.
99. Teter B, Weinstock-Guttman B, Mihai C, et al. Parity, education and sun exposure may predict long-term disability in female patients with multiple sclerosis. *Multiple Sclerosis*. Sep 2008;14:S203-S203.
100. Thouvenot E, Orsini M, Daures JP, Camu W. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. *European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies*. Mar 2015;22(3):564-569.
101. Torkildsen O, Wergeland S, Bakke S, et al. omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. *Archives of Neurology*. Aug 2012;69(8):1044-1051.
102. Tuzun E, Polat A, Akman-Demir G, et al. Impact of Earthquake on Multiple Sclerosis Attacks. *Noropsikiyatri Ars*. 2010;47(4):324-327.
103. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. *Journal of Neurology*. May 2007;254(5):581-590.
104. Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans. *Journal of Rehabilitation Research and Development*. Mar-Apr 2002;39(2):163-174.

105. Wallin M, Culpepper WJ, Kurtzke J. Risk Factors for Disease Progression in a Diverse US Population-based Multiple Sclerosis Cohort (S45.003). *Neurology*. 2015;84(14 Suppl 45.003).
106. Weiland TJ, Hadgkiss EJ, Jelinek GA, Pereira NG, Marck CH, van der Meer DM. The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. *Journal of the Neurological Sciences*. Jan 15 2014;336(1-2):211-219.
107. Weinstock-Guttman B, Baier M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*. Nov 2005;73(5):397-404.
108. Weinstock-Guttman B, Zivadinov R, Ramanathan M. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. *Journal of the Neurological Sciences*. Dec 15 2011;311(1-2):86-91.
109. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Feb 2001;70(2):174-179.
110. Yadav V, Marracci G, Kim E, et al. Effects of a low fat plant based diet in multiple sclerosis (MS): Results of a 1-year long randomized controlled (RC) study. *Neurology*. 2014;82(10):2014-2014.
111. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. *Neurology*. Aug 18 2009;73(7):504-510.
112. Tepavcevic DK, Kostic J, Stojisavljevic N, et al. Cigarette smoking as a predictor for change in disability in multiple sclerosis patients: a 6-year follow-up study in Belgrade (Serbia). *European Journal of Neurology*. Sep 2010;17:487-487.
113. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. *Brain: A Journal of Neurology*. Feb 1995;118 (Pt 1):253-261.
114. Brandes DW, Bigley K, Hornstein W, Cohen H, Au W, Shubin R. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. *Curr Med Res Opin*. Jul 2007;23(7):1667-1672.
115. Maciejek Z, Wojcik-Draczkowska H, Wawrzyniak S, Niezgodzinska-Maciejek A. Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. *Neurologia i Neurochirurgia Polska*. Mar-Apr 2013;47(2):145-151.
116. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMIS study): clinical predictors of post-partum relapse. *Brain: A Journal of Neurology*. Jun 2004;127(Pt 6):1353-1360.
117. Tavee J, Rensel M, Planchon SM, Butler RS, Stone L. Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. *International Journal of MS Care*. Winter 2011;13(4):163-168.

118. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. *Nutrition*. Feb 2003;19(2):161-162.
119. Swank RL. Multiple sclerosis: fat-oil relationship. *Nutrition*. Sep-Oct 1991;7(5):368-376.
120. D'Hooghe M B, Haentjens P, Nagels G, Garmyn M, De Keyser J. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2012;18(4):451-459.
121. D'Hooghe M B, Haentjens P, Nagels G, D'Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. *Journal of Neurology*. May 2012;259(5):855-861.
122. D'Hooghe M B, Nagels G, De Keyser J, Haentjens P. Self-reported health promotion and disability progression in multiple sclerosis. *Journal of the Neurological Sciences*. Feb 15 2013;325(1-2):120-126.
123. Marck CH, Hadgkiss EJ, Weiland TJ, van der Meer DM, Pereira NG, Jelinek GA. Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey. *BMC Neurol*. 2014;14:143.
124. Levin AB, Hadgkiss EJ, Weiland TJ, et al. Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study. *Behavioural Neurology*. 2014;2014:916519.
125. Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Oct 2013;84(10):1092-1099.
126. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet*. Nov 8 2003;362(9395):1517-1526.
127. Solari A, Motta A, Mendozzi L, et al. Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. *Journal of the Neurological Sciences*. Jul 15 2004;222(1-2):99-104.
128. Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. May 2012;83(5):565-571.
129. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. *Neuroepidemiology*. 2013;40(3):147-153.
130. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. *PloS One*. 2011;6(1):e16149.
131. Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G. Exercise therapy for multiple sclerosis - art. no. CD003980.pub2. *Cochrane Database Syst Rev*. 2005(1).
132. Feinstein A, Dalgas U. The benefits of exercise in progressive MS: some cautious optimism. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2014;20(3):269-270.

133. Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? *Therapeutic Advances in Neurological Disorders*. Mar 2012;5(2):81-95.
134. Sa MJ. Exercise therapy and multiple sclerosis: a systematic review. *Journal of Neurology*. Sep 2014;261(9):1651-1661.
135. Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. *Continuum (Minneapolis, Minn.)*. Aug 2013;19(4 Multiple Sclerosis):1046-1057.
136. Overs S, Hughes CM, Haselkorn JK, Turner AP. Modifiable comorbidities and disability in multiple sclerosis. *Current Neurology and Neuroscience reports*. Oct 2012;12(5):610-617.
137. Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2014;20(5):527-536.

APPENDIX A. SEARCH STRATEGIES

This appendix documents the exact search strings for all searched electronic databases. We designed a search strategy for each key question in order to maximize relevance and retrieval success.

SEARCH METHODOLOGY KQ1

DATABASE SEARCHED & TIME PERIOD COVERED:

PubMed – ~1946-2/27/2015

LANGUAGE:

English

SEARCH STRATEGY #1 (Study Design Filter):

multiple sclerosis[tiab] OR multiple sclerosis[majr]

AND

progression[tiab] OR progressive[tiab] OR progressing[tiab] OR mortality[tiab] OR disease course[tiab] OR disability[tiab]

AND

"cohort studies"[mh] OR "follow-up studies"[mh] OR prognos*[tiab] OR predict*[tiab] OR multivariate[tiab]

NOT

(animal OR animals) NOT (human OR humans)

SEARCH STRATEGY #2 (Risk Factor Filter):

multiple sclerosis[tiab] OR multiple sclerosis[majr]

AND

progression[tiab] OR progressive[tiab] OR progressing[tiab] OR mortality[tiab] OR disease course[tiab] OR disability[tiab]

AND

geographic[tiab] OR sun exposure[tiab] OR vitamin D[tiab] OR fatty acid[tiab] OR diet[tiab] OR dietary[tiab] OR nutrition*[tiab] OR obesity[tiab] OR smoking[tiab] OR tobacco[tiab] OR alcohol[tiab] OR exercise[tiab] OR physical activity[tiab] OR stress[tiab] OR anesthesia[tiab] OR radiation therapy[tiab] OR oral contraception[tiab] OR fertility treatment[tiab] OR pregnan*[tiab] OR delivery[tiab] OR breastfeeding[tiab] OR salt intake[tiab] OR milk[tiab] OR water[tiab] OR trace elements[tiab] OR trauma[tiab] OR traumatic[tiab] OR Epstein–Barr virus[tiab]

NOT

(animal OR animals) NOT (human OR humans)

DATABASE SEARCHED & TIME PERIOD COVERED:

Web of Science– Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH - 1980-2/27/2015

LANGUAGE:

English

SEARCH STRATEGY #1:

TS = (multiple sclerosis)

AND

TS = (progression OR progressive OR progressing)

AND

TS = (cohort OR prognos*OR predict* OR multivariate)

SEARCH STRATEGY #2:

TS = (multiple sclerosis)

AND

TS = (progression OR progressive OR progressing)

AND

TS = (geographic OR sun OR sunlight OR vitamin D OR fatty acid OR diet OR dietary OR nutrition* OR obesity OR obese OR smoking OR tobacco OR alcohol OR exercise OR physical activity OR stress* OR anesthesia OR radiation therapy OR oral contracepti* OR fertility treatment OR pregnan* OR breastfeed* OR salt OR milk OR water OR trace elements OR trauma OR traumatic OR Epstein-Barr OR "Epstein barr")

DATABASE SEARCHED & TIME PERIOD COVERED:

SCOPUS – ~1800's-3/2/2015

LANGUAGE:

English

SEARCH STRATEGY #1:

TITLE-ABS-KEY("multiple sclerosis")

AND

TITLE-ABS-KEY(progression OR progressive OR progressing)

AND

TITLE-ABS-KEY(cohort OR prognos*OR predict* OR multivariate)

SEARCH STRATEGY #2:

TITLE-ABS-KEY ("multiple sclerosis")

AND

TITLE-ABS-KEY (progression OR progressive OR progressing)

AND

vitamin d OR fatty acid OR diet OR dietary OR nutrition* OR obesity OR obese OR smoking OR tobacco OR alcohol) OR (geographic OR sun OR sunlight OR exercise OR physical activity OR stress* OR anesthesia OR radiation therapy OR oral contracepti*) OR (fertility treatment OR pregnan* OR breastfeed* OR salt OR milk OR water OR trace elements OR trauma OR traumatic OR epstein--barr OR "Epstein barr"

DATABASE SEARCHED & TIME PERIOD COVERED:

GreenFILE - ~1970's- 3/2/2015

SEARCH STRATEGY:

"multiple sclerosis"

SEARCH METHODOLOGY KQ2

DATABASE SEARCHED & TIME PERIOD COVERED:

PubMed – Earliest-3/16/2015

LANGUAGE:

English

SEARCH STRATEGY:

multiple sclerosis

AND

United States Department of Veterans Affairs[mh] OR Veterans Health[mh] OR Hospitals, Veterans[mh] OR Veterans Disability Claims[mh] OR Veterans[mh] OR military personnel[mh] OR military medicine[mh] OR veteran* or military or army or navy or naval or air force or marines or coast guard or

national guard or soldier* or guardsmen or reservist* or troops or infantry* or armed forces or armed service* or war or wars or war-related or combat* or battle* or service-member*

DATABASE SEARCHED & TIME PERIOD COVERED:

Embase – Earliest-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

'multiple sclerosis'

AND

military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members' OR 'veteran'/exp OR 'veteran' OR veteran*:ti OR 'veterans health'/de OR 'veterans health'

DATABASE SEARCHED & TIME PERIOD COVERED:

Web of Science Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH– 1/1/1980-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

TOPIC: ("multiple sclerosis")

AND

TOPIC: (veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members')

DATABASE SEARCHED & TIME PERIOD COVERED:

SCOPUS– Earliest-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

TITLE-ABS-KEY("multiple sclerosis")

AND

ALL(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle OR 'service member' OR 'service members')

DATABASE SEARCHED & TIME PERIOD COVERED:

AMED– Earliest-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

ti("multiple sclerosis") OR su("multiple sclerosis")

AND

ab(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR

'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members') OR ti(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members') OR su(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members')

DATABASE SEARCHED & TIME PERIOD COVERED:

GreenFILE– Earliest-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

multiple sclerosis

NUMBER OF RESULTS: 49

DATABASE SEARCHED & TIME PERIOD COVERED:

Proquest Military Collection – Earliest-3/23/2015

LANGUAGE:

English

SEARCH STRATEGY:

(ti("multiple sclerosis") OR ab("multiple sclerosis") OR su("multiple sclerosis"))

AND

(ab(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members') OR ti(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members') OR su(veteran* OR military OR army OR navy OR naval OR 'air force' OR marines OR 'coast guard' OR 'national guard' OR soldier* OR guardsmen OR reservist* OR troops OR infantry* OR 'armed forces' OR 'armed services' OR war OR wars OR 'war related' OR combat* OR battle* OR 'service member' OR 'service members'))

DATABASE SEARCHED & TIME PERIOD COVERED:

DTIC Technical Reports Collections – Earliest-3/17/2015

SEARCH STRATEGY:

exact phrase: Multiple sclerosis

AND

Veterans

SEARCH METHODOLOGY KQ3

This section documents the exact search strings used to identify studies relevant for KQ3.

DATABASE SEARCHED & TIME PERIOD COVERED:

PubMed – Earliest-1/13/2015

FILTERS:

English, Randomized Controlled Trial

SEARCH STRATEGY:

“multiple sclerosis”

DATABASE SEARCHED & TIME PERIOD COVERED:

AMED – Earliest-3/3/2015

SEARCH STRATEGY:

"multiple sclerosis" AND interven* AND (random* OR rct*)

DATABASE SEARCHED & TIME PERIOD COVERED:

Web of Science – Earliest-3/3/2015

SEARCH STRATEGY:

TS = (multiple sclerosis)

AND

TS = (geographic OR sun OR sunlight OR vitamin D OR fatty acid OR diet OR dietary OR nutrition* OR obesity OR obese OR smoking OR tobacco OR alcohol OR exercise OR physical activity OR stress* OR anesthesia OR radiation therapy OR oral contracepti* OR fertility treatment OR pregnan* OR breastfeed* OR salt OR milk OR water OR trace elements OR trauma OR traumatic OR Epstein–Barr OR "Epstein barr"))

AND

ts = (intervention* OR intervene*)

AND

LANGUAGE: (English)

APPENDIX B. STUDY SELECTION AND LIST OF EXCLUDED STUDIES

The search yield, title and abstract screening results; full text decisions, and the data extraction are documented in electronic databases which can be obtained from the authors, in compliance with standard data sharing requirements.

This appendix lists the citation of publications obtained as full text but not meeting inclusion criteria together with the reason for excluding the publication.

EXCLUDE: OUTCOME

Excluded publications not reporting on MS progression:

1. Acheson ED, Bachrach CA. The distribution of multiple sclerosis in U. S. veterans by birthplace. *American Journal of Hygiene*. Jul 1960;72:88-99.
2. Ackerman KD, Stover A, Heyman R, et al. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. *Brain Behav. Immun*. Jun 2003;17(3):141-151.
3. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Oct 2001;7(5):340-344.
4. Ayatollahi P, Nafissi S, Eshraghian MR, Kaviani H, Tarazi A. Impact of depression and disability on quality of life in Iranian patients with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2007;13(2):275-277.
5. Bansi J, Bloch W, Gamper U, Kesselring J. Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2013;19(5):613-621.
6. Barth SK, Kang HK, Bullman TA, Wallin MT. Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. *American Journal of Industrial Medicine*. Sep 2009;52(9):663-670.
7. Basak T, Unver V, Demirkaya S. Activities of Daily Living and Self-Care Agency in Patients with Multiple Sclerosis for the First 10 Years. *Rehabilitation Nursing: The Official Journal of the Association of Rehabilitation Nurses*. Mar 25 2014.
8. Baumstarck K, Pelletier J, Boucekine M, Auquier P. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study. *Rev Neurol (Paris)*. Feb 2015;171(2):173-180.
9. Bayraktar D, Guclu-Gunduz A, Yazici G, et al. Effects of Ai-Chi on balance, functional mobility, strength and fatigue in patients with multiple sclerosis: a pilot study. *NeuroRehabilitation*. 2013;33(3):431-437.
10. Bee YS, Lin MC, Wang CC, Sheu SJ. Optic neuritis: clinical analysis of 27 cases. *The Kaohsiung Journal of Medical Sciences*. Mar 2003;19(3):105-112.
11. Beebe GW, Kurtzke JF. Herpes zoster and multiple sclerosis. *British Medical Journal*. Nov 1 1969;4(5678):303.
12. Beebe GW, Kurtzke JF, Kurland LT, Auth TL, Nagler B. Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the army experience in World War II. *Neurology*. Jan 1967;17(1):1-17.
13. Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2008;14(2):231-236.
14. Beier M, D'Orio V, Spat J, Shuman M, Foley FW. Alcohol and substance use in multiple sclerosis. *Journal of the Neurological Sciences*. Mar 15 2014;338(1-2):122-127.
15. Bobowick AR, Kurtzke JF, Brody JA, Hrubec Z, Gillespie M. Twin study of multiple sclerosis: an epidemiologic inquiry. *Neurology*. Oct 1978;28(10):978-987.
16. Bombardier CH, Cunniffe M, Wadhvani R, Gibbons LE, Blake KD, Kraft GH. The efficacy of telephone counseling for health promotion in people with multiple sclerosis: a randomized controlled trial. *Archives of Physical Medicine and Rehabilitation*. Oct 2008;89(10):1849-1856.
17. Bombardier CH, Ehde DM, Gibbons LE, et al. Telephone-based physical activity counseling for major

- depression in people with multiple sclerosis. *Journal of Consulting and Clinical Psychology*. Feb 2013;81(1):89-99.
18. Briken S, Gold SM, Patra S, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2014;20(3):382-390.
 19. Broekmans T, Roelants M, Alders G, Feys P, Thijs H, Eijnde BO. Exploring the effects of a 20-week whole-body vibration training programme on leg muscle performance and function in persons with multiple sclerosis. *J Rehabil Med*. Oct 2010;42(9):866-872.
 20. Broekmans T, Roelants M, Feys P, et al. Effects of long-term resistance training and simultaneous electro-stimulation on muscle strength and functional mobility in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2011;17(4):468-477.
 21. Brown JS, Jr. Correlation of mollicutes and their viruses with multiple sclerosis and other demyelinating diseases. *Medical Hypotheses*. Feb 2003;60(2):298-303.
 22. Buljevac D, Hop WC, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. *BMJ*. Sep 20 2003;327(7416):646.
 23. Burschka JM, Keune PM, Oy UH, Oschmann P, Kuhn P. Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. *BMC Neurol*. 2014;14:165.
 24. Cakt BD, Nacir B, Genc H, et al. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. *American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists*. Jun 2010;89(6):446-457.
 25. Carter A, Daley A, Humphreys L, et al. Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jan 13 2014;20(8):1112-1122.
 26. Carvalho AT, Veiga A, Morgado J, et al. Multiple sclerosis and motherhood choice: an observational study in Portuguese women patients. *Revista de Neurologia*. Dec 16 2014;59(12):537-542.
 27. Castro-Sanchez AM, Mataran-Penarrocha GA, Lara-Palomo I, Saavedra-Hernandez M, Arroyo-Morales M, Moreno-Lorenzo C. Hydrotherapy for the treatment of pain in people with multiple sclerosis: a randomized controlled trial. *Evidence-based Complementary and Alternative Medicine: eCAM*. 2012;2012:473963.
 28. Cattaneo D, Jonsdottir J, Zocchi M, Regola A. Effects of balance exercises on people with multiple sclerosis: a pilot study. *Clin Rehabil*. Sep 2007;21(9):771-781.
 29. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet*. Jun 28 2014;383(9936):2213-2221.
 30. Chruzander C, Johansson S, Gottberg K, et al. A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: changes in disability and the value of different factors in predicting disability and mortality. *Journal of the Neurological Sciences*. Sep 15 2013;332(1-2):121-127.
 31. Cioncoloni D, Innocenti I, Bartalini S, et al. Individual factors enhance poor health-related quality of life outcome in multiple sclerosis patients. Significance of predictive determinants. *Journal of the Neurological Sciences*. Oct 15 2014;345(1-2):213-219.
 32. Claerhout M, Gebara B, Ilsbrouckx S, et al. Effects of 3 weeks' whole body vibration training on muscle strength and functional mobility in hospitalized persons with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2012;18(4):498-505.
 33. Collett J, Dawes H, Meaney A, et al. Exercise for multiple sclerosis: a single-blind randomized trial comparing three exercise intensities. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. May 2011;17(5):594-603.
 34. Coote S, Hughes L, Rainsford G, Minogue C, Donnelly A. Pilot randomized trial of progressive resistance exercise augmented by neuromuscular electrical stimulation for people with multiple sclerosis who use walking AIDS. *Archives of Physical Medicine and Rehabilitation*. Feb 2015;96(2):197-204.
 35. Dalgas U, Stenager E, Jakobsen J, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2010;16(4):480-490.
 36. Dettmers C, Sulzmann M, Ruchay-Plossl A, Gutler R, Vieten M. Endurance exercise improves walking distance in MS patients with fatigue. *Acta Neurologica Scandinavica*. Oct 2009;120(4):251-257.
 37. D'Hooghe M B, Feys P, Deltour S, et al. Impact of a 5-day expedition to machu picchu on persons with multiple sclerosis. *Multiple Sclerosis International*. 2014;2014:761210.
 38. Dlugonski D, Motl RW, Mohr DC, Sandroff BM. Internet-delivered behavioral intervention to increase

- physical activity in persons with multiple sclerosis: sustainability and secondary outcomes. *Psychology, Health & Medicine*. 2012;17(6):636-651.
39. Dodd KJ, Taylor NF, Shields N, Prasad D, McDonald E, Gillon A. Progressive resistance training did not improve walking but can improve muscle performance, quality of life and fatigue in adults with multiple sclerosis: a randomized controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Nov 2011;17(11):1362-1374.
 40. Eftekhari E, Mostahfezian M, Etemadifar M, Zafari A. Resistance training and vibration improve muscle strength and functional capacity in female patients with multiple sclerosis. *Asian Journal of Sports Medicine*. Dec 2012;3(4):279-284.
 41. Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. *Clin Rehabil*. Sep 2006;20(9):783-792.
 42. Fernandez-Jimenez E, Arnett PA. Impact of neurological impairment, depression, cognitive function and coping on quality of life of people with multiple sclerosis: A relative importance analysis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Dec 22 2014.
 43. Fryze W, Mirowska-Guzel D, Wiszniewska M, Darda-Ledzion L, Czlonkowska A, Czlonkowska A. Alternative methods of treatment used by multiple sclerosis patients in Poland. *Neurologia i Neurochirurgia Polska*. 2006;40(5):386-390.
 44. Garrett M, Hogan N, Larkin A, Saunders J, Jakeman P, Coote S. Exercise in the community for people with multiple sclerosis - a follow-up of people with minimal gait impairment. *Mult. Scler. J*. May 2013;19(6):790-798.
 45. Glad SB, Aarseth JH, Nyland H, Riise T, Myhr KM. Benign multiple sclerosis: a need for a consensus. *Acta Neurologica Scandinavica. Supplementum*. 2010(190):44-50.
 46. Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. *Annals of Neurology*. Aug 2008;64(2):143-148.
 47. Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. *Brain Behav Immun*. Aug 2013;32:180-185.
 48. Harrison T, Stuijbergen A, Adachi E, Becker H. Marriage, impairment, and acceptance in persons with multiple sclerosis. *Western Journal of Nursing Research*. Apr 2004;26(3):266-285; discussion 286-292.
 49. Hart S, Fonareva I, Merluzzi N, Mohr DC. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*. Apr 2005;14(3):695-703.
 50. Hayes HA, Gappmaier E, LaStayo PC. Effects of high-intensity resistance training on strength, mobility, balance, and fatigue in individuals with multiple sclerosis: a randomized controlled trial. *Journal of Neurologic Physical Therapy: JNPT*. Mar 2011;35(1):2-10.
 51. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord*. Sep 2012;5(5):247-253.
 52. Helmick CG, Wrigley JM, Zack MM, et al. Multiple sclerosis in Key West, Florida. *American Journal of Epidemiology*. Nov 1989;130(5):935-949.
 53. Hilgers C, Mundermann A, Riehle H, Dettmers C. Effects of whole-body vibration training on physical function in patients with multiple sclerosis. *NeuroRehabilitation*. 2013;32(3):655-663.
 54. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. *Maturitas*. May 20 2006;54(2):149-153.
 55. Jones F, Fletcher B. Occupational factors in multiple sclerosis: An analysis of occupational mortality statistics for men and married women in Great Britain. *Neuroepidemiology*. Jul-Aug 1996;15(4):222-228.
 56. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. *Journal of Neurology*. Sep 2008;255(9):1354-1360.
 57. Khalili M, Eghtesadi S, Mirshafiey A, et al. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial. *Nutritional Neuroscience*. Jan 2014;17(1):16-20.
 58. Khurana SR, Bamer AM, Turner AP, et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. *American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists*. Feb 2009;88(2):83-91.
 59. Klaren RE, Hubbard EA, Motl RW. Efficacy of a Behavioral Intervention for Reducing Sedentary Behavior in Persons with Multiple Sclerosis A Pilot Examination. *Am. J. Prev. Med*. Nov 2014;47(5):613-616.
 60. Klaren RE, Motl RW, Dlugonski D, Sandroff BM, Pilutti LA. Objectively quantified physical activity in



- persons with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Dec 2013;94(12):2342-2348.
61. Klefbeck B, Hamrah Nedjad J. Effect of inspiratory muscle training in patients with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Jul 2003;84(7):994-999.
 62. Koch M, Uyttenboogaart M, van Harten A, De Keyser J. Factors associated with the risk of secondary progression in multiple sclerosis. *Mult. Scler. J*. Jul 2008;14(6):799-803.
 63. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study - 9: Observations on the progressive phase of the disease. *Brain: A Journal of Neurology*. Mar 2006;129:584-594.
 64. Krokavcova M, van Dijk JP, Nagyova I, et al. Social support as a predictor of perceived health status in patients with multiple sclerosis. *Patient Education and Counseling*. Oct 2008;73(1):159-165.
 65. Kurtzke JF. Some epidemiologic features compatible with an infectious origin for multiple sclerosis. *International Archives of Allergy and Applied Immunology*. 1969;36:Suppl:59-82.
 66. Kurtzke JF. MS epidemiology world wide. One view of current status. *Acta Neurologica Scandinavica. Supplementum*. 1995;161:23-33.
 67. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. *Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. Dec 2000;21(6):383-403.
 68. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on natural history of multiple sclerosis. 4. Clinical features of the onset bout. *Acta Neurologica Scandinavica*. 1968;44(4):467-494.
 69. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. *Neurology*. Sep 1979;29(9 Pt 1):1228-1235.
 70. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. *Neurology*. May 1985;35(5):672-678.
 71. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. *Neurology*. Jan 1997;48(1):204-213.
 72. Kurtzke JF, Page WF, Murphy FM, Norman JE, Jr. Epidemiology of multiple sclerosis in US veterans. 4. Age at onset. *Neuroepidemiology*. 1992;11(4-6):226-235.
 73. Langer-Gould A, Huang S, Van Den Eeden SK, et al. Vitamin D, Pregnancy, Breastfeeding, and Postpartum Multiple Sclerosis Relapses. *Archives of Neurology*. Mar 2011;68(3):310-313.
 74. Lauer K. The risk of multiple sclerosis in the U.S.A. in relation to sociogeographic features: a factor-analytic study. *Journal of Clinical Epidemiology*. Jan 1994;47(1):43-48.
 75. Lavela SL, Prohaska TR, Furner S, Weaver FM. Chronic diseases in male veterans with multiple sclerosis. *Preventing Chronic Disease*. 2012;9:E55.
 76. Learmonth YC, Paul L, Miller L, Mattison P, McFadyen AK. The effects of a 12-week leisure centre-based, group exercise intervention for people moderately affected with multiple sclerosis: a randomized controlled pilot study. *Clin Rehabil*. Jul 2012;26(7):579-593.
 77. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: What is being used in South Australia and why? *Complementary Therapies in Medicine*. Aug 2009;17(4):216-223.
 78. Lotfi J, Sahraian MA, Khorramnia S, Ebrahim MM. Effects of pregnancy on the disease course in Iranian multiple sclerosis patients. *Multiple Sclerosis*. Sep 2008;14:S143-S144.
 79. Lozano-Quilis JA, Gil-Gomez H, Gil-Gomez JA, et al. Virtual Rehabilitation for Multiple Sclerosis Using a Kinect-Based System: Randomized Controlled Trial. *J. Med. Internet Res*. Nov 2014;16(11).
 80. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. *Neurology*. Feb 8 2011;76(6):540-548.
 81. Mackereth PA, Booth K, Hillier VF, Caress AL. Reflexology and progressive muscle relaxation training for people with multiple sclerosis: a crossover trial. *Complementary Therapies in Clinical Practice*. Feb 2009;15(1):14-21.
 82. Marandi SM, Nejad VS, Shanazari Z, Zolaktaf V. A comparison of 12 weeks of pilates and aquatic training on the dynamic balance of women with multiple sclerosis. *International Journal of Preventive Medicine*. Apr 2013;4(Suppl 1):S110-117.
 83. Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. *Acta Neurologica Scandinavica*. Aug 2011;124(2):135-141.
 84. McAuley E, Motl RW, Morris KS, et al. Enhancing physical activity adherence and well-being in multiple sclerosis: a randomised controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jun

- 2007;13(5):652-659.
85. McCullagh R, Fitzgerald AP, Murphy RP, Cooke G. Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. *Clin Rehabil*. Mar 2008;22(3):206-214.
 86. McDowell TY, Amr S, Culpepper WJ, et al. Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. *Neuroepidemiology*. 2011;36(1):39-45.
 87. McDowell TY, Amr S, Langenberg P, et al. Time of birth, residential solar radiation and age at onset of multiple sclerosis. *Neuroepidemiology*. 2010;34(4):238-244.
 88. Medina-Perez C, de Souza-Teixeira F, Fernandez-Gonzalo R, de Paz-Fernandez JA. Effects of a resistance training program and subsequent detraining on muscle strength and muscle power in multiple sclerosis patients. *NeuroRehabilitation*. 2014;34(3):523-530.
 89. Mills N, Allen J. Mindfulness of movement as a coping strategy in multiple sclerosis. A pilot study. *Gen Hosp Psychiatry*. Nov-Dec 2000;22(6):425-431.
 90. Mod RW, Snook EM, McAuley E, Scott JA, Gliottoni RC. Are physical activity and symptoms correlates of functional limitations and disability in multiple sclerosis? *Rehabilitation Psychology*. Nov 2007;52(4):463-469.
 91. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. *Archives of Neurology*. Jul 2001;58(7):1081-1086.
 92. Morrison W, Nelson J. Environmental triggers in multiple sclerosis. Fact or fallacy? *Axone*. Sep 1994;16(1):23-26.
 93. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2002;8(2):161-168.
 94. Motl RW, Dlugonski D, Wojcicki TR, McAuley E, Mohr DC. Internet intervention for increasing physical activity in persons with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jan 2011;17(1):116-128.
 95. Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Aug 2005;11(4):459-463.
 96. Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T. Clinical Importance of Steps Taken per Day among Persons with Multiple Sclerosis. *PLoS One*. Sep 2013;8(9).
 97. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. *Neurology*. Nov 10 2009;73(19):1543-1550.
 98. Negahban H, Rezaie S, Goharpey S. Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study. *Clin Rehabil*. Dec 2013;27(12):1126-1136.
 99. Nelson RE, Xie Y, Kamauu A, Schuerch M, Foskett N, Lafleur J. Multiple sclerosis increases the risk of infections resulting in a hospitalization among veterans. *Value in Health*. May 2013;16(3):A79-A80.
 100. Neuteboom RF, Janssens AC, Siepman TA, et al. Pregnancy in multiple sclerosis: clinical and self-report scales. *Journal of Neurology*. Feb 2012;259(2):311-317.
 101. Nilsagard YE, Forsberg AS, von Koch L. Balance exercise for persons with multiple sclerosis using Wii games: a randomised, controlled multi-centre study. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Feb 2013;19(2):209-216.
 102. Nisipeanu P, Korczyn AD. Psychological stress as risk factor for exacerbations in multiple sclerosis. *Neurology*. Jul 1993;43(7):1311-1312.
 103. Norman JE, Jr., Cook SD, Dowling PC. Household pets among veterans with multiple sclerosis and age-matched controls. Pilot survey. *Archives of Neurology*. Apr 1983;40(4):213-214.
 104. Norman JE, Jr., Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. *Journal of Chronic Diseases*. 1983;36(8):551-559.
 105. O'Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan M. Patterns of dietary and herbal supplement use by multiple sclerosis patients. *Journal of Neurology*. Apr 2012;259(4):637-644.
 106. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. *Neurology*. Jun 8 2004;62(11):2058-2064.
 107. Page WF, Kurtzke JF, Murphy FM, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. *Annals of Neurology*. Jun 1993;33(6):632-639.
 108. Page WF, Mack TM, Kurtzke JF, Murphy FM, Norman JE, Jr. Epidemiology of multiple sclerosis in US veterans. 6. Population ancestry and surname ethnicity as risk factors for multiple sclerosis.



- Neuroepidemiology*. 1995;14(6):286-296.
109. Pilutti LA, Dlugonski D, Sandroff BM, Klaren R, Motl RW. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2014;20(5):594-601.
110. Pilutti LA, Dlugonski D, Sandroff BM, Klaren RE, Motl RW. Internet-delivered lifestyle physical activity intervention improves body composition in multiple sclerosis: preliminary evidence from a randomized controlled trial. *Archives of Physical Medicine and Rehabilitation*. Jul 2014;95(7):1283-1288.
111. Plow M, Bethoux F, Mai K, Marcus B. A formative evaluation of customized pamphlets to promote physical activity and symptom self-management in women with multiple sclerosis. *Health Educ. Res.* Oct 2014;29(5):883-896.
112. Plow M, Bethoux F, McDaniel C, McGlynn M, Marcus B. Randomized controlled pilot study of customized pamphlets to promote physical activity and symptom self-management in women with multiple sclerosis. *Clin Rehabil.* Feb 2014;28(2):139-148.
113. Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. *Neurology*. Jul 12 2011;77(2):145-150.
114. Purdey M. Chronic barium intoxication disrupts sulphated proteoglycan synthesis: a hypothesis for the origins of multiple sclerosis. *Medical Hypotheses*. 2004;62(5):746-754.
115. Ross RT, Cheang M. Geographic similarities between varicella and multiple sclerosis: an hypothesis on the environmental factor of multiple sclerosis. *Journal of Clinical Epidemiology*. Jun 1995;48(6):731-737.
116. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. *Archives of Neurology*. Nov 2010;67(11):1329-1335.
117. Ruiz J, Labas MP, Triche EW, Lo AC. Combination of robot-assisted and conventional body-weight-supported treadmill training improves gait in persons with multiple sclerosis: a pilot study. *Journal of neurologic physical therapy: JNPT*. Dec 2013;37(4):187-193.
118. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. *Neurology*. Jul 17 2012;79(3):261-266.
119. Sabapathy NM, Minahan CL, Turner GT, Broadley SA. Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study. *Clin Rehabil.* Jan 2011;25(1):14-24.
120. Sadovnick AD, Eisen K, Hashimoto SA, et al. Pregnancy and multiple sclerosis. A prospective study. *Archives of Neurology*. Nov 1994;51(11):1120-1124.
121. Sandroff BM, Klaren RE, Pilutti LA, Dlugonski D, Benedict RH, Motl RW. Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis. *Journal of Neurology*. Feb 2014;261(2):363-372.
122. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. *Lancet*. Jun 8 1985;1(8441):1313-1315.
123. Somer E, Golan D, Dishon S, Cuzin-Disegni L, Lavi I, Miller A. Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2010;16(4):463-471.
124. Sosnoff JJ, Finlayson M, McAuley E, Morrison S, Motl RW. Home-based exercise program and fall-risk reduction in older adults with multiple sclerosis: phase 1 randomized controlled trial. *Clin Rehabil.* Mar 2014;28(3):254-263.
125. Stoll SS, Nieves C, Tabby DS, Schwartzman R. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study. *The Journal of the American Osteopathic Association*. Jan 2012;112(1):22-28.
126. Straudi S, Benedetti MG, Venturini E, Manca M, Foti C, Basaglia N. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial. *NeuroRehabilitation*. 2013;33(4):555-563.
127. Stuijbergen AK, Roberts GJ. Health promotion practices of women with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Dec 1997;78(12 Suppl 5):S3-9.
128. Surakka J, Romberg A, Ruutiainen J, et al. Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial. *Clin Rehabil.* Nov 2004;18(7):737-746.
129. Sutherland G, Andersen MB, Morris T. Relaxation and health-related quality of life in multiple sclerosis: the example of autogenic training. *Journal of Behavioral Medicine*. Jun 2005;28(3):249-256.
130. Sutherland G, Andersen MB, Stooove MA. Can aerobic exercise training affect health-related quality of life for people with multiple sclerosis? *J. Sport Exerc. Psychol.* Jun 2001;23(2):122-135.
131. Tarakci E, Yeldan I, Huseyinsinoglu BE, Zenginler Y, Eraksoy M. Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.



- Clin Rehabil.* Sep 2013;27(9):813-822.
132. Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. *Journal of Neurology.* Feb 26 2015.
 133. Tesar N, Bandion K, Baumhackl U. Efficacy of a neuropsychological training programme for patients with multiple sclerosis -- a randomised controlled trial. *Wiener Klinische Wochenschrift.* Nov 2005;117(21-22):747-754.
 134. Tinghog P, Bjorkenstam C, Carstensen J, et al. Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study. *BMC Neurol.* 2014;14:117.
 135. Tosh J, Dixon S, Carter A, et al. Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial. *Mult. Scler. J.* Jul 2014;20(8):1123-1130.
 136. Turner AP, Hartoonian N, Maynard C, Leipertz SL, Haselkorn JK. Examining Health Behaviors and 15 year Mortality among Individuals with Multiple Sclerosis. *Archives of Physical Medicine and Rehabilitation.* Nov 6 2014.
 137. Turner AP, Hartoonian N, Maynard C, Leipertz SL, Haselkorn JK. Smoking and physical activity: examining health behaviors and 15-year mortality among individuals with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation.* Mar 2015;96(3):402-409.
 138. Turner AP, Hawkins EJ, Haselkorn JK, Kivlahan DR. Alcohol misuse and multiple sclerosis. *Archives of Physical Medicine and Rehabilitation.* May 2009;90(5):842-848.
 139. Turner AP, Kivlahan DR, Haselkorn JK. Exercise and quality of life among people with multiple sclerosis: looking beyond physical functioning to mental health and participation in life. *Archives of Physical Medicine and Rehabilitation.* Mar 2009;90(3):420-428.
 140. Turner AP, Kivlahan DR, Kazis LE, Haselkorn JK. Smoking among veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need for services. *Archives of Physical Medicine and Rehabilitation.* Nov 2007;88(11):1394-1399.
 141. Turner AP, Williams RM, Bowen JD, Kivlahan DR, Haselkorn JK. Suicidal ideation in multiple sclerosis. *Archives of Physical Medicine and Rehabilitation.* Aug 2006;87(8):1073-1078.
 142. Tyler ME, Kaczmarek KA, Rust KL, Subbotin AM, Skinner KL, Danilov YP. Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial. *J Neuroeng Rehabil.* 2014;11:79.
 143. van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. *Journal of Neurology, Neurosurgery, and Psychiatry.* Apr 2006;77(4):531-533.
 144. van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. *BMJ.* Aug 9 2003;327(7410):316.
 145. Vaney C, Gattlen B, Lugon-Moulin V, et al. Robotic-assisted step training (lokomat) not superior to equal intensity of over-ground rehabilitation in patients with multiple sclerosis. *Neurorehabil Neural Repair.* Mar-Apr 2012;26(3):212-221.
 146. Velikonja O, Curic K, Ozura A, Jazbec SS. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. *Clinical Neurology and Neurosurgery.* Sep 2010;112(7):597-601.
 147. Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. *Brain: A Journal of Neurology.* Jun 2012;135(Pt 6):1778-1785.
 148. Wallin MT, Kurtzke JF, Culpepper WJ, et al. Multiple sclerosis in gulf war era veterans. 2. Military deployment and risk of multiple sclerosis in the first gulf war. *Neuroepidemiology.* 2014;42(4):226-234.
 149. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. *Brain: A Journal of Neurology.* Aug 2000;123 (Pt 8):1677-1687.
 150. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. *Annals of Neurology.* Jan 2004;55(1):65-71.
 151. Wallin MT, Page WF, Kurtzke JF. Migration and multiple sclerosis in Alaskan military veterans. *Journal of Neurology.* Sep 2009;256(9):1413-1417.
 152. Wang L, Li L, Zhang J, Baser O. Comorbidities and economic burden of multiple sclerosis patients in the united states veteran population. *Value in Health.* May 2013;16(3):A101.
 153. Weikert M, Motl RW, Mohr DC. Associations among physical activity, stress, disability, and relapse occurrence in multiple sclerosis. *Mult. Scler. J.* Aug 2010;16(8):1020-1020.
 154. Weiland TJ, Jelinek GA, Marck CH, et al. Clinically Significant Fatigue: Prevalence and Associated Factors in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet. *PLoS One.*



- 2015;10(2):e0115541.
155. Widener GL, Allen DD, Gibson-Horn C. Randomized clinical trial of balance-based torso weighting for improving upright mobility in people with multiple sclerosis. *Neurorehabil Neural Repair*. Oct 2009;23(8):784-791.
 156. Williams RM, Turner AP, Hatzakis M, Jr., Bowen JD, Rodriquez AA, Haselkorn JK. Prevalence and correlates of depression among veterans with multiple sclerosis. *Neurology*. Jan 11 2005;64(1):75-80.
 157. Yamout B, Itani S, Hourany R, Sibaii AM, Yaghi S. The effect of war stress on multiple sclerosis exacerbations and radiological disease activity. *Journal of the Neurological Sciences*. Jan 15 2010;288(1-2):42-44.
 158. Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. *Swiss Med Wkly*. 2011;141:w13192.
 159. Zeqiraj K, Kruja J, Kabashi S, Mucaj S. Epidemiological characteristics and functional disability of multiple sclerosis patients in Kosovo. *Medicinski Arhiv*. 2014;68(3):178-181.

EXCLUDE: INTERVENTION/EXPOSURE

Publications not reporting on a risk factor of interest:

1. Aisen ML, Sevilla D, Fox N. Inpatient rehabilitation for multiple sclerosis. *J. Neurol. Rehabil*. 1996;10(1):43-46.
2. Akhtar N, Elsetouhy A, Deleu D, et al. Newly diagnosed multiple sclerosis in state of Qatar. *Clinical Neurology and Neurosurgery*. Aug 2013;115(8):1333-1337.
3. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. *Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2000;21(4 Suppl 2):S831-838.
4. Artemiadis AK, Vervainioti AA, Alexopoulos EC, Rombos A, Anagnostouli MC, Darviri C. Stress management and multiple sclerosis: a randomized controlled trial. *Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists*. Jun 2012;27(4):406-416.
5. Ashtari F, Ajalli M, Shaygannejad V, Akbari M, Hovsepian S. The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis. *Journal of research in medical sciences: The Official Journal of Isfahan University of Medical Sciences*. Mar 2013;18(3):193-197.
6. Askari F, Ghajarzadeh M, Mohammadifar M, Azimi A, Sahraian MA, Owji M. Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. *Acta Medica Iranica*. 2014;52(12):889-892.
7. Baumhackl U, Kappos L, Radue EW, et al. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2005;11(2):166-168.
8. Baumstarck K, Pelletier J, Butzkueven H, et al. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. *European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies*. Jun 2013;20(6):907-914, e978-909.
9. Benito-Leon J, Mitchell AJ, Rivera-Navarro J, Morales-Gonzalez JM. Impaired health-related quality of life predicts progression of disability in multiple sclerosis. *European journal of neurology: the official journal of the European Federation of Neurological Societies*. Jan 2013;20(1):79-86.
10. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. *Journal of the Neurological Sciences*. Aug 15 2001;189(1-2):13-21.
11. Berg-Hansen P, Smestad C, Sandvik L, Harbo HF, Celius EG. Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway. *European Journal of Neurology*. Dec 2013;20(12):1546-1552.
12. Broadley SA, Vanags D, Williams B, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2009;15(3):329-336.
13. Calabrese M, Romualdi C, Poretto V, et al. The changing clinical course of multiple sclerosis: a matter of gray matter. *Annals of Neurology*. Jul 2013;74(1):76-83.
14. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med*. Nov 16 2000;343(20):1430-1438.
15. D'Alisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A. Depression is the main determinant of quality

- of life in multiple sclerosis: a classification-regression (CART) study. *Disability and Rehabilitation*. Mar 15 2006;28(5):307-314.
16. Damasceno A, Von Glehn F, Brandao CO, Damasceno BP, Cendes F. Prognostic indicators for long-term disability in multiple sclerosis patients. *Journal of the Neurological Sciences*. Jan 15 2013;324(1-2):29-33.
 17. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. *European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies*. Sep 2008;15(9):916-921.
 18. D'Hooghe M B, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. *Journal of Neurology, Neurosurgery, and Psychiatry*. Jan 2010;81(1):38-41.
 19. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. *Gen Hosp Psychiatry*. Jan-Feb 2008;30(1):40-48.
 20. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. *Brain: A Journal of Neurology*. Oct 2007;130(Pt 10):2577-2588.
 21. El-Salem K, Al-Shimmery E, Horany K, Al-Refai A, Al-Hayk K, Khader Y. Multiple sclerosis in Jordan: A clinical and epidemiological study. *Journal of Neurology*. Sep 2006;253(9):1210-1216.
 22. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jun 2003;9(3):260-274.
 23. Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jun 2005;11(3):286-295.
 24. Guarnaccia JB, Aslan M, O'Connor TZ, et al. Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability. *Journal of Rehabilitation Research and Development*. Jan-Feb 2006;43(1):35-44.
 25. Guerra E, di Cagno A, Mancini P, et al. Physical fitness assessment in multiple sclerosis patients: a controlled study. *Research in Developmental Disabilities*. Oct 2014;35(10):2527-2533.
 26. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Aug 2007;13(7):900-908.
 27. Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. May 2014;20(6):739-746.
 28. Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. *Journal of Neuroimmunology*. Jun 25 2009;211(1-2):124-130.
 29. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet*. Aug 4 2007;370(9585):389-397.
 30. Karp I, Manganas A, Sylvestre MP, Roger E, Ho A, Duquette P. The impact of pregnancy on progression of relapsing-remitting multiple sclerosis. *Mult. Scler. J*. Oct 2012;18:102-103.
 31. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. *American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists*. Aug 2003;82(8):582-590.
 32. Keyhanian K, Davoudi V, Etemadifar M, Amin M. Better prognosis of multiple sclerosis in patients who experienced a full-term pregnancy. *European Neurology*. 2012;68(3):150-155.
 33. Khaleeli Z, Ciccarelli O, Manfredonia F, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*. Jun 2008;63(6):790-793.
 34. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. *The American Journal of Clinical Nutrition*. Sep 2007;86(3):645-651.
 35. Koch M, Mostert J, Heerings M, Uyttenboogaart M, De Keyser J. Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study. *European Journal of Neurology*. Mar 2009;16(3):348-352.
 36. Koch M, Ramsaransing GS, Fokkema MR, Heersema DJ, De Keyser J. Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis. *Journal of the Neurological Sciences*. May 15 2006;244(1-2):123-126.
 37. Koch M, Uyttenboogaart M, Heerings M, Heersema D, Mostert J, De Keyser J. Progression in familial and nonfamilial MS. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2008;14(3):300-306.
 38. Koch M, Uyttenboogaart M, Heersema D, Steen C, De Keyser J. Parity and secondary progression in multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Jun 2009;80(6):676-678.
 39. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J. Fatigue, depression and progression in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jul 2008;14(6):815-822.



40. Koch MW, Patten S, Berzins S, et al. Depression in multiple sclerosis: A long-term longitudinal study. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jan 2015;21(1):76-82.
41. Kochs L, Wegener S, Suhnel A, Voigt K, Zettl UK. The use of complementary and alternative medicine in patients with multiple sclerosis: a longitudinal study. *Complementary Therapies in Medicine*. Feb 2014;22(1):166-172.
42. Kurtzke JF, Auth TL, Beebe GW, Kurland LT, Nagler B, Nefzger MD. Survival in multiple sclerosis. *Transactions of the American Neurological Association*. 1969;94:134-139.
43. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. *Archives of Neurology*. Mar 1970;22(3):215-225.
44. Lambert CP, Lee Archer R, Evans WJ. Body composition in ambulatory women with multiple sclerosis. *Archives of Physical Medicine and Rehabilitation*. Nov 2002;83(11):1559-1561.
45. Lincoln NB, Yuill F, Holmes J, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Oct 2011;17(10):1250-1257.
46. Locke S, Kruper DC, Yakovlev PI. FIVE-YEAR FOLLOW-UP ON MULTIPLE SCLEROSIS. REPORT ON VETERANS ADMINISTRATION COOPERATIVE STUDY. *Archives of Neurology*. Dec 1964;11:583-592.
47. Lucas RM, Hughes AM, Lay ML, et al. Epstein-Barr virus and multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Oct 2011;82(10):1142-1148.
48. Mandel M, Gauthier SA, Guttmann CRG, Weiner HL, Betensky RA. Estimating time to event from longitudinal categorical data: An analysis of multiple sclerosis progression. *J. Am. Stat. Assoc.* Dec 2007;102(480):1254-1266.
49. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. *Neurology*. Jan 13 2009;72(2):117-124.
50. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. *Neurology*. Mar 2010;74(13):1041-1047.
51. Maser S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Dec 22 2014.
52. Maser S, Prosperini L, Petsas N, et al. Multiple sclerosis and pregnancy: relationship with progression of disability. *Multiple Sclerosis*. Sep 2008;14:S192-S192.
53. Mastorodemos V, Nikolakaki H, Tzagournissakis M, et al. Benign multiple sclerosis in Crete. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jun 2010;16(6):701-706.
54. Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis. *Journal of Managed Care Pharmacy*. Jan-Feb 2013;19(1):S24-S40.
55. Milanlioglu A, Ozdemir PG, Cilingir V, Gulec TC, Aydin MN, Tombul T. Coping strategies and mood profiles in patients with multiple sclerosis. *Arq Neuropsiquiatr*. Jul 2014;72(7):490-495.
56. Mitsonis CI, Zervas IM, Potagas CM, et al. Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. *European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology*. Feb 2010;20(2):123-131.
57. Moghaddasi M, Mamarabadi M, Mohebi N, Razjouyan H, Aghaei M. Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: A case control study. *Clinical Neurology and Neurosurgery*. 2013;115(9):1802-1805.
58. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. *Journal of Consulting and Clinical Psychology*. Dec 2001;69(6):942-949.
59. Mohr DC, Hart S, Vella L. Reduction in disability in a randomized controlled trial of telephone-administered cognitive-behavioral therapy. *Health psychology: official journal of the Division of Health Psychology, American Psychological Association*. Sep 2007;26(5):554-563.
60. Mutluay FK, Demir R, Ozyilmaz S, Caglar AT, Altintas A, Gurses HN. Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. *Clin Rehabil*. Jul 2007;21(7):595-602.
61. Nelson RE, Xie Y, Du Vall SL, et al. Multiple sclerosis subtypes and infections resulting in a hospitalization in the veterans health administration. *Pharmacoepidemiology and Drug Safety*. October 2013;22 SUPPL. 1:406.
62. Patti F, Ciancio MR, Cacopardo M, et al. Effects of a short outpatient rehabilitation treatment on disability

- of multiple sclerosis patients--a randomised controlled trial. *Journal of Neurology*. Jul 2003;250(7):861-866.
63. Patti F, Ciancio MR, Reggio E, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. *Journal of Neurology*. Aug 2002;249(8):1027-1033.
 64. Pilutti LA. Adapted exercise interventions for persons with progressive multiple sclerosis. *Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition et Metabolisme*. Mar 2013;38(3):357.
 65. Pilutti LA, Lelli DA, Paulseth JE, et al. Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. *Archives of Physical Medicine and Rehabilitation*. Jan 2011;92(1):31-36.
 66. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. *Neurology*. Jan 13 2004;62(1):51-59.
 67. Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Nov 2007;13(9):1107-1117.
 68. Ponichtera JA, Rodgers MM, Glaser RM, Mathews TA, Camaione DN. Concentric and eccentric isokinetic lower extremity strength in persons with multiple sclerosis. *The Journal of Orthopaedic and Sports Physical Therapy*. 1992;16(3):114-122.
 69. Pozzilli C, Palmisano L, Mainero C, et al. Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Aug 2004;10(4):442-446.
 70. Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. *Journal of Neurology, Neurosurgery, and Psychiatry*. Aug 2012;83(8):793-795.
 71. Riise T, Gronning M, Fernandez O, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. *Acta Neurologica Scandinavica*. Mar 1992;85(3):212-218.
 72. Rinker IJR, Cossey TC, Cutter GR, Culpepper WJ. A retrospective review of lithium usage in veterans with multiple sclerosis. *Multiple Sclerosis and Related Disorders*. October 2013;2(4):327-333.
 73. Romberg A, Virtanen A, Aunola S, Karppi SL, Karanko H, Ruutiainen J. Exercise capacity, disability and leisure physical activity of subjects with multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. Apr 2004;10(2):212-218.
 74. Rouillet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. *Journal of Neurology, Neurosurgery, and Psychiatry*. Oct 1993;56(10):1062-1065.
 75. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. *Brain: A Journal of Neurology*. Feb 1995;118 (Pt 1):253-261.
 76. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. *Journal of Neurology*. Oct 1994;241(10):597-604.
 77. Salhofer-Polanyi S, Windt J, Sumper H, et al. Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. *NeuroRehabilitation*. 2013;33(2):285-292.
 78. Samonds RJ, Cammermeyer M. Perceptions of body image in subjects with multiple sclerosis: a pilot study. *The Journal of Neuroscience Nursing: Journal of the American Association of Neuroscience Nurses*. Jun 1989;21(3):190-194.
 79. Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M. Relationship between Sleep Quality and Quality of Life in Patients with Multiple Sclerosis. *International Journal of Preventive Medicine*. Dec 2014;5(12):1582-1586.
 80. Schroeder B, Doig J, Premkumar K. The effects of massage therapy on multiple sclerosis patients' quality of life and leg function. *Evidence-based Complementary and Alternative Medicine: eCAM*. 2014;2014:640916.
 81. Schwartz CE, Foley FW, Rao SM, Bernardin LJ, Lee H, Genderson MW. Stress and course of disease in multiple sclerosis. *Behavioral Medicine (Washington, D.C.)*. Fall 1999;25(3):110-116.
 82. Sorgun MH, Yucesan C, Tegin C. Is malnutrition a problem for multiple sclerosis patients? *Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia*. Sep 2014;21(9):1603-1605.
 83. Stenager E, Stenager EN, Jensen K. Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation. *Acta Neurologica Scandinavica*. Nov 1994;90(5):305-308.
 84. Stroud N, Minahan C, Sabapathy S. The perceived benefits and barriers to exercise participation in persons

- with multiple sclerosis. *Disability and Rehabilitation*. 2009;31(26):2216-2222.
85. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. *Advances in Therapy*. Jan 2011;28(1):51-61.
 86. Tavee J, Rensel M, Planchon SM, Butler RS, Stone L. Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. *International Journal of MS Care*. Winter 2011;13(4):163-168.
 87. Terzi M, Kocamanoglu B, Guz H, Onar M. The Eating Attitudes in Multiple Sclerosis Patients. *J. Neurol. Sci.-Turk*. 2009;26(3):311-317.
 88. Teter B, Apatoff B, Coyle P, et al. Pregnancy Related to Disability Outcomes for Women with Progressive Multiple Sclerosis. *Neurology*. Mar 2011;76(9):A610-A610.
 89. Thompson DS, Nelson LM, Burns A, Burks JS, Franklin GM. The effects of pregnancy in multiple sclerosis: a retrospective study. *Neurology*. Aug 1986;36(8):1097-1099.
 90. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. *Neurology*. Dec 27 2005;65(12):1919-1923.
 91. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2008;14(3):314-324.
 92. Tremlett HL, Wiles CM, Luscombe DK. Nonprescription medicine use in a multiple sclerosis clinic population. *British Journal of Clinical Pharmacology*. Jul 2000;50(1):55-60.
 93. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. *Journal of Neurology, Neurosurgery, and Psychiatry*. Mar 1995;58(3):300-306.
 94. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. *Annals of Neurology*. Oct 2009;66(4):513-520.
 95. van der Linden ML, Bulley C, Geneen LJ, Hooper JE, Cowan P, Mercer TH. Pilates for people with multiple sclerosis who use a wheelchair: feasibility, efficacy and participant experiences. *Disability and Rehabilitation*. 2014;36(11):932-939.
 96. Verdru P, Theys P, D'Hooghe MB, Carton H. Pregnancy and multiple sclerosis: the influence on long term disability. *Clinical Neurology and Neurosurgery*. Feb 1994;96(1):38-41.
 97. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. *Neurology*. May 12 2009;72(19):1630-1633.
 98. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. *Journal of the Neurological Sciences*. Feb 15 2003;206(2):135-137.
 99. Wade DT, Young CA, Chaudhuri KR, Davidson DL. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Sep 2002;73(3):246-249.
 100. Weinshenker BG, Hader W, Carriere W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. *Neurology*. Nov 1989;39(11):1438-1440.
 101. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. *Brain: A Journal of Neurology*. Apr 1991;114 (Pt 2):1045-1056.
 102. Woessner R, Grauer MT, Frese A, et al. Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis. *Infection*. Dec 2006;34(6):342-344.
 103. Worthington J, Jones R, Crawford M, Forti A. Pregnancy and multiple sclerosis--a 3-year prospective study. *Journal of Neurology*. Feb 1994;241(4):228-233.
 104. Yamout B, Itani S, Arabi A, Hamzeh D, Yaghi S. Prognostic factors of multiple sclerosis in Lebanon. *The International Journal of Neuroscience*. Mar 2010;120(3):206-210.
 105. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. *The Lancet. Neurology*. Sep 2013;12(9):857-865.

EXCLUDE: DESIGN

Publications not meeting study design inclusion criteria:

1. Amezcua L, Chung RH, Conti DV, Langer-Gould AM. Vitamin D levels in Hispanics with multiple sclerosis. *Journal of Neurology*. Dec 2012;259(12):2565-2570.
2. Anens E, Emtner M, Zetterberg L, Hellstrom K. Physical activity in subjects with multiple sclerosis with focus on gender differences: a survey. *BMC Neurol*. 2014;14:47.
3. Bamford CR, Sibley WA, Laguna JF. Swine influenza vaccination in patients with multiple sclerosis. *Archives of Neurology*. Apr 1978;35(4):242-243.
4. Bhargava P, Cassard S, Steele SU, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. *Contemporary Clinical Trials*. Nov 2014;39(2):288-293.
5. Brichetto G, Rinaldi S, Spallarossa P, Battaglia MA, de Carvalho ML. Efficacy of physical therapy in multiple sclerosis as measured with the modified fatigue impact scale and ambulation index: a retrospective study. *NeuroRehabilitation*. 2013;33(1):107-112.
6. D'Hoghe MB, De Keyser J. Multiparity in women with multiple sclerosis causes less long-term disability: Yes. *Mult. Scler. J*. Oct 2014;20(11):1432-1434.
7. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. *American Journal of Epidemiology*. Oct 1 1995;142(7):733-737.
8. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev*. 2007(1):Cd004192.
9. Freedman DM, Dosemeci H, Alavanja MCR. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. *Occup. Environ. Med*. Jun 2000;57(6):418-421.
10. Goodin DS. The impact of war-stress on MS exacerbations. *Annals of neurology*. Aug 2008;64(2):114-115.
11. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. *Prog. Biophys. Mol. Biol*. Sep 2006;92(1):65-79.
12. Griffith G, Klaren RE, Motl RW, Baynard T, Fernhall B. Experimental protocol of a randomized controlled clinical trial investigating exercise, subclinical atherosclerosis, and walking mobility in persons with multiple sclerosis. *Contemporary Clinical Trials*. Feb 14 2015.
13. Heine M, Hoogervorst EL, Hacking HG, Verschuren O, Kwakkel G. Validity of maximal exercise testing in people with multiple sclerosis and low to moderate levels of disability. *Physical Therapy*. Aug 2014;94(8):1168-1175.
14. Holmoy T, Kampman MT. Alaska, multiple sclerosis, and the vitamin D hypothesis. *Journal of Neurology*. Feb 2010;257(2):305-306.
15. Kileff J, Ashburn A. A pilot study of the effect of aerobic exercise on people with moderate disability multiple sclerosis. *Clin Rehabil*. Mar 2005;19(2):165-169.
16. Kurtzke JF. Some contributions of the Department of Veterans Affairs to the epidemiology of multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Sep 2008;14(8):1007-1012.
17. Mason RR, Cochrane DJ, Denny GJ, Firth EC, Stannard SR. Is 8 weeks of side-alternating whole-body vibration a safe and acceptable modality to improve functional performance in multiple sclerosis? *Disability and Rehabilitation*. 2012;34(8):647-654.
18. McCombe PA, Callaway LK. Multiparity in women with multiple sclerosis causes less long-term disability: No. *Mult. Scler. J*. Oct 2014;20(11):1435-1436.
19. Munoz-Lasa S, Ferriero G, Valero R, Gomez-Muniz F, Rabini A, Varela E. Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis. *Giornale Italiano di Medicina del Lavoro ed Ergonomia*. Oct-Dec 2011;33(4):462-467.
20. Namaka M, Turcotte D, Leong C, Grossberndt A, Klassen D. Multiple sclerosis: Etiology and treatment strategies. *Consultant Pharmacist*. 2008;23(11):886-896.
21. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. *Acta Neurologica Scandinavica*. Sep 2000;102(3):143-149.
22. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. *Journal of Bone and Mineral Metabolism*. 2005;23(4):309-313.
23. Pariser G, Madras D, Weiss E. Outcomes of an aquatic exercise program including aerobic capacity, lactate threshold, and fatigue in two individuals with multiple sclerosis. *Journal of neurologic physical therapy*:

- JNPT*. Jun 2006;30(2):82-90.
24. Pimentel ML. Multiple sclerosis in the Southern and Northern hemispheres: the month of birth at different latitudes has the same influence on the prevalence and progression of the disease in the Northern and Southern hemispheres? *Arq Neuropsiquiatr*. Sep 2013;71(9A):569-570.
 25. Poser S, Wikstrom J, Bauer HJ. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. *Journal of the Neurological Sciences*. Feb 1979;40(2-3):159-168.
 26. Singh V, Hintzen RQ, Luiders TM, Stoop MP. Proteomics technologies for biomarker discovery in multiple sclerosis. *Journal of Neuroimmunology*. Jul 15 2012;248(1-2):40-47.
 27. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. *Journal of the Neurological Sciences*. Dec 15 2011;311(1-2):44-49.
 28. Torkildsen O, Grytten N, Aarseth J, Myhr KM, Kampman MT. Month of birth as a risk factor for multiple sclerosis: an update. *Acta Neurologica Scandinavica. Supplementum*. 2012(195):58-62.
 29. Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMs. *Clinical Neurology and Neurosurgery*. Mar 2006;108(3):266-270.
 30. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*. Sep 2005;76(9):1294-1296.
 31. Wojcicki TR, Roberts SA, Learmonth YC, et al. Improving physical functional and quality of life in older adults with multiple sclerosis via a DVD-delivered exercise intervention: a study protocol. *BMJ Open*. 2014;4(12):e006250.
 32. Yadav V, Bever C, Jr., Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*. Mar 25 2014;82(12):1083-1092.

EXCLUDE: PARTICIPANTS

Excluded publications not reporting on participants with MS and risk factor studies excluding progressive MS:

1. Harandi AA, Shahbeigi S, Pakdaman H, Fereshtehnejad SM, Nikravesh E, Jalilzadeh R. Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. *Iranian Journal of Neurology*. 2012;11(2):54-58.
2. Henderson VW. Alzheimer's disease and other neurological disorders. *Climacteric*. Oct 2007;10 Suppl 2:92-96.

EXCLUDE: LANGUAGE

Excluded non-English language publications:

1. Ragonese P, Castiglia G, Cusimano V, Battaglieri F, Salemi G. Cigarette smoking, coffee consumption and multiple sclerosis risk: A case - Control study. *Acta Medica Mediterranea*. 2007;23(3):133-140.

EXCLUDE: DUPLICATE

Duplicate publications:

1. Sandroff BM, Klaren RE, Pilutti LA, Dlugonski D, Benedict RHB, Motl RW. Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis. *Journal of Neurology*. Feb 2014;261(2):363-372.

BACKGROUND

Reviews screened for additional references and multiple publications of included studies:

1. Multiple sclerosis - management of multiple sclerosis in primary and secondary care. October 2014.
2. Ascherio A. Environmental factors in multiple sclerosis. *Expert Review of Neurotherapeutics*. Dec 2013;13(12 Suppl):3-9.
3. Ascherio A, Munger K, White R, et al. Vitamin D as a predictor of multiple sclerosis activity and progression. *Mult. Scler. J*. Oct 2013;19(11):23-24.
4. Bowling AC, Stewart TM. Current Complementary and Alternative Therapies for Multiple Sclerosis. *Curr Treat Options Neurol*. Jan 2003;5(1):55-68.
5. Carrithers MD. Update on Disease-Modifying Treatments for Multiple Sclerosis. *Clinical Therapeutics*. Dec 1 2014;36(12):1938-1945.
6. Compston A, Coles A. Multiple sclerosis. *Lancet*. Apr 6 2002;359(9313):1221-1231.
7. Constantinescu C, Manouchehrinia A, Tench C, Bibani R, Britton J. Cigarette Smoking and Disease Progression in Patients with Multiple Sclerosis: A Study of a Large United Kingdom Cohort. *Neurology*. Apr 2012;78.
8. Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? *Therapeutic Advances in Neurological Disorders*. Mar 2012;5(2):81-95.
9. Dalgas U, Stenager E, Sloth M, Stenager E. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. *European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies*. Mar 2015;22(3):443-e434.
10. D'Hooghe M B, Haentjens P, Nagels G, D'Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. *Journal of Neurology*. May 2012;259(5):855-861.
11. D'Hooghe M B, Haentjens P, Nagels G, Garmyn M, De Keyser J. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2012;18(4):451-459.
12. D'Hooghe M B, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Jul 2010;16(7):773-785.
13. D'Hooghe M B, Nagels G, De Keyser J, Haentjens P. Self-reported health promotion and disability progression in multiple sclerosis. *Journal of the Neurological Sciences*. Feb 15 2013;325(1-2):120-126.
14. Faridar A, Eskandari G, Sahraian MA, Minagar A, Azimi A. Vitamin D and multiple sclerosis: a critical review and recommendations on treatment. *Acta Neurol Belg*. Dec 2012;112(4):327-333.
15. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev*. 2012;12:CD004192.
16. Feinstein A, Dalgas U. The benefits of exercise in progressive MS: some cautious optimism. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Mar 2014;20(3):269-270.
17. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. *PloS One*. 2011;6(1):e16149.
18. Haselkorn JK. Veterans Health Administration Multiple Sclerosis Centers of Excellence: Clinical care, education, informatics, and research. *Journal of Rehabilitation Research and Development*. Jan-Feb 2006;43(1):vii-x.
19. Herndon RM. Medical hypothesis: why secondary progressive multiple sclerosis is a relentlessly progressive illness. *Archives of Neurology*. Feb 2002;59(2):301-304.
20. Hutchinson M. Multiparity in women with multiple sclerosis causes less long-term disability: Commentary. *Mult. Scler. J*. Oct 2014;20(11):1437-1438.
21. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. *Cochrane Database Syst Rev*. 2010(12):CD008422.
22. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. *Mult. Scler. J*. Oct 2013;19(12):1571-1579.
23. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. *Brain: A Journal of Neurology*. Oct 2002;125(Pt 10):2202-2212.
24. Kurland LT, Molgaard CA, Kurland EM, Wiederholt WC, Kirkpatrick JW. Swine flu vaccine and multiple sclerosis. *JAMA*. May 25 1984;251(20):2672-2675.
25. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. *Annals of Neurology*. 1994;36

- Suppl:S73-79.
26. Levin AB, Hadgkiss EJ, Weiland TJ, Jelinek GA. Meditation as an adjunct to the management of multiple sclerosis. *Neurology Research International*. 2014;2014:704691.
 27. Levin AB, Hadgkiss EJ, Weiland TJ, et al. Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study. *Behavioural Neurology*. 2014;2014:916519.
 28. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. Jul 15 2014;83(3):278-286.
 29. Manouchehrinia A, Weston M, Tench CR, Britton J, Constantinescu CS. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. *Journal of Neurology, Neurosurgery, and Psychiatry*. Oct 2014;85(10):1091-1095.
 30. Marck CH, Hadgkiss EJ, Weiland TJ, van der Meer DM, Pereira NG, Jelinek GA. Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey. *BMC Neurol*. 2014;14:143.
 31. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. *Mult. Scler. J*. Dec 2011;17(12):1464-1471.
 32. Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. *Continuum (Minneapolis, Minn.)*. Aug 2013;19(4 Multiple Sclerosis):1046-1057.
 33. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. *The Lancet. Neurology*. Aug 2010;9(8):820-828.
 34. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Annals of Neurology*. Jul 2001;50(1):121-127.
 35. Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Apr 2014;20(5):527-536.
 36. Motl RW, McAuley E, Sandroff BM. Longitudinal change in physical activity and its correlates in relapsing-remitting multiple sclerosis. *Physical Therapy*. Aug 2013;93(8):1037-1048.
 37. Octavia JR, Coninx K. Adaptive Personalized Training Games for Individual and Collaborative Rehabilitation of People with Multiple Sclerosis. *Biomed Res. Int*. 2014.
 38. Overs S, Hughes CM, Haselkorn JK, Turner AP. Modifiable comorbidities and disability in multiple sclerosis. *Current Neurology and Neuroscience Reports*. Oct 2012;12(5):610-617.
 39. Pilutti LA, Platta ME, Motl RW, Latimer-Cheung AE. The safety of exercise training in multiple sclerosis: A systematic review. *Journal of the Neurological Sciences*. Aug 2014;343(1-2):3-7.
 40. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Annals of Neurology*. Mar 1983;13(3):227-231.
 41. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. *Neuroepidemiology*. 2013;40(3):147-153.
 42. Rezapour-Firouzi S, Arefhosseini SR, Mehdi F, et al. Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. *Complementary Therapies in Medicine*. Oct 2013;21(5):473-480.
 43. Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G. Exercise therapy for multiple sclerosis - art. no. CD003980.pub2. *Cochrane Database Syst Rev*. 2005(1).
 44. Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. *Journal of Neurology*. Jul 2005;252(7):839-845.
 45. Sa MJ. Exercise therapy and multiple sclerosis: a systematic review. *Journal of Neurology*. Sep 2014;261(9):1651-1661.
 46. Schwarz S, Leweling H. Multiple sclerosis and nutrition. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. Feb 2005;11(1):24-32.
 47. Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S. Mindfulness based interventions in multiple sclerosis--a systematic review. *BMC Neurol*. 2014;14:15.
 48. Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. *PLoS One*. 2014;9(3):e92761.
 49. Swank RL. Multiple sclerosis: fat-oil relationship. *Nutrition*. Sep-Oct 1991;7(5):368-376.
 50. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. *Nutrition*. Feb 2003;19(2):161-162.



51. Toomey E, Coote SB. Physical rehabilitation interventions in nonambulatory people with multiple sclerosis: a systematic review. *International Journal of Rehabilitation Research. Internationale Zeitschrift für Rehabilitationsforschung. Revue Internationale de Recherches de Readaptation*. Dec 2012;35(4):281-291.
52. Tremlett HL, Devonshire VA. Does the season or month of birth influence disease progression in multiple sclerosis? *Neuroepidemiology*. 2006;26(4):195-198.
53. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. *Brain: A Journal of Neurology*. Jun 2004;127(Pt 6):1353-1360.
54. Wallin MT, Wilken JA, Turner AP, Williams RM, Kane R. Depression and multiple sclerosis: Review of a lethal combination. *Journal of Rehabilitation Research and Development*. Jan-Feb 2006;43(1):45-62.
55. Wergeland S, Torkildsen O, Bo L, Myhr KM. Polyunsaturated fatty acids in multiple sclerosis therapy. *Acta Neurologica Scandinavica*. Dec 2012;126:70-75.
56. Wier LM, Hatcher MS, Triche EW, Lo AC. Effect of robot-assisted versus conventional body-weight-supported treadmill training on quality of life for people with multiple sclerosis. *Journal of Rehabilitation Research and Development*. 2011;48(4):483-492.
57. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. *Ther Adv Neurol Disord*. Jan 2012;5(1):13-22.
58. Yeh EA, Weinstock-Guttman B. Multiple sclerosis: predicting risk and delaying progression. *The Lancet. Neurology*. Jan 2010;9(1):7-9.

APPENDIX C. CRITERIA USED IN QUALITY ASSESSMENT

This appendix documents the individual risk of bias criteria used to assess included studies. In addition, it documents the criteria used to rate the quality of evidence across studies.

RISK OF BIAS ASSESSMENT OF KQ1 AND KQ2 STUDIES

A large number of diverse studies contributed to the review. We broadly categorized risk factor studies into concurrent, retrospective, and prospective studies. Concurrent and retrospective studies can provide only limited information on questions of progression, regardless of their methodological quality, and these studies were not further differentiated.

The identified prospective studies relevant to KQ1 and KQ2 were assessed with QUIPS (Quality In Prognosis Studies), a critical appraisal tool for prognostic studies. QUIPS assesses the domains study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting.¹⁵ For each domain we determined whether the study indicates high risk of bias, moderate risk of bias, or low risk of bias.

Appendix Table 1. Risk of Bias: KQ1 and KQ2 Prospective Studies

Author, year	Study Participation	Study Attrition	Prognostic Factor Measurement	Outcome Measurement	Study Confounding	Statistical Analysis and Reporting	KQ1 and KQ2
Ascherio, 2014 ²⁰	High	Moderate	Low	Low	Moderate	Low	
Confavreux, 1998 ³⁰	Low	Low	Low	Low	High	Low	
Detels, 1982 ³⁵	Low	Moderate	Moderate	High	Moderate	Moderate	
Mowry, 2012 ⁶⁹	Low	Low	Low	Low	Low	Low	
Pasto, 2012 ⁷²	Low	Low	Low	Low	High	Low	
Pittas, 2009 ⁷⁶	Moderate	Low	Low	Low	Low	Low	
Runmarker, 1995 ¹¹³	Moderate	Low	Low	Low	High	Moderate	
Shammas, 2014 ⁸⁷	High	Low	Low	Low	Moderate	High	
Soilu-Hanninen, 2007 ⁹¹	High	Low	Low	Low	Moderate	High	
Stuifbergen, 2006 ⁹⁶	Low	Low	Low	Low	Low	Low	
Sundstrom, 2008 ⁹⁷	Moderate	Low	Moderate	Low	Low	Moderate	
Swank, 1990 ⁹⁸	Low	Low	High	Low	Low	Moderate	
Tepavcevic, 2010 ¹¹²	Moderate	Moderate	High	Low	Moderate	High	

Legend:

Study participation: Prompting items: a. Adequate participation in the study by eligible persons, b. Description of the source population or population of interest, c. Description of the baseline study sample, d. Adequate description of the sampling frame, and recruitment, e. Adequate description of the period and place of recruitment, f. Adequate description of inclusion and exclusion criteria. Ratings: High risk: The relationship between the PF and outcome is very likely to be different for participants and eligible nonparticipants; Moderate bias: The relationship between the PF and outcome may be different for participants and eligible nonparticipants; Low bias: The relationship between the PF and outcome is unlikely to be different for participants and eligible nonparticipants

Study attrition: a. Adequate response rate for study participants, b. Description of attempts to collect information on participants who dropped out, c. Reasons for loss to follow-up are provided, d. Adequate description of participants lost to follow-up, e. There are no important differences between participants who completed the study and those who did not. Ratings: High bias: The relationship between the PF and outcome is very likely to be different for completing and non-completing participants; Moderate bias: The relationship between the PF and outcome may be different for completing and non-completing participants; Low bias: The relationship between the PF and outcome is unlikely to be different for completing and non-completing participants

Prognostic Factor Measurement: Prompting items: a. A clear definition or description of the PF is provided, b. Method of PF measurement is adequately valid and reliable, c. Continuous variables are reported or appropriate cut points are used, d. The method and setting of measurement of PF is the same for all study participants, e. Adequate proportion of the study sample has complete data for the PF, f. Appropriate methods of imputation are used for missing PF data. Ratings: High bias: The measurement of the PF is very likely to be different for different levels of the outcome of interest, Moderate bias: The measurement of the PF may be different for different levels of the outcome of interest, Low bias: The measurement of the PF is unlikely to be different for different levels of the outcome of interest

Outcome Measurement: Prompting items: a. clear definition of the outcome is provided, b. Method of outcome measurement used is adequately valid and reliable, c. The method and setting of outcome measurement is the same for all study participants. Ratings: High bias: The measurement of the outcome is very likely to be different related to the baseline level of the PF, Moderate bias: The measurement of the outcome may be different related to the baseline level of the PF, Low bias: The measurement of the outcome is unlikely to be different related to the baseline level of the PF

Study Confounding: Prompting items: a. All important confounders are measured, b. Clear definitions of the important confounders measured are provided, c. Measurement of all important confounders is adequately valid and reliable, d. The method and setting of confounding measurement are the same for all study participants, e. Appropriate methods are used if imputation is used for missing confounder data, f. Important potential confounders are accounted for in the study design, g. Important potential confounders are accounted for in the analysis. Ratings: High bias: The observed effect of the PF on the outcome is very likely to be distorted by another factor related to PF and outcome, Moderate bias: The observed effect of the PF on outcome may be distorted by another factor related to PF and outcome, Low bias: The observed effect of the PF on outcome is unlikely to be distorted by another factor related to PF and outcome

Statistical Analysis and Reporting: Prompting items: a. Sufficient presentation of data to assess the adequacy of the analytic strategy, b. Strategy for model building is appropriate and is based on a conceptual framework or model, c. The selected statistical model is adequate for the design of the study, d. There is no selective reporting of results. Ratings: High bias: The reported results are very likely to be spurious or biased related to analysis or reporting, Moderate bias: The reported results may be spurious or biased related to analysis or reporting, Low bias: The reported results are unlikely to be spurious or biased related to analysis or reporting

RISK OF BIAS ASSESSMENT OF KQ3 STUDIES

Studies relevant to KQ3 were assessed with the Cochrane risk of bias tool. The tool assesses random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessors (detection bias), completeness of reporting outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias (if appropriate) for each of the included studies. For each domain

we determined whether the study indicates a high risk of bias, a low risk of bias, or an unclear risk of bias.

Appendix Table 2. Risk of Bias: KQ3 Studies

Author, year	Random sequence generation	Allocation concealment	Blinding of participants/providers	Blinding of outcome assessors	Incomplete outcome data	Selective reporting	Other bias
Armutlu, 2001 ¹⁹	Unclear	Unclear	High risk	Low risk	Low risk	Low risk	Low risk
Bates, 1977 ²⁴	Unclear	Unclear	Low risk	Low risk	Low risk	High risk	Low risk
Bates, 1978 ²⁵	Unclear	Unclear	Low risk	Low risk	Unclear	Unclear	Unclear
Bates, 1989 ²³	Unclear	Unclear	Low risk	Low risk	Unclear	Unclear	Unclear
Bjarnadottir, 2007 ²⁶	Unclear	Low risk	High risk	High risk	Unclear	Unclear	High risk
Burton, 2010 ²⁸	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk
Carter, 2013 ²⁹	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	Low risk
Conklyn, 2010 ³¹	Unclear	Unclear	High risk	High risk	Low risk	Low risk	High risk
Dalgas, 2009 ³²	Unclear	Low risk	High risk	Low risk	Low risk	Low risk	Low risk
DeBolt, 2004 ³⁴	Unclear	Unclear	High risk	High risk	Unclear	Unclear	Unclear
Fimland, 2010 ³⁷	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	High risk
Golzari, 2010 ⁴²	Unclear	Unclear	High risk	Low risk	Unclear	Unclear	High risk
Harbige, 2007 ⁴⁴	Unclear	Unclear	Low risk	Low risk	Unclear	Unclear	High risk
Kampman, 2012 ⁴⁹	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Lo, 2008 ⁵⁶	Unclear	Unclear	High risk	Low risk	Low risk	Low risk	High risk
Millar, 1973 ⁶⁵	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk
Miller, 2011 ⁶⁶	Unclear	Unclear	High risk	Unclear	Low risk	Low risk	Unclear
Mosayebi, 2011 ⁶⁷	Unclear	Low risk	Low risk	Low risk	High risk	Low risk	Unclear
Pantzaris, 2013 ⁷¹	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear	Unclear
Paty, 1978 ⁷³	Unclear	Unclear	Low risk	Low risk	High risk	Unclear	Unclear
Petajan, 1996 ⁷⁴	Unclear	Unclear	High risk	Low risk	High risk	Low risk	High risk
Pfalzer, 2011 ⁷⁵	Unclear	Unclear	High risk	Unclear	Unclear	Low risk	Low risk
Ramirez-Ramirez, 2013 ⁷⁸	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk
Rampello, 2007 ⁷⁹	Low risk	Low risk	Unclear	Unclear	High risk	Unclear	Unclear
Rezapour-Firouzi, 2013 ⁸⁰	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	High risk
Romberg, 2004 ⁸¹	Unclear	Unclear	High risk	High risk	Low risk	Unclear	Unclear
Sangelaji, 2014 ⁸³	Unclear	Low risk	High risk	Unclear	High risk	Low risk	Low risk
Schwartz, 2012 ⁸⁴	Low risk	Low risk	High risk	Low risk	High risk	Low risk	High risk
Shaygannejad, 2012 ⁸⁸	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Soilu-Hanninen, 2012 ¹²⁸	Low risk	Low risk	Low risk	Low risk	High risk	Unclear	High risk
Solari, 1999 ⁹²	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	Low risk

Stein, 2011 ⁹⁴	Low risk	Low risk	High risk	Low risk	Low risk	High risk	High risk
Torkildsen, 2012 ¹⁰¹	Low risk	Low risk	Low risk	Low risk	Unclear	Low risk	Unclear
Weinstock-Guttman, 2005 ¹⁰⁷	Unclear	Unclear	Low risk	Low risk	High risk	Low risk	High risk
Wiles, 2001 ¹⁰⁹	Unclear	Unclear	High risk	Low risk	Low risk	Low risk	Low risk
Yadav, 2014 ¹¹⁰	Unclear	Unclear	High risk	Low risk	High risk	Low risk	High risk

Legend:

Random sequence generation: Low risk: The investigators describe a random component in the sequence generation process such as: Referring to a random number table, Using a computer random number generator; Coin tossing; Shuffling cards or envelopes; Throwing dice; Drawing of lots; Minimization; High risk: The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example: Sequence generated by odd or even date of birth; Sequence generated by some rule based on date (or day) of admission; Sequence generated by some rule based on hospital or clinic record number; Allocation by judgment of the clinician; Allocation by preference of the participant; Allocation based on the results of a laboratory test or a series of tests; Allocation by availability of the intervention. Unclear: Insufficient information about the sequence generation process to permit judgment of 'Low risk' or 'High risk'.

Allocation concealment: Low risk: Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: Central allocation (including telephone, web-based and pharmacy-controlled randomization); Sequentially numbered drug containers of identical appearance; Sequentially numbered, opaque, sealed envelopes. High risk: Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: Using an open random allocation schedule (eg, a list of random numbers); Assignment envelopes were used without appropriate safeguards (eg, if envelopes were unsealed or non-opaque or not sequentially numbered); Alternation or rotation; Date of birth; Case record number; Any other explicitly unconcealed procedure. Unclear: Insufficient information to permit judgment of 'Low risk' or 'High risk'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgment – for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

Blinding of participants and personnel: Low risk: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken. High risk: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding. Unclear: Insufficient information to permit judgment of 'Low risk' or 'High risk'; The study did not address this outcome.

Blinding of outcome assessment: Low risk: No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. High risk: No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding. Unclear: Insufficient information to permit judgment of 'Low risk' or 'High risk'; The study did not address this outcome.

Incomplete outcome data: Low risk: No missing outcome data; Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; Missing data have been imputed using appropriate methods. High risk:

Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomization; Potentially inappropriate application of simple imputation. Unclear: Insufficient reporting of attrition/exclusions to permit judgment of ‘Low risk’ or ‘High risk’ (eg, number randomized not stated, no reasons for missing data provided); The study did not address this outcome.

Selective reporting: Low risk: The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon). High risk: Not all of the study’s pre-specified primary outcomes have been reported; One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (eg, subscales) that were not pre-specified; One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; The study report fails to include results for a key outcome that would be expected to have been reported for such a study. Unclear: Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’. It is likely that the majority of studies will fall into this category.

Other bias: Low risk: The study appears to be free of other sources of bias. High risk: There is at least one important risk of bias. For example the study had a potential source of bias related to the specific study design used; has been claimed to have been fraudulent; or had some other problem. Unclear: There may be a risk of bias, but there is either: Insufficient information to assess whether an important risk of bias exists; or insufficient rationale or evidence that an identified problem will introduce bias.

CRITERIA TO RATE THE BODY OF EVIDENCE FOR KQ1 AND KQ2

The GRADE framework for prognostic factor research¹⁸ differentiates 8 criteria that are used to evaluate the quality of the evidence across all identified studies:

The *phase of investigation* differentiates whether the risk factor evidence is primarily based on a study that aimed to identify potential prognostic factors (moderate quality) rather than based on studies aiming to confirm identified associations or explanatory research aiming to understand prognostic pathways (high quality).

Study limitations took the assessment frame into account by differentiating whether the risk factor status and the outcome variable were assessed at the same time (concurrently), retrospectively, or prospectively. Prospective studies were further differentiated by the risk of bias based on the QUIPS scores.

Inconsistency assessed whether the identified association was consistently present across studies and across study designs (eg, present in concurrent and prospective studies).

Indirectness took into account whether the available research studies does not accurately reflect the review question. Examples are cases where the only available research studies reported on vitamin D status, rather than a directly patient-modifiable risk factor such as vitamin D intake.

Evidence was downgraded for *imprecision* if the sample size was insufficient, the confidence interval was wide and overlapped the value of no effect, there were less than 10 outcome events for each prognostic variable, or there were less than 100 cases reaching endpoints.

Evidence was downgraded for *publication bias* unless the value of the risk or protective factor in predicting the outcome has been repetitively investigated.

Evidence for individual risk factors may be upgraded if *effects* are moderate or large or there is evidence of *exposure-gradient* response for factors measured at different doses.

CRITERIA TO RATE THE BODY OF EVIDENCE FOR KQ3

For KQ3 we took the criteria *risk of bias*, *inconsistency*, *indirectness*, *imprecision*, *publication bias*, *large effect*, *dose response*, and *all plausible residual confounding would reduce a demonstrated effect and/or would suggest a spurious effect if no effect was observed* into account. The starting point was high evidence because the data are based on RCTs.

Risk of bias, inconsistency, indirectness, imprecision, and publication bias can lower the quality. Large effect, dose response, and all plausible residual confounding can upgrade the quality of the body of evidence.¹⁷

Risk of bias evaluations were based on the above documented Cochrane Risk of Bias tool assessments. *Inconsistency* took the direction and the size of effects across studies into account. *Indirectness* may assess whether comparative effects are based on head-to-head trial evidence or was obtained from meta-regressions and subgroup analyses. *Imprecision* takes the confidence interval around the point estimate into account. *Publication bias* was assessed to determine whether there is evidence that pertinent studies, in this case negative effect studies are missing.

APPENDIX D. PEER REVIEW COMMENTS/AUTHOR RESPONSES

Comment	Response
<p>Studies missing - Yes - Studies evaluating geography itself as a risk factor, studies prior to 1973, studies involving co-morbidity</p>	<p>The identified studies on associations between geography and progression are shown in the “other” and the “multiple” risk factor section. Studies published prior to 1973 were eligible for inclusion in the review and all databases were searched without date restriction. We have added the eligibility criteria after the description of the included studies in the result section to avoid ambiguity. In addition, we have emphasized that databases were searched from inception. Co-morbidities were outside the scope of this review but we have expanded the future research section to indicate that sufficient literature exists for systematic reviews on several individual co-morbidities.</p>
<p>It would have been useful to add obesity related studies in the review as it appears to be an important co-morbid condition and related information would have been of great research as well as clinical significance.</p>	<p>See above. In particular there is a growing literature on weight and MS progression; we have expanded on this issue in the future research section.</p>
<p>Several typographical errors are present in the draft, that I assume will be reviewed carefully towards the final draft.</p>	<p>Typographical errors will be correct before publication</p>
<p>Pg 1/Line 8: Traumatic brain injury is more common than MS in younger adults but is not progressive. I'd reword this sentence as follows: Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age.</p>	<p>Revised as suggested</p>
<p>Pg 1/Line 21: Use “MS” throughout the manuscript after it's defined.</p>	<p>We have revised the text accordingly but left the key questions as is to avoid ambiguity</p>
<p>Pg 1/Line 49: Is this a preliminary report vs. final?</p>	<p>The draft report is subjected to peer review</p>
<p>Pg 3/Line 16: “Concurrent” is not commonly used and is confusing. It should be replaced with retrospective.</p>	<p>To address this point, we have added a definition to avoid confusion (measuring the exposure status and the outcome at the same time point, eg, current alcohol intake)</p>
<p>Pg 5/Line 5: Change “Out” to Our.</p>	<p>Changed</p>
<p>Pg 5/Line 25: There are several redundant and inaccurate statements in the conclusion. The association between MS progression and vitamin D supplementation is not significant but the conclusions imply it is related. The conclusion should be modified to something like the following: Our systematic review documents the available evidence on modifiable risk factors for MS progression. Associations with MS progression are strongest for smoking. None of the intervention studies examining exercise, dietary, and vitamin D supplementation reported a statistically significant effect on MS disability. Other than smoking cessation, there are no other modifiable risk factors that can be given support from this review as an intervention worthy of slowing MS progression.</p>	<p>To address the perceived redundancy we have divided the conclusions into multiple paragraphs: one characterizes the overall evidence base, one summarizes the risk factor studies, one summarizes the intervention RCTs, and the last one describes the evidence for factors that were addressed in both, risk factor and in intervention studies. The correlation between EDSS scores and vitamin D level was statistically significant. We have revised the sentence to avoid the perceived inaccuracy.</p>



Pg 8/Line 3: There are several reviews of MS risk factors published in the literature. Some are comprehensive in scope. The statement below is confusing in implying there are multiple reviews of risk factors translated into treatment options. Is this referring to dietary or exercise treatments? There is an emerging body of research that evaluates risk factors translated into treatment options but no systematic review has to date comprehensively synthesized the available evidence.	We have deleted the sentence
Pg 18/Line 8: Why was 1973 used as the starting year (vs. 1970)?	See above
Pg 51/Line 5: There is no figure in the box.	Unfortunately the conversion to PDF in the online editorial manager system did not display the figure; this will be corrected in the final report.
Forest plots: There is no confidence interval represented on the summary measure of risk in the diagram. This should be included.	We were not sure how this perception came about, confidence intervals are shown for individual studies and the pooled effect in all forest plots
Please see editorial suggestions and comments in the uploaded document.	Thank you for your careful review; we have accepted all editorial changes
p. 10: So if I understand correctly, a study on solely Relapsing Remitting MS (RR MS), the most common disease type, would have been excluded - even though patients with RR MS often progress over time?	We have revised the sentence to avoid confusion
p. 24: Sentence is unclear. Which of the studies does this phrase refer to?	Author name added to avoid ambiguity
p. 50: awkward wording	Revised to clarify that the individually assessed risk factors as well as predicted outcomes were very specific
p. 51: Figure missing from draft	See above
p. 51: I assume you mean since the Vit D values were dichotomized, rather than reported as a continuous variable? The statement is unclear as written, since the study did in fact use the EDSS.	The studies did not report on a correlation, hence they could not be added to the meta-analysis; we have clarified this in the text
p. 52: Graphs have a diagonal line, which should be deleted.	Formatting changes are due to converting to PDF and will be corrected in the final report
p. 54: Which - any alcohol consumption, or heavy drinking, or both?	Clarified
p. 56: Explain the "downgrades" (or refer to the text in the legend)	Added
p. 69: Unclear in this context	We have added more explanation regarding the waitlist condition
p. 78: Would this be better expressed as "pregnancy" rather than "children"?	See above
p. 82: Unclear. Do you mean "for which the published evidence demonstrates their amenability...". Need a clear statement to conclude the review!	We have revised the draft conclusions
Did any study examine the impact of moving to a different region/climate/latitude during childhood or early adulthood?	We did not identify such a study
I have a general concern that there may be confusion in discussion of studies between change from Relapsing-Remitting MS (RR MS) to Secondary Progressive MS (SP MS), and progression of disability caused by MS, which can occur both in RR MS and SP MS.	Yes, several studies did not restrict to RR MS and studies used a variety of outcome measures. To address this concern, we have highlighted those studies in the summary of findings section that specifically reported on the change from RR to SP MS and those that only included patients with RR MS at baseline

Was the post-partum period also analyzed separate from pregnancy itself? It is commonly held that MS is likely to be quiescent during pregnancy, but the risk for relapses or progression is increased from baseline during the immediate post-partum interval.	Given the complexity of the topic and the diversity across the large number of studies that should be addressed in a separate systematic review we have added this topic to the list of suggested future research studies.
Page 5, line 5: Change "Out" to "Our"	See above
Page 7, line 16: Change "described" to "characterized pathologically" and add "focal areas of" before "inflammation..."	Changed as suggested
Page 7, lines 35 to 37: Change "Progressive relapsing MS" to "Active progressive MS" The classification system for MS subtypes was revised in 2014 to remove the classification of "progressive relapsing" and replace it with the classification of "active progressive" This is given in Reference 8.	Changed as suggested
Page 10, line 60: Azathioprine is listed as a medication specifically designed for MS, which . Azathioprine was originally developed as an antineoplastic agent it is now used for immunosuppression in autoimmune diseases and organ transplantation. Other drugs in this class that were omitted from the list include methotrexate and cyclophosphamide. Cladribine, listed later, probably belongs in the same list.	We have removed the specific examples and reduced the text to one example per medication type to address this point
Page 13, line 54: Move "presented" to after "statistics"	We have revised the sentence
Page 15, line 14: After "East" add ", Professor, Departments of Neurology, Pharmacology and Physical Therapy, University of Maryland School of Medicine"	Added
Page 15, line 14: After "MPH" add ", Director, MS Center of Excellence - West"	Added
Page 15, line 26: Change,"PHD" to "PhD"	Changed
Tables 1 to 7: I may not be reading the tables correctly but I did not see a column indicating the rating of the quality of the evidence in each study. I believe that Appendix C deals with that issue in detail but should some summary indication be included on these tables?	The studies were assessed with a number of individual risk of bias criteria which exceeded the available space in the evidence tables. To address this point we have systematically added information on the risk of bias to the result sections following the evidence tables
Tables 1 to 7, case definition: I may not be understanding what is being reported here. I am used to this column being used to report whether an acceptable case definition was used by the study in question. In most cases this would involve a diagnosis of MS based on published criteria such as the Poser, McDonald or modified McDonald criteria. Cases might be further restricted based on disability range using a scale like the EDSS score. The entries in this column don't seem to fit this so I am unclear on what is being displayed here. I am also not clear on whether publications were reviewed to ensure that accepted case definitions were used.	We have revised the term to "predicted variable" to avoid confusion with MS diagnostic criteria. In addition, we have added the diagnostic criteria for prospective studies to the evidence tables.